<response><result><id>33769253</id><source>MED</source><pmid>33769253</pmid><doi>10.3201/eid2705.210397</doi><title>Detecting Rapid Spread of SARS-CoV-2 Variants, France, January 26-February 16, 2021.</title><authorString>Haim-Boukobza S, Roquebert B, Trombert-Paolantoni S, Lecorche E, Verdurme L, Foulongne V, Selinger C, Michalakis Y, Sofonea MT, Alizon S.</authorString><authorList><author><fullName>Haim-Boukobza S</fullName><firstName>Stéphanie</firstName><lastName>Haim-Boukobza</lastName><initials>S</initials></author><author><fullName>Roquebert B</fullName><firstName>Bénédicte</firstName><lastName>Roquebert</lastName><initials>B</initials></author><author><fullName>Trombert-Paolantoni S</fullName><firstName>Sabine</firstName><lastName>Trombert-Paolantoni</lastName><initials>S</initials></author><author><fullName>Lecorche E</fullName><firstName>Emmanuel</firstName><lastName>Lecorche</lastName><initials>E</initials></author><author><fullName>Verdurme L</fullName><firstName>Laura</firstName><lastName>Verdurme</lastName><initials>L</initials></author><author><fullName>Foulongne V</fullName><firstName>Vincent</firstName><lastName>Foulongne</lastName><initials>V</initials></author><author><fullName>Selinger C</fullName><firstName>Christian</firstName><lastName>Selinger</lastName><initials>C</initials></author><author><fullName>Michalakis Y</fullName><firstName>Yannis</firstName><lastName>Michalakis</lastName><initials>Y</initials></author><author><fullName>Sofonea MT</fullName><firstName>Mircea T</firstName><lastName>Sofonea</lastName><initials>MT</initials></author><author><fullName>Alizon S</fullName><firstName>Samuel</firstName><lastName>Alizon</lastName><initials>S</initials></author></authorList><dataLinksTagsList><dataLinkstag>altmetrics</dataLinkstag></dataLinksTagsList><journalInfo><issue>5</issue><volume>27</volume><journalIssueId>3121371</journalIssueId><dateOfPublication>2021 Mar</dateOfPublication><monthOfPublication>3</monthOfPublication><yearOfPublication>2021</yearOfPublication><printPublicationDate>2021-03-01</printPublicationDate><journal><title>Emerging infectious diseases</title><ISOAbbreviation>Emerg Infect Dis</ISOAbbreviation><medlineAbbreviation>Emerg Infect Dis</medlineAbbreviation><NLMid>9508155</NLMid><ISSN>1080-6040</ISSN><ESSN>1080-6059</ESSN></journal></journalInfo><pubYear>2021</pubYear><abstractText>Variants of severe acute respiratory syndrome coronavirus 2 raise concerns regarding the control of coronavirus disease epidemics. We analyzed 40,000 specific reverse transcription PCR tests performed on positive samples during January 26-February 16, 2021 in France. We found high transmission advantage of variants and more advanced spread than anticipated.</abstractText><publicationStatus>aheadofprint</publicationStatus><language>eng</language><pubModel>Print-Electronic</pubModel><pubTypeList><pubType>Journal Article</pubType></pubTypeList><keywordList><keyword>Viruses</keyword><keyword>Variants</keyword><keyword>Virus</keyword><keyword>Transmission</keyword><keyword>RT-PCR</keyword><keyword>Screening</keyword><keyword>epidemiology</keyword><keyword>France</keyword><keyword>GLM</keyword><keyword>Zoonoses</keyword><keyword>Respiratory Infections</keyword><keyword>Statistical Modelling</keyword><keyword>Covid-19</keyword><keyword>Sars-cov-2</keyword><keyword>Severe Acute Respiratory Syndrome Coronavirus 2</keyword><keyword>Coronavirus Disease</keyword></keywordList><subsetList><subset><code>IM</code><name>Index Medicus</name></subset></subsetList><fullTextUrlList><fullTextUrl><availability>Subscription required</availability><availabilityCode>S</availabilityCode><documentStyle>doi</documentStyle><site>DOI</site><url>https://doi.org/10.3201/eid2705.210397</url></fullTextUrl></fullTextUrlList><isOpenAccess>N</isOpenAccess><inEPMC>N</inEPMC><inPMC>N</inPMC><hasPDF>N</hasPDF><hasBook>N</hasBook><hasSuppl>N</hasSuppl><citedByCount>0</citedByCount><hasData>N</hasData><hasReferences>N</hasReferences><hasTextMinedTerms>Y</hasTextMinedTerms><hasDbCrossReferences>N</hasDbCrossReferences><hasLabsLinks>Y</hasLabsLinks><authMan>N</authMan><epmcAuthMan>N</epmcAuthMan><nihAuthMan>N</nihAuthMan><hasTMAccessionNumbers>N</hasTMAccessionNumbers><dateOfCreation>2021-03-26</dateOfCreation><firstIndexDate>2021-03-27</firstIndexDate><dateOfRevision>2021-03-26</dateOfRevision><electronicPublicationDate>2021-03-26</electronicPublicationDate><firstPublicationDate>2021-03-26</firstPublicationDate></result>
<result><id>PPR297589</id><source>PPR</source><doi>10.1101/2021.03.15.21253653</doi><title>Epidemiological and clinical insights from SARS-CoV-2 RT-PCR cycle amplification values</title><authorString>Alizon S, Selinger C, Sofonea MT, Haim-Boukobza S, Giannoli J, Ninove L, Pillet S, Vincent T, de Rougemont A, Tumiotto C, Solis M, Stephan R, Bressollette-Bodin C, Salmona M, L’Honneur A, Behillil S, Lefeuvre C, Dina J, Hantz S, Hartard C, Veyer D, Delagrèverie HM, Fourati S, Visseaux B, Henquell C, Lina B, Foulongne V, Burrel S, SFM COVID-19 study group.</authorString><authorList><author><fullName>Alizon S</fullName><firstName>Samuel</firstName><lastName>Alizon</lastName><initials>S</initials><authorId type="ORCID">0000-0002-0779-9543</authorId></author><author><fullName>Selinger C</fullName><firstName>Christian</firstName><lastName>Selinger</lastName><initials>C</initials></author><author><fullName>Sofonea MT</fullName><firstName>Mircea</firstName><lastName>Sofonea</lastName><initials>MT</initials></author><author><fullName>Haim-Boukobza S</fullName><firstName>Stéphanie</firstName><lastName>Haim-Boukobza</lastName><initials>S</initials></author><author><fullName>Giannoli J</fullName><firstName>Jean-Marc</firstName><lastName>Giannoli</lastName><initials>J</initials></author><author><fullName>Ninove L</fullName><firstName>Laetitia</firstName><lastName>Ninove</lastName><initials>L</initials></author><author><fullName>Pillet S</fullName><firstName>Sylvie</firstName><lastName>Pillet</lastName><initials>S</initials></author><author><fullName>Vincent T</fullName><firstName>Thibault</firstName><lastName>Vincent</lastName><initials>T</initials></author><author><fullName>de Rougemont A</fullName><firstName>Alexis</firstName><lastName>de Rougemont</lastName><initials>A</initials><authorId type="ORCID">0000-0002-3084-9414</authorId></author><author><fullName>Tumiotto C</fullName><firstName>Camille</firstName><lastName>Tumiotto</lastName><initials>C</initials></author><author><fullName>Solis M</fullName><firstName>Morgane</firstName><lastName>Solis</lastName><initials>M</initials></author><author><fullName>Stephan R</fullName><firstName>Robin</firstName><lastName>Stephan</lastName><initials>R</initials></author><author><fullName>Bressollette-Bodin C</fullName><firstName>Céline</firstName><lastName>Bressollette-Bodin</lastName><initials>C</initials></author><author><fullName>Salmona M</fullName><firstName>Maud</firstName><lastName>Salmona</lastName><initials>M</initials></author><author><fullName>L’Honneur A</fullName><firstName>Anne-Sophie</firstName><lastName>L’Honneur</lastName><initials>A</initials></author><author><fullName>Behillil S</fullName><firstName>Sylvie</firstName><lastName>Behillil</lastName><initials>S</initials></author><author><fullName>Lefeuvre C</fullName><firstName>Caroline</firstName><lastName>Lefeuvre</lastName><initials>C</initials></author><author><fullName>Dina J</fullName><firstName>Julia</firstName><lastName>Dina</lastName><initials>J</initials></author><author><fullName>Hantz S</fullName><firstName>Sébastien</firstName><lastName>Hantz</lastName><initials>S</initials></author><author><fullName>Hartard C</fullName><firstName>Cédric</firstName><lastName>Hartard</lastName><initials>C</initials></author><author><fullName>Veyer D</fullName><firstName>David</firstName><lastName>Veyer</lastName><initials>D</initials></author><author><fullName>Delagrèverie HM</fullName><firstName>Héloïse</firstName><lastName>Delagrèverie</lastName><initials>HM</initials></author><author><fullName>Fourati S</fullName><firstName>Slim</firstName><lastName>Fourati</lastName><initials>S</initials></author><author><fullName>Visseaux B</fullName><firstName>Benoît</firstName><lastName>Visseaux</lastName><initials>B</initials></author><author><fullName>Henquell C</fullName><firstName>Cécile</firstName><lastName>Henquell</lastName><initials>C</initials></author><author><fullName>Lina B</fullName><firstName>Bruno</firstName><lastName>Lina</lastName><initials>B</initials></author><author><fullName>Foulongne V</fullName><firstName>Vincent</firstName><lastName>Foulongne</lastName><initials>V</initials></author><author><fullName>Burrel S</fullName><firstName>Sonia</firstName><lastName>Burrel</lastName><initials>S</initials></author><author><collectiveName>SFM COVID-19 study group</collectiveName></author></authorList><authorIdList><authorId type="ORCID">0000-0002-0779-9543</authorId><authorId type="ORCID">0000-0002-3084-9414</authorId></authorIdList><dataLinksTagsList><dataLinkstag>altmetrics</dataLinkstag></dataLinksTagsList><pubYear>2021</pubYear><abstractText>The SARS-CoV-2 pandemic has led to an unprecedented daily use of molecular RT-PCR tests. These tests are interpreted qualitatively for diagnosis, and the relevance of the test result intensity, i.e. the number of amplification cycles ( C t ), is debated because of strong potential biases. We analyze a national database of tests performed on more than 2 million individuals between January and November 2020. Although we find C t values to vary depending on the testing laboratory or the assay used, we detect strong significant trends with patient age, number of days after symptoms onset, or the state of the epidemic (the temporal reproduction number) at the time of the test. These results suggest that C t values can be used to improve short-term predictions for epidemic surveillance.</abstractText><pubTypeList><pubType>Preprint</pubType></pubTypeList><bookOrReportDetails><publisher>medRxiv</publisher><yearOfPublication>2021</yearOfPublication></bookOrReportDetails><fullTextUrlList><fullTextUrl><availability>Subscription required</availability><availabilityCode>S</availabilityCode><documentStyle>doi</documentStyle><site>DOI</site><url>https://doi.org/10.1101/2021.03.15.21253653</url></fullTextUrl></fullTextUrlList><isOpenAccess>N</isOpenAccess><inEPMC>N</inEPMC><inPMC>N</inPMC><hasPDF>N</hasPDF><hasBook>N</hasBook><hasSuppl>N</hasSuppl><citedByCount>0</citedByCount><hasData>N</hasData><hasReferences>N</hasReferences><hasTextMinedTerms>Y</hasTextMinedTerms><hasDbCrossReferences>N</hasDbCrossReferences><hasLabsLinks>Y</hasLabsLinks><authMan>N</authMan><epmcAuthMan>N</epmcAuthMan><nihAuthMan>N</nihAuthMan><hasTMAccessionNumbers>N</hasTMAccessionNumbers><dateOfCreation>2021-03-18</dateOfCreation><firstIndexDate>2021-03-18</firstIndexDate><firstPublicationDate>2021-03-17</firstPublicationDate></result>
<result><id>PPR287950</id><source>PPR</source><fullTextIdList><fullTextId>PPR287950</fullTextId></fullTextIdList><doi>10.1101/2021.02.20.21251927</doi><title>Rapid SARS-CoV-2 variants spread detected in France using specific RT-PCR testing</title><authorString>Haim-Boukobza S, Roquebert B, Trombert-Paolantoni S, Lecorche E, Verdurme L, Foulongne V, Selinger C, Michalakis Y, Sofonea MT, Alizon S.</authorString><authorList><author><fullName>Haim-Boukobza S</fullName><firstName>Stéphanie</firstName><lastName>Haim-Boukobza</lastName><initials>S</initials></author><author><fullName>Roquebert B</fullName><firstName>Benedicte</firstName><lastName>Roquebert</lastName><initials>B</initials></author><author><fullName>Trombert-Paolantoni S</fullName><firstName>Sabine</firstName><lastName>Trombert-Paolantoni</lastName><initials>S</initials></author><author><fullName>Lecorche E</fullName><firstName>Emmanuel</firstName><lastName>Lecorche</lastName><initials>E</initials></author><author><fullName>Verdurme L</fullName><firstName>Laura</firstName><lastName>Verdurme</lastName><initials>L</initials></author><author><fullName>Foulongne V</fullName><firstName>Vincent</firstName><lastName>Foulongne</lastName><initials>V</initials></author><author><fullName>Selinger C</fullName><firstName>Christian</firstName><lastName>Selinger</lastName><initials>C</initials></author><author><fullName>Michalakis Y</fullName><firstName>Yannis</firstName><lastName>Michalakis</lastName><initials>Y</initials></author><author><fullName>Sofonea MT</fullName><firstName>Mircea</firstName><lastName>Sofonea</lastName><initials>MT</initials></author><author><fullName>Alizon S</fullName><firstName>Samuel</firstName><lastName>Alizon</lastName><initials>S</initials><authorId type="ORCID">0000-0002-0779-9543</authorId></author></authorList><authorIdList><authorId type="ORCID">0000-0002-0779-9543</authorId></authorIdList><dataLinksTagsList><dataLinkstag>altmetrics</dataLinkstag></dataLinksTagsList><pubYear>2021</pubYear><abstractText>SARS-CoV-2 variants raise major concerns regarding the control of COVID-19 epidemics. We analyse 40,000 specific RT-PCR tests performed on SARS-CoV-2-positive samples collected between Jan 26 and Feb 16, 2021. We find a high transmission advantage of variants and show that their spread in the country is more advanced than anticipated.</abstractText><pubTypeList><pubType>Preprint</pubType></pubTypeList><bookOrReportDetails><publisher>medRxiv</publisher><yearOfPublication>2021</yearOfPublication></bookOrReportDetails><fullTextUrlList><fullTextUrl><availability>Subscription required</availability><availabilityCode>S</availabilityCode><documentStyle>doi</documentStyle><site>DOI</site><url>https://doi.org/10.1101/2021.02.20.21251927</url></fullTextUrl><fullTextUrl><availability>Open access</availability><availabilityCode>OA</availabilityCode><documentStyle>html</documentStyle><site>Europe_PMC</site><url>https://europepmc.org/article/PPR/PPR287950</url></fullTextUrl><fullTextUrl><availability>Open access</availability><availabilityCode>OA</availabilityCode><documentStyle>pdf</documentStyle><site>Europe_PMC</site><url>https://europepmc.org/api/fulltextRepo?pprId=PPR287950&amp;type=FILE&amp;fileName=EMS117487-pdf.pdf&amp;mimeType=application/pdf</url></fullTextUrl></fullTextUrlList><isOpenAccess>Y</isOpenAccess><inEPMC>Y</inEPMC><inPMC>N</inPMC><hasPDF>Y</hasPDF><hasBook>N</hasBook><hasSuppl>Y</hasSuppl><citedByCount>0</citedByCount><hasData>N</hasData><hasReferences>N</hasReferences><hasTextMinedTerms>Y</hasTextMinedTerms><hasDbCrossReferences>N</hasDbCrossReferences><hasLabsLinks>Y</hasLabsLinks><license>cc by-nc</license><authMan>N</authMan><epmcAuthMan>N</epmcAuthMan><nihAuthMan>N</nihAuthMan><hasTMAccessionNumbers>N</hasTMAccessionNumbers><dateOfCreation>2021-02-25</dateOfCreation><firstIndexDate>2021-02-25</firstIndexDate><fullTextReceivedDate>2021-03-12</fullTextReceivedDate><firstPublicationDate>2021-02-23</firstPublicationDate></result>
<result><id>PPR286483</id><source>PPR</source><doi>10.1101/2021.02.18.21251983</doi><title>The source of individual heterogeneity shapes infectious disease outbreaks</title><authorString>Elie B, Selinger C, Alizon S.</authorString><authorList><author><fullName>Elie B</fullName><firstName>Baptiste</firstName><lastName>Elie</lastName><initials>B</initials></author><author><fullName>Selinger C</fullName><firstName>Christian</firstName><lastName>Selinger</lastName><initials>C</initials></author><author><fullName>Alizon S</fullName><firstName>Samuel</firstName><lastName>Alizon</lastName><initials>S</initials><authorId type="ORCID">0000-0002-0779-9543</authorId></author></authorList><authorIdList><authorId type="ORCID">0000-0002-0779-9543</authorId></authorIdList><dataLinksTagsList><dataLinkstag>altmetrics</dataLinkstag></dataLinksTagsList><pubYear>2021</pubYear><abstractText>Infectious disease transmission patterns in some outbreaks can be more heterogeneous than in others, with striking effects on the way epidemics unfold. Some studies show that the biological sources of heterogeneity may matter, but they tend to do so without controlling for the overall heterogeneity in the number of secondary cases caused by an infection. Here, we control for this important bias to explore the role of individual variation in infection duration and transmission rate on parasite emergence and spread. We simulate outbreaks using a stochastic SIR model, with and without parasite evolution. Consistently with existing studies, we show that the variance in the number of secondary infections has the strongest effect on outbreak emergence probability but has little effect on the epidemic dynamic once emergence is certain. The origin of heterogeneity also affects the probability of emergence, but its more striking effects are about properties of epidemics that do emerge. In particular, assuming more realistic variances in infection duration distributions lead to faster outbreaks and a higher peak of incidence. When the parasite requires evolutionary changes to be able to spread, the impact of heterogeneity depends on the underlying evolutionary model. If the parasite evolves within the host, decreasing the infection duration variance decreases the probability of emergence. These results show that using realistic distributions for infection duration is necessary to accurately capture the effect of individual heterogeneity on epidemiological dynamics, which has implications for the monitoring and control of infectious diseases, as well as data collection.</abstractText><pubTypeList><pubType>Preprint</pubType></pubTypeList><bookOrReportDetails><publisher>medRxiv</publisher><yearOfPublication>2021</yearOfPublication></bookOrReportDetails><fullTextUrlList><fullTextUrl><availability>Subscription required</availability><availabilityCode>S</availabilityCode><documentStyle>doi</documentStyle><site>DOI</site><url>https://doi.org/10.1101/2021.02.18.21251983</url></fullTextUrl></fullTextUrlList><isOpenAccess>N</isOpenAccess><inEPMC>N</inEPMC><inPMC>N</inPMC><hasPDF>N</hasPDF><hasBook>N</hasBook><hasSuppl>N</hasSuppl><citedByCount>0</citedByCount><hasData>N</hasData><hasReferences>N</hasReferences><hasTextMinedTerms>Y</hasTextMinedTerms><hasDbCrossReferences>N</hasDbCrossReferences><hasLabsLinks>Y</hasLabsLinks><authMan>N</authMan><epmcAuthMan>N</epmcAuthMan><nihAuthMan>N</nihAuthMan><hasTMAccessionNumbers>N</hasTMAccessionNumbers><dateOfCreation>2021-02-22</dateOfCreation><firstIndexDate>2021-02-22</firstIndexDate><firstPublicationDate>2021-02-20</firstPublicationDate></result>
<result><id>PPR283602</id><source>PPR</source><doi>10.1101/2021.02.10.21251486</doi><title>Cytokine response following perturbation of the cervicovaginal milieu during HPV genital infection</title><authorString>Selinger C, Rahmoun M, Murall CL, Bernat C, Boué V, Bonneau M, Graf C, Grasset S, Groc S, Reynes J, Hirtz C, Jacobs N, Alizon S.</authorString><authorList><author><fullName>Selinger C</fullName><firstName>Christian</firstName><lastName>Selinger</lastName><initials>C</initials></author><author><fullName>Rahmoun M</fullName><firstName>Massilva</firstName><lastName>Rahmoun</lastName><initials>M</initials></author><author><fullName>Murall CL</fullName><firstName>Carmen Lia</firstName><lastName>Murall</lastName><initials>CL</initials></author><author><fullName>Bernat C</fullName><firstName>Claire</firstName><lastName>Bernat</lastName><initials>C</initials></author><author><fullName>Boué V</fullName><firstName>Vanina</firstName><lastName>Boué</lastName><initials>V</initials></author><author><fullName>Bonneau M</fullName><firstName>Marine</firstName><lastName>Bonneau</lastName><initials>M</initials></author><author><fullName>Graf C</fullName><firstName>Christelle</firstName><lastName>Graf</lastName><initials>C</initials></author><author><fullName>Grasset S</fullName><firstName>Sophie</firstName><lastName>Grasset</lastName><initials>S</initials></author><author><fullName>Groc S</fullName><firstName>Soraya</firstName><lastName>Groc</lastName><initials>S</initials></author><author><fullName>Reynes J</fullName><firstName>Jacques</firstName><lastName>Reynes</lastName><initials>J</initials></author><author><fullName>Hirtz C</fullName><firstName>Christophe</firstName><lastName>Hirtz</lastName><initials>C</initials></author><author><fullName>Jacobs N</fullName><firstName>Nathalie</firstName><lastName>Jacobs</lastName><initials>N</initials></author><author><fullName>Alizon S</fullName><firstName>Samuel</firstName><lastName>Alizon</lastName><initials>S</initials></author></authorList><dataLinksTagsList><dataLinkstag>altmetrics</dataLinkstag></dataLinksTagsList><pubYear>2021</pubYear><abstractText>Human papillomaviruses (HPVs) are the most oncogenic viruses known to human, causing nearly all cervical cancers worldwide. Highly prevalent in young, sexually active women, most HPV infections are cleared within 3 years, and only a minority of those infections persist and lead to cancer later in life. To better characterize the immuno-modulatory impact of early HPV infection and more generally perturbations of the cervicovaginal milieu, we measured changes in a panel of 20 cytokines, known as highly dynamic effector molecules implicated in cell signaling. We analyzed 92 cervicovaginal samples collected from young, sexually active women who were tested for or diagnosed with HPV, chlamydia, and bacterial vaginosis. Also, symptoms associated with genital inflammation and infection were collected through self-reporting. Following a parsimonious multi-factor modeling approach, our statistical analyses revealed that increased IL-1Alpha and IL-12/IL-23p40 concentrations were associated with HPV infection. Cytokine network analysis further highlighted the role of IL-1Alpha and macrophage inflammatory proteins (MIP-3Alpha) in HPV-associated immuno-modulation.</abstractText><pubTypeList><pubType>Preprint</pubType></pubTypeList><bookOrReportDetails><publisher>medRxiv</publisher><yearOfPublication>2021</yearOfPublication></bookOrReportDetails><fullTextUrlList><fullTextUrl><availability>Subscription required</availability><availabilityCode>S</availabilityCode><documentStyle>doi</documentStyle><site>DOI</site><url>https://doi.org/10.1101/2021.02.10.21251486</url></fullTextUrl></fullTextUrlList><isOpenAccess>N</isOpenAccess><inEPMC>N</inEPMC><inPMC>N</inPMC><hasPDF>N</hasPDF><hasBook>N</hasBook><hasSuppl>N</hasSuppl><citedByCount>0</citedByCount><hasData>N</hasData><hasReferences>N</hasReferences><hasTextMinedTerms>Y</hasTextMinedTerms><hasDbCrossReferences>N</hasDbCrossReferences><hasLabsLinks>Y</hasLabsLinks><authMan>N</authMan><epmcAuthMan>N</epmcAuthMan><nihAuthMan>N</nihAuthMan><hasTMAccessionNumbers>N</hasTMAccessionNumbers><dateOfCreation>2021-02-17</dateOfCreation><firstIndexDate>2021-02-17</firstIndexDate><firstPublicationDate>2021-02-16</firstPublicationDate></result>
<result><id>PPR247306</id><source>PPR</source><fullTextIdList><fullTextId>PPR247306</fullTextId></fullTextIdList><doi>10.1101/2020.11.27.20239913</doi><title>Wearing masks and establishing COVID-19 areas reduces secondary attack risk in nursing homes</title><authorString>Reyné B, Selinger C, Sofonea MT, Miot S, Pisoni A, Tuaillon E, Bousquet J, Blain H, Alizon S.</authorString><authorList><author><fullName>Reyné B</fullName><firstName>Bastien</firstName><lastName>Reyné</lastName><initials>B</initials></author><author><fullName>Selinger C</fullName><firstName>Christian</firstName><lastName>Selinger</lastName><initials>C</initials></author><author><fullName>Sofonea MT</fullName><firstName>Mircea</firstName><lastName>Sofonea</lastName><initials>MT</initials></author><author><fullName>Miot S</fullName><firstName>Stéphanie</firstName><lastName>Miot</lastName><initials>S</initials></author><author><fullName>Pisoni A</fullName><firstName>Amandine</firstName><lastName>Pisoni</lastName><initials>A</initials></author><author><fullName>Tuaillon E</fullName><firstName>Edouard</firstName><lastName>Tuaillon</lastName><initials>E</initials><authorId type="ORCID">0000-0001-5866-9530</authorId></author><author><fullName>Bousquet J</fullName><firstName>Jean</firstName><lastName>Bousquet</lastName><initials>J</initials></author><author><fullName>Blain H</fullName><firstName>Hubert</firstName><lastName>Blain</lastName><initials>H</initials></author><author><fullName>Alizon S</fullName><firstName>Samuel</firstName><lastName>Alizon</lastName><initials>S</initials><authorId type="ORCID">0000-0002-0779-9543</authorId></author></authorList><authorIdList><authorId type="ORCID">0000-0001-5866-9530</authorId><authorId type="ORCID">0000-0002-0779-9543</authorId></authorIdList><dataLinksTagsList><dataLinkstag>altmetrics</dataLinkstag></dataLinksTagsList><pubYear>2020</pubYear><abstractText>&lt;h4&gt;Background&lt;/h4&gt; COVID-19 is spreading rapidly in nursing homes (NHs). It is urgent to evaluate the effect of infection prevention and control (IPC) measures to reduce COVID spreading. &lt;h4&gt;Methods&lt;/h4&gt; We analysed COVID-19 outbreaks in 12 NH using rRT-PCR for SARS-CoV-2. We estimated secondary attack risks (SARs) and identified cofactors associated with the proportion of infected residents. &lt;h4&gt;Results&lt;/h4&gt; The SAR was below 5%, suggesting a high efficiency of IPC measures. Mask-wearing or establishment of COVID-19 zones for infected residents were associated with lower SAR. &lt;h4&gt;Conclusions&lt;/h4&gt; Wearing masks and isolating potentially infected residents appear to limit SARS-CoV-2 spread in nursing homes.</abstractText><pubTypeList><pubType>Preprint</pubType></pubTypeList><bookOrReportDetails><publisher>medRxiv</publisher><yearOfPublication>2020</yearOfPublication></bookOrReportDetails><fullTextUrlList><fullTextUrl><availability>Subscription required</availability><availabilityCode>S</availabilityCode><documentStyle>doi</documentStyle><site>DOI</site><url>https://doi.org/10.1101/2020.11.27.20239913</url></fullTextUrl><fullTextUrl><availability>Open access</availability><availabilityCode>OA</availabilityCode><documentStyle>html</documentStyle><site>Europe_PMC</site><url>https://europepmc.org/article/PPR/PPR247306</url></fullTextUrl><fullTextUrl><availability>Open access</availability><availabilityCode>OA</availabilityCode><documentStyle>pdf</documentStyle><site>Europe_PMC</site><url>https://europepmc.org/api/fulltextRepo?pprId=PPR247306&amp;type=FILE&amp;fileName=EMS107604-pdf.pdf&amp;mimeType=application/pdf</url></fullTextUrl></fullTextUrlList><isOpenAccess>Y</isOpenAccess><inEPMC>Y</inEPMC><inPMC>N</inPMC><hasPDF>Y</hasPDF><hasBook>N</hasBook><hasSuppl>Y</hasSuppl><citedByCount>0</citedByCount><hasData>N</hasData><hasReferences>N</hasReferences><hasTextMinedTerms>Y</hasTextMinedTerms><hasDbCrossReferences>N</hasDbCrossReferences><hasLabsLinks>Y</hasLabsLinks><authMan>N</authMan><epmcAuthMan>N</epmcAuthMan><nihAuthMan>N</nihAuthMan><hasTMAccessionNumbers>N</hasTMAccessionNumbers><dateOfCreation>2020-12-03</dateOfCreation><firstIndexDate>2020-12-03</firstIndexDate><fullTextReceivedDate>2020-12-26</fullTextReceivedDate><firstPublicationDate>2020-12-02</firstPublicationDate></result>
<result><id>33168348</id><source>MED</source><pmid>33168348</pmid><doi>10.1016/j.vaccine.2020.10.078</doi><title>HPV cervical infections and serological status in vaccinated and unvaccinated women.</title><authorString>Murall CL, Reyné B, Selinger C, Bernat C, Boué V, Grasset S, Groc S, Rahmoun M, Bender N, Bonneau M, Foulongne V, Graf C, Picot E, Picot MC, Tribout V, Waterboer T, Bravo IG, Reynes J, Segondy M, Boulle N, Alizon S.</authorString><authorList><author><fullName>Murall CL</fullName><firstName>Carmen Lía</firstName><lastName>Murall</lastName><initials>CL</initials><authorAffiliationDetailsList><authorAffiliation><affiliation>Laboratoire MIVEGEC (UMR CNRS 5290, IRD 224, UM), Montpellier, France.</affiliation></authorAffiliation></authorAffiliationDetailsList></author><author><fullName>Reyné B</fullName><firstName>Bastien</firstName><lastName>Reyné</lastName><initials>B</initials><authorAffiliationDetailsList><authorAffiliation><affiliation>Laboratoire MIVEGEC (UMR CNRS 5290, IRD 224, UM), Montpellier, France.</affiliation></authorAffiliation></authorAffiliationDetailsList></author><author><fullName>Selinger C</fullName><firstName>Christian</firstName><lastName>Selinger</lastName><initials>C</initials><authorAffiliationDetailsList><authorAffiliation><affiliation>Laboratoire MIVEGEC (UMR CNRS 5290, IRD 224, UM), Montpellier, France.</affiliation></authorAffiliation></authorAffiliationDetailsList></author><author><fullName>Bernat C</fullName><firstName>Claire</firstName><lastName>Bernat</lastName><initials>C</initials><authorAffiliationDetailsList><authorAffiliation><affiliation>Laboratoire MIVEGEC (UMR CNRS 5290, IRD 224, UM), Montpellier, France.</affiliation></authorAffiliation></authorAffiliationDetailsList></author><author><fullName>Boué V</fullName><firstName>Vanina</firstName><lastName>Boué</lastName><initials>V</initials><authorAffiliationDetailsList><authorAffiliation><affiliation>Laboratoire MIVEGEC (UMR CNRS 5290, IRD 224, UM), Montpellier, France.</affiliation></authorAffiliation></authorAffiliationDetailsList></author><author><fullName>Grasset S</fullName><firstName>Sophie</firstName><lastName>Grasset</lastName><initials>S</initials><authorAffiliationDetailsList><authorAffiliation><affiliation>Laboratoire MIVEGEC (UMR CNRS 5290, IRD 224, UM), Montpellier, France.</affiliation></authorAffiliation></authorAffiliationDetailsList></author><author><fullName>Groc S</fullName><firstName>Soraya</firstName><lastName>Groc</lastName><initials>S</initials><authorAffiliationDetailsList><authorAffiliation><affiliation>Laboratoire MIVEGEC (UMR CNRS 5290, IRD 224, UM), Montpellier, France.</affiliation></authorAffiliation></authorAffiliationDetailsList></author><author><fullName>Rahmoun M</fullName><firstName>Massilva</firstName><lastName>Rahmoun</lastName><initials>M</initials><authorAffiliationDetailsList><authorAffiliation><affiliation>Laboratoire MIVEGEC (UMR CNRS 5290, IRD 224, UM), Montpellier, France.</affiliation></authorAffiliation></authorAffiliationDetailsList></author><author><fullName>Bender N</fullName><firstName>Noemi</firstName><lastName>Bender</lastName><initials>N</initials><authorId type="ORCID">0000-0003-2542-9949</authorId><authorAffiliationDetailsList><authorAffiliation><affiliation>German Cancer Research Center (DKFZ), Infections and Cancer Epidemiology, Im Neuenheimer Feld 280, Heidelberg, Germany.</affiliation></authorAffiliation></authorAffiliationDetailsList></author><author><fullName>Bonneau M</fullName><firstName>Marine</firstName><lastName>Bonneau</lastName><initials>M</initials><authorAffiliationDetailsList><authorAffiliation><affiliation>Department of Obstetrics and Gynaecology, Centre Hospitalier Universitaire de Montpellier, Unversity of Montpellier, France.</affiliation></authorAffiliation></authorAffiliationDetailsList></author><author><fullName>Foulongne V</fullName><firstName>Vincent</firstName><lastName>Foulongne</lastName><initials>V</initials><authorAffiliationDetailsList><authorAffiliation><affiliation>Department of Biology &amp; Pathology, Centre Hospitalier Universitaire de Montpellier, Montpellier, France.</affiliation></authorAffiliation></authorAffiliationDetailsList></author><author><fullName>Graf C</fullName><firstName>Christelle</firstName><lastName>Graf</lastName><initials>C</initials><authorAffiliationDetailsList><authorAffiliation><affiliation>Department of Obstetrics and Gynaecology, Centre Hospitalier Universitaire de Montpellier, Unversity of Montpellier, France.</affiliation></authorAffiliation></authorAffiliationDetailsList></author><author><fullName>Picot E</fullName><firstName>Eric</firstName><lastName>Picot</lastName><initials>E</initials><authorAffiliationDetailsList><authorAffiliation><affiliation>Center for Free Information, Screening and Diagnosis (CeGIDD), Centre Hospitalier Universitaire de Montpellier, Montpellier, France.</affiliation></authorAffiliation></authorAffiliationDetailsList></author><author><fullName>Picot MC</fullName><firstName>Marie-Christine</firstName><lastName>Picot</lastName><initials>MC</initials><authorAffiliationDetailsList><authorAffiliation><affiliation>Department of Medical Information (DIM), Centre Hospitalier Universitaire de Montpellier, Montpellier, France.</affiliation></authorAffiliation></authorAffiliationDetailsList></author><author><fullName>Tribout V</fullName><firstName>Vincent</firstName><lastName>Tribout</lastName><initials>V</initials><authorAffiliationDetailsList><authorAffiliation><affiliation>Center for Free Information, Screening and Diagnosis (CeGIDD), Centre Hospitalier Universitaire de Montpellier, Montpellier, France.</affiliation></authorAffiliation></authorAffiliationDetailsList></author><author><fullName>Waterboer T</fullName><firstName>Tim</firstName><lastName>Waterboer</lastName><initials>T</initials><authorAffiliationDetailsList><authorAffiliation><affiliation>German Cancer Research Center (DKFZ), Infections and Cancer Epidemiology, Im Neuenheimer Feld 280, Heidelberg, Germany.</affiliation></authorAffiliation></authorAffiliationDetailsList></author><author><fullName>Bravo IG</fullName><firstName>Ignacio G</firstName><lastName>Bravo</lastName><initials>IG</initials><authorId type="ORCID">0000-0003-3389-3389</authorId><authorAffiliationDetailsList><authorAffiliation><affiliation>Laboratoire MIVEGEC (UMR CNRS 5290, IRD 224, UM), Montpellier, France.</affiliation></authorAffiliation></authorAffiliationDetailsList></author><author><fullName>Reynes J</fullName><firstName>Jacques</firstName><lastName>Reynes</lastName><initials>J</initials><authorAffiliationDetailsList><authorAffiliation><affiliation>Department of Infectious and Tropical Diseases, Centre Hospitalier Universitaire de Montpellier, Montpellier, France.</affiliation></authorAffiliation></authorAffiliationDetailsList></author><author><fullName>Segondy M</fullName><firstName>Michel</firstName><lastName>Segondy</lastName><initials>M</initials><authorAffiliationDetailsList><authorAffiliation><affiliation>Department of Biology &amp; Pathology, Centre Hospitalier Universitaire de Montpellier, Montpellier, France.</affiliation></authorAffiliation></authorAffiliationDetailsList></author><author><fullName>Boulle N</fullName><firstName>Nathalie</firstName><lastName>Boulle</lastName><initials>N</initials><authorAffiliationDetailsList><authorAffiliation><affiliation>Department of Biology &amp; Pathology, Centre Hospitalier Universitaire de Montpellier, Montpellier, France.</affiliation></authorAffiliation></authorAffiliationDetailsList></author><author><fullName>Alizon S</fullName><firstName>Samuel</firstName><lastName>Alizon</lastName><initials>S</initials><authorAffiliationDetailsList><authorAffiliation><affiliation>Laboratoire MIVEGEC (UMR CNRS 5290, IRD 224, UM), Montpellier, France. Electronic address: samuel.alizon@cnrs.fr.</affiliation></authorAffiliation></authorAffiliationDetailsList></author></authorList><authorIdList><authorId type="ORCID">0000-0003-2542-9949</authorId><authorId type="ORCID">0000-0003-3389-3389</authorId></authorIdList><dataLinksTagsList><dataLinkstag>altmetrics</dataLinkstag></dataLinksTagsList><journalInfo><issue>51</issue><volume>38</volume><journalIssueId>3057763</journalIssueId><dateOfPublication>2020 Dec</dateOfPublication><monthOfPublication>12</monthOfPublication><yearOfPublication>2020</yearOfPublication><printPublicationDate>2020-12-01</printPublicationDate><journal><title>Vaccine</title><ISOAbbreviation>Vaccine</ISOAbbreviation><medlineAbbreviation>Vaccine</medlineAbbreviation><NLMid>8406899</NLMid><ISSN>0264-410X</ISSN><ESSN>1873-2518</ESSN></journal></journalInfo><pubYear>2020</pubYear><pageInfo>8167-8174</pageInfo><abstractText>Understanding genital infections by Human papillomaviruses (HPVs) remains a major public health issue, especially in countries where vaccine uptake is low. We investigate HPV prevalence and antibody status in 150 women (ages 18 to 25) in Montpellier, France. At inclusion and one month later, cervical swabs, blood samples and questionnaires (for demographics and behavioural variables) were collected. Oncogenic, non-vaccine genotypes HPV51, HPV66, HPV53, and HPV52 were the most frequently detected viral genotypes overall. Vaccination status, which was well-balanced in the cohort, showed the strongest (protective) effect against HPV infections, with an associated odds ratio for alphapapillomavirus detection of 0.45 (95% confidence interval: [0.22;0.58]). We also identified significant effects of age, number of partners, body mass index, and contraception status on HPV detection and on coinfections. Type-specific IgG serological status was also largely explained by the vaccination status. IgM seropositivity was best explained by HPV detection at inclusion only. Finally, we identify a strong significant effect of vaccination on genotype prevalence, with a striking under-representation of HPV51 in vaccinated women. Variations in HPV prevalence correlate with key demographic and behavioural variables. The cross-protective effect of the vaccine against HPV51 merits further investigation.</abstractText><affiliation>Laboratoire MIVEGEC (UMR CNRS 5290, IRD 224, UM), Montpellier, France.</affiliation><publicationStatus>ppublish</publicationStatus><language>eng</language><pubModel>Print-Electronic</pubModel><pubTypeList><pubType>Research Support, Non-U.S. Gov't</pubType><pubType>Journal Article</pubType></pubTypeList><keywordList><keyword>Serology</keyword><keyword>Vaccination</keyword><keyword>HPV</keyword><keyword>Cross-protection</keyword><keyword>Acute Infections</keyword><keyword>Genital Infections</keyword></keywordList><subsetList><subset><code>IM</code><name>Index Medicus</name></subset></subsetList><fullTextUrlList><fullTextUrl><availability>Subscription required</availability><availabilityCode>S</availabilityCode><documentStyle>doi</documentStyle><site>DOI</site><url>https://doi.org/10.1016/j.vaccine.2020.10.078</url></fullTextUrl></fullTextUrlList><commentCorrectionList><commentCorrection><id>PPR184348</id><source>PPR</source><type>Preprint in</type><note>CrossRef Pre-print loader</note><orderIn>10002</orderIn></commentCorrection></commentCorrectionList><isOpenAccess>N</isOpenAccess><inEPMC>N</inEPMC><inPMC>N</inPMC><hasPDF>N</hasPDF><hasBook>N</hasBook><hasSuppl>N</hasSuppl><citedByCount>1</citedByCount><hasData>N</hasData><hasReferences>N</hasReferences><hasTextMinedTerms>Y</hasTextMinedTerms><hasDbCrossReferences>N</hasDbCrossReferences><hasLabsLinks>Y</hasLabsLinks><authMan>N</authMan><epmcAuthMan>N</epmcAuthMan><nihAuthMan>N</nihAuthMan><hasTMAccessionNumbers>N</hasTMAccessionNumbers><dateOfCreation>2020-11-10</dateOfCreation><firstIndexDate>2020-11-11</firstIndexDate><dateOfRevision>2021-02-01</dateOfRevision><electronicPublicationDate>2020-11-07</electronicPublicationDate><firstPublicationDate>2020-11-07</firstPublicationDate></result>
<result><id>33163106</id><source>MED</source><pmid>33163106</pmid><pmcid>PMC7604046</pmcid><fullTextIdList><fullTextId>PMC7604046</fullTextId></fullTextIdList><doi>10.1016/s1773-035x(20)30315-4</doi><title>[Mathematical epidemiology and modeling of the Covid-19 pandemic: issues and diversity].</title><authorString>Djidjou-Demasse R, Selinger C, Sofonea MT.</authorString><authorList><author><fullName>Djidjou-Demasse R</fullName><firstName>Ramsès</firstName><lastName>Djidjou-Demasse</lastName><initials>R</initials><authorId type="ORCID">0000-0003-1684-5190</authorId><authorAffiliationDetailsList><authorAffiliation><affiliation>Maladies infectieuses et vecteurs : écologie, génétique, évolution et contrôle (Mivegec), université de Montpellier, CNRS, IRD, 39 Avenue Charles-Flahault, 34090 Montpellier, France.</affiliation></authorAffiliation></authorAffiliationDetailsList></author><author><fullName>Selinger C</fullName><firstName>Christian</firstName><lastName>Selinger</lastName><initials>C</initials><authorAffiliationDetailsList><authorAffiliation><affiliation>Maladies infectieuses et vecteurs : écologie, génétique, évolution et contrôle (Mivegec), université de Montpellier, CNRS, IRD, 39 Avenue Charles-Flahault, 34090 Montpellier, France.</affiliation></authorAffiliation></authorAffiliationDetailsList></author><author><fullName>Sofonea MT</fullName><firstName>Mircea T</firstName><lastName>Sofonea</lastName><initials>MT</initials><authorAffiliationDetailsList><authorAffiliation><affiliation>Maladies infectieuses et vecteurs : écologie, génétique, évolution et contrôle (Mivegec), université de Montpellier, CNRS, IRD, 39 Avenue Charles-Flahault, 34090 Montpellier, France.</affiliation></authorAffiliation></authorAffiliationDetailsList></author></authorList><authorIdList><authorId type="ORCID">0000-0003-1684-5190</authorId></authorIdList><dataLinksTagsList><dataLinkstag>altmetrics</dataLinkstag></dataLinksTagsList><journalInfo><issue>526</issue><volume>2020</volume><journalIssueId>3050842</journalIssueId><dateOfPublication>2020 Nov</dateOfPublication><monthOfPublication>11</monthOfPublication><yearOfPublication>2020</yearOfPublication><printPublicationDate>2020-11-01</printPublicationDate><journal><title>Revue francophone des laboratoires : RFL</title><ISOAbbreviation>Rev Francoph Lab</ISOAbbreviation><medlineAbbreviation>Rev Francoph Lab</medlineAbbreviation><NLMid>101264920</NLMid><ISSN>1773-035X</ISSN><ESSN>1773-0368</ESSN></journal></journalInfo><pubYear>2020</pubYear><pageInfo>63-69</pageInfo><abstractText>During the COVID-19 pandemic, the field of mathematical epidemiology experienced an exceptional production and media coverage of its work. Even though data and knowledge on the emerging disease were patchy, a wide variety of models were developed and applied in unprecedented timeframes, with the aim of estimating the reproduction number, the starting date of the epidemic or the cumulative incidence, but also to explore different scenarios of non-pharmaceutical interventions. Their results have made a major contribution to epidemiological surveillance and informed public health policy decisions.</abstractText><affiliation>Maladies infectieuses et vecteurs : écologie, génétique, évolution et contrôle (Mivegec), université de Montpellier, CNRS, IRD, 39 Avenue Charles-Flahault, 34090 Montpellier, France.</affiliation><publicationStatus>ppublish</publicationStatus><language>fre</language><pubModel>Print-Electronic</pubModel><pubTypeList><pubType>research-article</pubType><pubType>Journal Article</pubType><pubType>English Abstract</pubType></pubTypeList><keywordList><keyword>Statistics</keyword><keyword>epidemiology</keyword><keyword>Modelling</keyword><keyword>Reproduction Number</keyword><keyword>Covid-19</keyword></keywordList><fullTextUrlList><fullTextUrl><availability>Subscription required</availability><availabilityCode>S</availabilityCode><documentStyle>doi</documentStyle><site>DOI</site><url>https://doi.org/10.1016/S1773-035X(20)30315-4</url></fullTextUrl><fullTextUrl><availability>Open access</availability><availabilityCode>OA</availabilityCode><documentStyle>html</documentStyle><site>Europe_PMC</site><url>https://europepmc.org/articles/PMC7604046</url></fullTextUrl><fullTextUrl><availability>Open access</availability><availabilityCode>OA</availabilityCode><documentStyle>pdf</documentStyle><site>Europe_PMC</site><url>https://europepmc.org/articles/PMC7604046?pdf=render</url></fullTextUrl></fullTextUrlList><isOpenAccess>Y</isOpenAccess><inEPMC>Y</inEPMC><inPMC>N</inPMC><hasPDF>Y</hasPDF><hasBook>N</hasBook><hasSuppl>N</hasSuppl><citedByCount>0</citedByCount><hasData>N</hasData><hasReferences>N</hasReferences><hasTextMinedTerms>Y</hasTextMinedTerms><hasDbCrossReferences>N</hasDbCrossReferences><hasLabsLinks>Y</hasLabsLinks><authMan>N</authMan><epmcAuthMan>N</epmcAuthMan><nihAuthMan>N</nihAuthMan><hasTMAccessionNumbers>N</hasTMAccessionNumbers><dateOfCreation>2020-11-09</dateOfCreation><firstIndexDate>2020-11-10</firstIndexDate><fullTextReceivedDate>2020-11-06</fullTextReceivedDate><dateOfRevision>2020-11-12</dateOfRevision><electronicPublicationDate>2020-10-31</electronicPublicationDate><firstPublicationDate>2020-10-31</firstPublicationDate></result>
<result><id>PPR166839</id><source>PPR</source><fullTextIdList><fullTextId>PPR166839</fullTextId></fullTextIdList><doi>10.1101/2020.05.22.20110593</doi><title>Epidemiological monitoring and control perspectives: application of a parsimonious modelling framework to the COVID-19 dynamics in France</title><authorString>Sofonea MT, Reyné B, Elie B, Djidjou-Demasse R, Selinger C, Michalakis Y, Alizon S.</authorString><authorList><author><fullName>Sofonea MT</fullName><firstName>Mircea</firstName><lastName>Sofonea</lastName><initials>MT</initials><authorId type="ORCID">0000-0002-4499-0435</authorId></author><author><fullName>Reyné B</fullName><firstName>Bastien</firstName><lastName>Reyné</lastName><initials>B</initials></author><author><fullName>Elie B</fullName><firstName>Baptiste</firstName><lastName>Elie</lastName><initials>B</initials></author><author><fullName>Djidjou-Demasse R</fullName><firstName>Ramsès</firstName><lastName>Djidjou-Demasse</lastName><initials>R</initials><authorId type="ORCID">0000-0003-1684-5190</authorId></author><author><fullName>Selinger C</fullName><firstName>Christian</firstName><lastName>Selinger</lastName><initials>C</initials></author><author><fullName>Michalakis Y</fullName><firstName>Yannis</firstName><lastName>Michalakis</lastName><initials>Y</initials></author><author><fullName>Alizon S</fullName><firstName>Samuel</firstName><lastName>Alizon</lastName><initials>S</initials><authorId type="ORCID">0000-0002-0779-9543</authorId></author></authorList><authorIdList><authorId type="ORCID">0000-0002-0779-9543</authorId><authorId type="ORCID">0000-0002-4499-0435</authorId><authorId type="ORCID">0000-0003-1684-5190</authorId></authorIdList><dataLinksTagsList><dataLinkstag>altmetrics</dataLinkstag></dataLinksTagsList><pubYear>2020</pubYear><abstractText>SARS-Cov-2 virus has spread over the world creating one of the fastest pandemics ever. The absence of immunity, asymptomatic transmission, and the relatively high level of virulence of the COVID-19 infection it causes led to a massive flow of patients in intensive care units (ICU). This unprecedented situation calls for rapid and accurate mathematical models to best inform public health policies. We develop an original parsimonious model that accounts for the effect of the age of infection on the natural history of the disease. Analysing the ongoing COVID-19 in France, we estimate the value of the key epidemiological parameters, such as the basic reproduction number , and the efficiency of the national control strategy. We then use our deterministic model to explore several scenarios posterior to lock-down lifting and compare the efficiency of non pharmaceutical interventions (NPI) described in the literature.</abstractText><pubTypeList><pubType>Preprint</pubType></pubTypeList><bookOrReportDetails><publisher>medRxiv</publisher><yearOfPublication>2020</yearOfPublication></bookOrReportDetails><fullTextUrlList><fullTextUrl><availability>Subscription required</availability><availabilityCode>S</availabilityCode><documentStyle>doi</documentStyle><site>DOI</site><url>https://doi.org/10.1101/2020.05.22.20110593</url></fullTextUrl><fullTextUrl><availability>Free</availability><availabilityCode>F</availabilityCode><documentStyle>html</documentStyle><site>Europe_PMC</site><url>https://europepmc.org/article/PPR/PPR166839</url></fullTextUrl><fullTextUrl><availability>Free</availability><availabilityCode>F</availabilityCode><documentStyle>doi</documentStyle><site>DOI</site><url>https://doi.org/10.1101/2020.05.22.20110593</url></fullTextUrl></fullTextUrlList><isOpenAccess>N</isOpenAccess><inEPMC>N</inEPMC><inPMC>N</inPMC><hasPDF>N</hasPDF><hasBook>N</hasBook><hasSuppl>Y</hasSuppl><citedByCount>0</citedByCount><hasData>N</hasData><hasReferences>N</hasReferences><hasTextMinedTerms>Y</hasTextMinedTerms><hasDbCrossReferences>N</hasDbCrossReferences><hasLabsLinks>Y</hasLabsLinks><authMan>N</authMan><epmcAuthMan>N</epmcAuthMan><nihAuthMan>N</nihAuthMan><hasTMAccessionNumbers>N</hasTMAccessionNumbers><dateOfCreation>2020-05-26</dateOfCreation><firstIndexDate>2020-05-26</firstIndexDate><fullTextReceivedDate>2020-09-16</fullTextReceivedDate><firstPublicationDate>2020-05-24</firstPublicationDate></result>
<result><id>PPR85558</id><source>PPR</source><doi>10.1101/701946</doi><title>Using multiple infection history to infer contact network structure</title><authorString>Selinger C, Alizon S.</authorString><authorList><author><fullName>Selinger C</fullName><firstName>Christian</firstName><lastName>Selinger</lastName><initials>C</initials></author><author><fullName>Alizon S</fullName><firstName>Samuel</firstName><lastName>Alizon</lastName><initials>S</initials></author></authorList><dataLinksTagsList><dataLinkstag>altmetrics</dataLinkstag></dataLinksTagsList><pubYear>2019</pubYear><abstractText>The structure of host interactions within a population shapes the spread of infectious diseases but contact patterns between hosts are difficult to access. We hypothesised that key properties of these patterns can be inferred by using multiple infections data from individual longitudinal follow-ups. To show this, we simulated multiple infections on a contact network in an unbiased way by implementing a non-Markovian extension of the Gillespie algorithm for a community of parasites spreading on this network. We then analysed the resulting individual infection time series in an original way by introducing the concept of ‘infection barcodes’ to represent the infection history in each host. We find that, depending on infection multiplicity and immunity assumptions, knowledge about the barcode topology makes it possible to recover key properties of the network topology and even of individual nodes. The combination of individual-based simulations and barcode analysis of infection histories opens promising perspectives for the study of infectious disease transmission networks. &lt;h4&gt;Significance Statement&lt;/h4&gt; The way hosts interact with each other is known to shape epidemics spread. However, these interactions are difficult to infer, especially in human populations. Using recent developments in stochastic epidemiological modeling and barcode theory, we show that the diversity of infections each host has undergone over time contains key information about contact network between hosts. This means that longitudinal follow-ups of some individuals in a population can tell us how hosts are in contact with each other. It can also inform us on how connected a particular individual is. This opens new possibilities regarding the use of genetic diversity of infectious diseases in epidemiology.</abstractText><pubTypeList><pubType>Preprint</pubType></pubTypeList><bookOrReportDetails><publisher>bioRxiv</publisher><yearOfPublication>2019</yearOfPublication></bookOrReportDetails><fullTextUrlList><fullTextUrl><availability>Subscription required</availability><availabilityCode>S</availabilityCode><documentStyle>doi</documentStyle><site>DOI</site><url>https://doi.org/10.1101/701946</url></fullTextUrl></fullTextUrlList><isOpenAccess>N</isOpenAccess><inEPMC>N</inEPMC><inPMC>N</inPMC><hasPDF>N</hasPDF><hasBook>N</hasBook><hasSuppl>N</hasSuppl><citedByCount>0</citedByCount><hasData>N</hasData><hasReferences>N</hasReferences><hasTextMinedTerms>Y</hasTextMinedTerms><hasDbCrossReferences>N</hasDbCrossReferences><hasLabsLinks>Y</hasLabsLinks><authMan>N</authMan><epmcAuthMan>N</epmcAuthMan><nihAuthMan>N</nihAuthMan><hasTMAccessionNumbers>N</hasTMAccessionNumbers><dateOfCreation>2019-07-16</dateOfCreation><firstIndexDate>2019-07-16</firstIndexDate><firstPublicationDate>2019-07-13</firstPublicationDate></result>
<result><id>31189673</id><source>MED</source><pmid>31189673</pmid><pmcid>PMC6576111</pmcid><fullTextIdList><fullTextId>PMC6576111</fullTextId></fullTextIdList><doi>10.1136/bmjopen-2018-025129</doi><title>Natural history, dynamics, and ecology of human papillomaviruses in genital infections of young women: protocol of the PAPCLEAR cohort study.</title><authorString>Murall CL, Rahmoun M, Selinger C, Baldellou M, Bernat C, Bonneau M, Boué V, Buisson M, Christophe G, D'Auria G, Taroni F, Foulongne V, Froissart R, Graf C, Grasset S, Groc S, Hirtz C, Jaussent A, Lajoie J, Lorcy F, Picot E, Picot MC, Ravel J, Reynes J, Rousset T, Seddiki A, Teirlinck M, Tribout V, Tuaillon É, Waterboer T, Jacobs N, Bravo IG, Segondy M, Boulle N, Alizon S.</authorString><authorList><author><fullName>Murall CL</fullName><firstName>Carmen Lía</firstName><lastName>Murall</lastName><initials>CL</initials><authorAffiliationDetailsList><authorAffiliation><affiliation>MIVEGEC (UMR 5290 CNRS, IRD, UM), CNRS, Montpellier, France.</affiliation></authorAffiliation></authorAffiliationDetailsList></author><author><fullName>Rahmoun M</fullName><firstName>Massilva</firstName><lastName>Rahmoun</lastName><initials>M</initials><authorAffiliationDetailsList><authorAffiliation><affiliation>MIVEGEC (UMR 5290 CNRS, IRD, UM), CNRS, Montpellier, France.</affiliation></authorAffiliation></authorAffiliationDetailsList></author><author><fullName>Selinger C</fullName><firstName>Christian</firstName><lastName>Selinger</lastName><initials>C</initials><authorAffiliationDetailsList><authorAffiliation><affiliation>MIVEGEC (UMR 5290 CNRS, IRD, UM), CNRS, Montpellier, France.</affiliation></authorAffiliation></authorAffiliationDetailsList></author><author><fullName>Baldellou M</fullName><firstName>Monique</firstName><lastName>Baldellou</lastName><initials>M</initials><authorAffiliationDetailsList><authorAffiliation><affiliation>Center for Free Information, Screening and Diagnosis (CGIDD), Centre Hospitalier Universitaire de Montpellier, Montpellier, France.</affiliation></authorAffiliation></authorAffiliationDetailsList></author><author><fullName>Bernat C</fullName><firstName>Claire</firstName><lastName>Bernat</lastName><initials>C</initials><authorAffiliationDetailsList><authorAffiliation><affiliation>MIVEGEC (UMR 5290 CNRS, IRD, UM), CNRS, Montpellier, France.</affiliation></authorAffiliation></authorAffiliationDetailsList></author><author><fullName>Bonneau M</fullName><firstName>Marine</firstName><lastName>Bonneau</lastName><initials>M</initials><authorAffiliationDetailsList><authorAffiliation><affiliation>Department of Obstetrics and Gynaecology, Centre Hospitalier Universitaire de Montpellier, Montpellier, France.</affiliation></authorAffiliation></authorAffiliationDetailsList></author><author><fullName>Boué V</fullName><firstName>Vanina</firstName><lastName>Boué</lastName><initials>V</initials><authorAffiliationDetailsList><authorAffiliation><affiliation>MIVEGEC (UMR 5290 CNRS, IRD, UM), CNRS, Montpellier, France.</affiliation></authorAffiliation></authorAffiliationDetailsList></author><author><fullName>Buisson M</fullName><firstName>Mathilde</firstName><lastName>Buisson</lastName><initials>M</initials><authorAffiliationDetailsList><authorAffiliation><affiliation>Department of Research and Innovation (DRI), Centre Hospitalier Universitaire de Montpellier, Montpellier, France.</affiliation></authorAffiliation></authorAffiliationDetailsList></author><author><fullName>Christophe G</fullName><firstName>Guillaume</firstName><lastName>Christophe</lastName><initials>G</initials><authorAffiliationDetailsList><authorAffiliation><affiliation>Center for Free Information, Screening and Diagnosis (CGIDD), Centre Hospitalier Universitaire de Montpellier, Montpellier, France.</affiliation></authorAffiliation></authorAffiliationDetailsList></author><author><fullName>D'Auria G</fullName><firstName>Giuseppe</firstName><lastName>D'Auria</lastName><initials>G</initials><authorId type="ORCID">0000-0003-0672-2541</authorId><authorAffiliationDetailsList><authorAffiliation><affiliation>CIBER en Epidemiología y Salud Pública (CIBEResp), Madrid, Spain.</affiliation></authorAffiliation><authorAffiliation><affiliation>Sequencing and Bioinformatics Service, Fundaciónpara el Fomento de la Investigación Sanitaria y Biomédica de laComunidad Valenciana (FISABIO-Salud Pública), Valencia, Spain.</affiliation></authorAffiliation></authorAffiliationDetailsList></author><author><fullName>Taroni F</fullName><firstName>Florence De</firstName><lastName>Taroni</lastName><initials>F</initials><authorAffiliationDetailsList><authorAffiliation><affiliation>Center for Free Information, Screening and Diagnosis (CGIDD), Centre Hospitalier Universitaire de Montpellier, Montpellier, France.</affiliation></authorAffiliation></authorAffiliationDetailsList></author><author><fullName>Foulongne V</fullName><firstName>Vincent</firstName><lastName>Foulongne</lastName><initials>V</initials><authorAffiliationDetailsList><authorAffiliation><affiliation>Pathogenesis and Control of Chronic Infections, INSERM, CHU, University of Montpellier, Montpellier, France.</affiliation></authorAffiliation><authorAffiliation><affiliation>Department of Virology, Centre Hospitalier Universitaire de Montpellier, Montpellier, France.</affiliation></authorAffiliation></authorAffiliationDetailsList></author><author><fullName>Froissart R</fullName><firstName>Rémy</firstName><lastName>Froissart</lastName><initials>R</initials><authorAffiliationDetailsList><authorAffiliation><affiliation>MIVEGEC (UMR 5290 CNRS, IRD, UM), CNRS, Montpellier, France.</affiliation></authorAffiliation></authorAffiliationDetailsList></author><author><fullName>Graf C</fullName><firstName>Christelle</firstName><lastName>Graf</lastName><initials>C</initials><authorAffiliationDetailsList><authorAffiliation><affiliation>Department of Obstetrics and Gynaecology, Centre Hospitalier Universitaire de Montpellier, Montpellier, France.</affiliation></authorAffiliation></authorAffiliationDetailsList></author><author><fullName>Grasset S</fullName><firstName>Sophie</firstName><lastName>Grasset</lastName><initials>S</initials><authorAffiliationDetailsList><authorAffiliation><affiliation>MIVEGEC (UMR 5290 CNRS, IRD, UM), CNRS, Montpellier, France.</affiliation></authorAffiliation><authorAffiliation><affiliation>Center for Free Information, Screening and Diagnosis (CGIDD), Centre Hospitalier Universitaire de Montpellier, Montpellier, France.</affiliation></authorAffiliation></authorAffiliationDetailsList></author><author><fullName>Groc S</fullName><firstName>Soraya</firstName><lastName>Groc</lastName><initials>S</initials><authorAffiliationDetailsList><authorAffiliation><affiliation>MIVEGEC (UMR 5290 CNRS, IRD, UM), CNRS, Montpellier, France.</affiliation></authorAffiliation><authorAffiliation><affiliation>Department of Virology, Centre Hospitalier Universitaire de Montpellier, Montpellier, France.</affiliation></authorAffiliation></authorAffiliationDetailsList></author><author><fullName>Hirtz C</fullName><firstName>Christophe</firstName><lastName>Hirtz</lastName><initials>C</initials><authorId type="ORCID">0000-0002-7313-0629</authorId><authorAffiliationDetailsList><authorAffiliation><affiliation>LBPC/PPC- IRMB, CHU de Montpellier and Université de Montpellier, Montpellier, France.</affiliation></authorAffiliation></authorAffiliationDetailsList></author><author><fullName>Jaussent A</fullName><firstName>Audrey</firstName><lastName>Jaussent</lastName><initials>A</initials><authorAffiliationDetailsList><authorAffiliation><affiliation>Department of Medical Information (DIM), Centre Hospitalier Universitaire de Montpellier, Montpellier, France.</affiliation></authorAffiliation></authorAffiliationDetailsList></author><author><fullName>Lajoie J</fullName><firstName>Julie</firstName><lastName>Lajoie</lastName><initials>J</initials><authorAffiliationDetailsList><authorAffiliation><affiliation>Department of Medical microbiology, University of Manitoba, Winnipeg, Manitoba, Canada.</affiliation></authorAffiliation></authorAffiliationDetailsList></author><author><fullName>Lorcy F</fullName><firstName>Frédérique</firstName><lastName>Lorcy</lastName><initials>F</initials><authorAffiliationDetailsList><authorAffiliation><affiliation>Department of pathology and oncobiology, Centre Hospitalier Universitaire de Montpellier, Montpellier, France.</affiliation></authorAffiliation></authorAffiliationDetailsList></author><author><fullName>Picot E</fullName><firstName>Eric</firstName><lastName>Picot</lastName><initials>E</initials><authorAffiliationDetailsList><authorAffiliation><affiliation>Center for Free Information, Screening and Diagnosis (CGIDD), Centre Hospitalier Universitaire de Montpellier, Montpellier, France.</affiliation></authorAffiliation></authorAffiliationDetailsList></author><author><fullName>Picot MC</fullName><firstName>Marie-Christine</firstName><lastName>Picot</lastName><initials>MC</initials><authorAffiliationDetailsList><authorAffiliation><affiliation>Department of Medical Information (DIM), Centre Hospitalier Universitaire de Montpellier, Montpellier, France.</affiliation></authorAffiliation></authorAffiliationDetailsList></author><author><fullName>Ravel J</fullName><firstName>Jacques</firstName><lastName>Ravel</lastName><initials>J</initials><authorAffiliationDetailsList><authorAffiliation><affiliation>Institute for Genome Sciences, University of Maryland School of Medicine, Baltimore, Maryland, USA.</affiliation></authorAffiliation></authorAffiliationDetailsList></author><author><fullName>Reynes J</fullName><firstName>Jacques</firstName><lastName>Reynes</lastName><initials>J</initials><authorAffiliationDetailsList><authorAffiliation><affiliation>Department of Infectious and Tropical Diseases, Centre Hospitalier Universitaire de Montpellier, Montpellier, France.</affiliation></authorAffiliation></authorAffiliationDetailsList></author><author><fullName>Rousset T</fullName><firstName>Thérèse</firstName><lastName>Rousset</lastName><initials>T</initials><authorAffiliationDetailsList><authorAffiliation><affiliation>Department of pathology and oncobiology, Centre Hospitalier Universitaire de Montpellier, Montpellier, France.</affiliation></authorAffiliation></authorAffiliationDetailsList></author><author><fullName>Seddiki A</fullName><firstName>Aziza</firstName><lastName>Seddiki</lastName><initials>A</initials><authorAffiliationDetailsList><authorAffiliation><affiliation>Department of Research and Innovation (DRI), Centre Hospitalier Universitaire de Montpellier, Montpellier, France.</affiliation></authorAffiliation></authorAffiliationDetailsList></author><author><fullName>Teirlinck M</fullName><firstName>Martine</firstName><lastName>Teirlinck</lastName><initials>M</initials><authorAffiliationDetailsList><authorAffiliation><affiliation>Center for Free Information, Screening and Diagnosis (CGIDD), Centre Hospitalier Universitaire de Montpellier, Montpellier, France.</affiliation></authorAffiliation></authorAffiliationDetailsList></author><author><fullName>Tribout V</fullName><firstName>Vincent</firstName><lastName>Tribout</lastName><initials>V</initials><authorAffiliationDetailsList><authorAffiliation><affiliation>Center for Free Information, Screening and Diagnosis (CGIDD), Centre Hospitalier Universitaire de Montpellier, Montpellier, France.</affiliation></authorAffiliation></authorAffiliationDetailsList></author><author><fullName>Tuaillon É</fullName><firstName>Édouard</firstName><lastName>Tuaillon</lastName><initials>É</initials><authorId type="ORCID">0000-0001-5866-9530</authorId><authorAffiliationDetailsList><authorAffiliation><affiliation>Pathogenesis and Control of Chronic Infections, INSERM, CHU, University of Montpellier, Montpellier, France.</affiliation></authorAffiliation><authorAffiliation><affiliation>Department of Virology, Centre Hospitalier Universitaire de Montpellier, Montpellier, France.</affiliation></authorAffiliation></authorAffiliationDetailsList></author><author><fullName>Waterboer T</fullName><firstName>Tim</firstName><lastName>Waterboer</lastName><initials>T</initials><authorAffiliationDetailsList><authorAffiliation><affiliation>German Cancer Research Center (DKFZ), Infections and Cancer Epidemiology, Heidelberg, Germany.</affiliation></authorAffiliation></authorAffiliationDetailsList></author><author><fullName>Jacobs N</fullName><firstName>Nathalie</firstName><lastName>Jacobs</lastName><initials>N</initials><authorAffiliationDetailsList><authorAffiliation><affiliation>GIGA-Research, Cellular and molecular immunology, University of Liège, Liège, Belgium.</affiliation></authorAffiliation></authorAffiliationDetailsList></author><author><fullName>Bravo IG</fullName><firstName>Ignacio G</firstName><lastName>Bravo</lastName><initials>IG</initials><authorAffiliationDetailsList><authorAffiliation><affiliation>MIVEGEC (UMR 5290 CNRS, IRD, UM), CNRS, Montpellier, France.</affiliation></authorAffiliation></authorAffiliationDetailsList></author><author><fullName>Segondy M</fullName><firstName>Michel</firstName><lastName>Segondy</lastName><initials>M</initials><authorAffiliationDetailsList><authorAffiliation><affiliation>Pathogenesis and Control of Chronic Infections, INSERM, CHU, University of Montpellier, Montpellier, France.</affiliation></authorAffiliation><authorAffiliation><affiliation>Department of Virology, Centre Hospitalier Universitaire de Montpellier, Montpellier, France.</affiliation></authorAffiliation></authorAffiliationDetailsList></author><author><fullName>Boulle N</fullName><firstName>Nathalie</firstName><lastName>Boulle</lastName><initials>N</initials><authorAffiliationDetailsList><authorAffiliation><affiliation>Pathogenesis and Control of Chronic Infections, INSERM, CHU, University of Montpellier, Montpellier, France.</affiliation></authorAffiliation><authorAffiliation><affiliation>Department of pathology and oncobiology, Centre Hospitalier Universitaire de Montpellier, Montpellier, France.</affiliation></authorAffiliation></authorAffiliationDetailsList></author><author><fullName>Alizon S</fullName><firstName>Samuel</firstName><lastName>Alizon</lastName><initials>S</initials><authorId type="ORCID">0000-0002-0779-9543</authorId><authorAffiliationDetailsList><authorAffiliation><affiliation>MIVEGEC (UMR 5290 CNRS, IRD, UM), CNRS, Montpellier, France.</affiliation></authorAffiliation></authorAffiliationDetailsList></author></authorList><authorIdList><authorId type="ORCID">0000-0001-5866-9530</authorId><authorId type="ORCID">0000-0002-0779-9543</authorId><authorId type="ORCID">0000-0002-7313-0629</authorId><authorId type="ORCID">0000-0003-0672-2541</authorId></authorIdList><dataLinksTagsList><dataLinkstag>supporting_data</dataLinkstag><dataLinkstag>altmetrics</dataLinkstag></dataLinksTagsList><journalInfo><issue>6</issue><volume>9</volume><journalIssueId>2823348</journalIssueId><dateOfPublication>2019 Jun</dateOfPublication><monthOfPublication>6</monthOfPublication><yearOfPublication>2019</yearOfPublication><printPublicationDate>2019-06-01</printPublicationDate><journal><title>BMJ open</title><ISOAbbreviation>BMJ Open</ISOAbbreviation><medlineAbbreviation>BMJ Open</medlineAbbreviation><NLMid>101552874</NLMid><ISSN>2044-6055</ISSN><ESSN>2044-6055</ESSN></journal></journalInfo><pubYear>2019</pubYear><pageInfo>e025129</pageInfo><abstractText>&lt;h4&gt;Introduction&lt;/h4&gt;Human papillomaviruses (HPVs) are responsible for one-third of all cancers caused by infections. Most HPV studies focus on chronic infections and cancers, and we know little about the early stages of the infection. Our main objective is to better understand the course and natural history of cervical HPV infections in healthy, unvaccinated and vaccinated, young women, by characterising the dynamics of various infection-related populations (virus, epithelial cells, vaginal microbiota and immune effectors). Another objective is to analyse HPV diversity within hosts, and in the study population, in relation to co-factors (lifestyle characteristics, vaccination status, vaginal microbiota, human genetics).&lt;h4&gt;Methods and analysis&lt;/h4&gt;The PAPCLEAR study is a single center longitudinal study following 150 women, aged 18-25 years, for up to 2 years. Visits occur every 2 or 4 months (depending on HPV status) during which several variables are measured, such as behaviours (via questionnaires), vaginal pH, HPV presence and viral load (via qPCR), local concentrations of cytokines (via MesoScale Discovery technology) and immune cells (via flow cytometry). Additional analyses are outsourced, such as titration of circulating anti-HPV antibodies, vaginal microbiota sequencing (16S and ITS1 loci) and human genotyping. To increase the statistical power of the epidemiological arm of the study, an additional 150 women are screened cross-sectionally. Finally, to maximise the resolution of the time series, participants are asked to perform weekly self-samples at home. Statistical analyses will involve classical tools in epidemiology, genomics and virus kinetics, and will be performed or coordinated by the Centre National de la Recherche Scientifique (CNRS) in Montpellier.&lt;h4&gt;Ethics and dissemination&lt;/h4&gt;This study has been approved by the Comité de Protection des Personnes Sud Méditerranée I (reference number 2016-A00712-49); by the Comité Consultatif sur le Traitement de l'Information en matière de Recherche dans le domaine de la Santé (reference number 16.504); by the Commission Nationale Informatique et Libertés (reference number MMS/ABD/AR1612278, decision number DR-2016-488) and by the Agence Nationale de Sécurité du Médicament et des Produits de Santé (reference 20160072000007). Results will be published in preprint servers, peer-reviewed journals and disseminated through conferences.&lt;h4&gt;Trial registration number&lt;/h4&gt;NCT02946346; Pre-results.</abstractText><affiliation>MIVEGEC (UMR 5290 CNRS, IRD, UM), CNRS, Montpellier, France.</affiliation><publicationStatus>epublish</publicationStatus><language>eng</language><pubModel>Electronic</pubModel><pubTypeList><pubType>protocol</pubType><pubType>Research Support, Non-U.S. Gov't</pubType><pubType>Journal Article</pubType></pubTypeList><meshHeadingList><meshHeading><majorTopic_YN>N</majorTopic_YN><descriptorName>Vagina</descriptorName><meshQualifierList><meshQualifier><abbreviation>VI</abbreviation><qualifierName>virology</qualifierName><majorTopic_YN>N</majorTopic_YN></meshQualifier></meshQualifierList></meshHeading><meshHeading><majorTopic_YN>N</majorTopic_YN><descriptorName>Humans</descriptorName></meshHeading><meshHeading><majorTopic_YN>N</majorTopic_YN><descriptorName>Papillomavirus Infections</descriptorName><meshQualifierList><meshQualifier><abbreviation>IM</abbreviation><qualifierName>immunology</qualifierName><majorTopic_YN>N</majorTopic_YN></meshQualifier><meshQualifier><abbreviation>EP</abbreviation><qualifierName>epidemiology</qualifierName><majorTopic_YN>Y</majorTopic_YN></meshQualifier><meshQualifier><abbreviation>VI</abbreviation><qualifierName>virology</qualifierName><majorTopic_YN>Y</majorTopic_YN></meshQualifier></meshQualifierList></meshHeading><meshHeading><majorTopic_YN>N</majorTopic_YN><descriptorName>Genital Diseases, Female</descriptorName><meshQualifierList><meshQualifier><abbreviation>IM</abbreviation><qualifierName>immunology</qualifierName><majorTopic_YN>N</majorTopic_YN></meshQualifier><meshQualifier><abbreviation>EP</abbreviation><qualifierName>epidemiology</qualifierName><majorTopic_YN>Y</majorTopic_YN></meshQualifier><meshQualifier><abbreviation>VI</abbreviation><qualifierName>virology</qualifierName><majorTopic_YN>Y</majorTopic_YN></meshQualifier></meshQualifierList></meshHeading><meshHeading><majorTopic_YN>N</majorTopic_YN><descriptorName>Cytokines</descriptorName><meshQualifierList><meshQualifier><abbreviation>IM</abbreviation><qualifierName>immunology</qualifierName><majorTopic_YN>N</majorTopic_YN></meshQualifier></meshQualifierList></meshHeading><meshHeading><majorTopic_YN>Y</majorTopic_YN><descriptorName>Clinical Protocols</descriptorName></meshHeading><meshHeading><majorTopic_YN>N</majorTopic_YN><descriptorName>Viral Load</descriptorName><meshQualifierList><meshQualifier><abbreviation>IM</abbreviation><qualifierName>immunology</qualifierName><majorTopic_YN>N</majorTopic_YN></meshQualifier></meshQualifierList></meshHeading><meshHeading><majorTopic_YN>N</majorTopic_YN><descriptorName>Longitudinal Studies</descriptorName></meshHeading><meshHeading><majorTopic_YN>N</majorTopic_YN><descriptorName>Cross-Sectional Studies</descriptorName></meshHeading><meshHeading><majorTopic_YN>N</majorTopic_YN><descriptorName>Hydrogen-Ion Concentration</descriptorName></meshHeading><meshHeading><majorTopic_YN>N</majorTopic_YN><descriptorName>Adolescent</descriptorName></meshHeading><meshHeading><majorTopic_YN>N</majorTopic_YN><descriptorName>France</descriptorName><meshQualifierList><meshQualifier><abbreviation>EP</abbreviation><qualifierName>epidemiology</qualifierName><majorTopic_YN>N</majorTopic_YN></meshQualifier></meshQualifierList></meshHeading><meshHeading><majorTopic_YN>N</majorTopic_YN><descriptorName>Female</descriptorName></meshHeading><meshHeading><majorTopic_YN>N</majorTopic_YN><descriptorName>Young Adult</descriptorName></meshHeading><meshHeading><majorTopic_YN>N</majorTopic_YN><descriptorName>Microbiota</descriptorName><meshQualifierList><meshQualifier><abbreviation>IM</abbreviation><qualifierName>immunology</qualifierName><majorTopic_YN>N</majorTopic_YN></meshQualifier></meshQualifierList></meshHeading><meshHeading><majorTopic_YN>N</majorTopic_YN><descriptorName>Surveys and Questionnaires</descriptorName></meshHeading></meshHeadingList><keywordList><keyword>Persistence</keyword><keyword>Immunity</keyword><keyword>Microbiota</keyword><keyword>HPV</keyword><keyword>Viral Kinetics</keyword><keyword>Virus Load</keyword><keyword>Acute Infection</keyword></keywordList><chemicalList><chemical><name>Cytokines</name><registryNumber>0</registryNumber></chemical></chemicalList><subsetList><subset><code>IM</code><name>Index Medicus</name></subset></subsetList><fullTextUrlList><fullTextUrl><availability>Subscription required</availability><availabilityCode>S</availabilityCode><documentStyle>doi</documentStyle><site>DOI</site><url>https://doi.org/10.1136/bmjopen-2018-025129</url></fullTextUrl><fullTextUrl><availability>Open access</availability><availabilityCode>OA</availabilityCode><documentStyle>html</documentStyle><site>Europe_PMC</site><url>https://europepmc.org/articles/PMC6576111</url></fullTextUrl><fullTextUrl><availability>Open access</availability><availabilityCode>OA</availabilityCode><documentStyle>pdf</documentStyle><site>Europe_PMC</site><url>https://europepmc.org/articles/PMC6576111?pdf=render</url></fullTextUrl></fullTextUrlList><isOpenAccess>Y</isOpenAccess><inEPMC>Y</inEPMC><inPMC>N</inPMC><hasPDF>Y</hasPDF><hasBook>N</hasBook><hasSuppl>Y</hasSuppl><citedByCount>2</citedByCount><hasData>Y</hasData><hasReferences>Y</hasReferences><hasTextMinedTerms>Y</hasTextMinedTerms><hasDbCrossReferences>N</hasDbCrossReferences><hasLabsLinks>Y</hasLabsLinks><license>cc by-nc</license><authMan>N</authMan><epmcAuthMan>N</epmcAuthMan><nihAuthMan>N</nihAuthMan><hasTMAccessionNumbers>Y</hasTMAccessionNumbers><tmAccessionTypeList><accessionType>nct</accessionType></tmAccessionTypeList><dateOfCompletion>2020-05-18</dateOfCompletion><dateOfCreation>2019-06-14</dateOfCreation><firstIndexDate>2019-06-14</firstIndexDate><fullTextReceivedDate>2020-07-09</fullTextReceivedDate><dateOfRevision>2020-05-18</dateOfRevision><electronicPublicationDate>2019-06-11</electronicPublicationDate><firstPublicationDate>2019-06-11</firstPublicationDate></result>
<result><id>30982082</id><source>MED</source><pmid>30982082</pmid><pmcid>PMC6614161</pmcid><fullTextIdList><fullTextId>PMC6614161</fullTextId></fullTextIdList><doi>10.1007/s00038-019-01234-z</doi><title>The future of a partially effective HIV vaccine: assessing limitations at the population level.</title><authorString>Selinger C, Dimitrov DT, Welkhoff PA, Bershteyn A.</authorString><authorList><author><fullName>Selinger C</fullName><firstName>Christian</firstName><lastName>Selinger</lastName><initials>C</initials><authorId type="ORCID">0000-0002-4361-549X</authorId><authorAffiliationDetailsList><authorAffiliation><affiliation>Institute for Disease Modeling, 3150 139th Ave SE, Bellevue, WA, 98005, USA.</affiliation></authorAffiliation></authorAffiliationDetailsList></author><author><fullName>Dimitrov DT</fullName><firstName>Dobromir T</firstName><lastName>Dimitrov</lastName><initials>DT</initials><authorAffiliationDetailsList><authorAffiliation><affiliation>Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, Seattle, WA, 98109, USA.</affiliation></authorAffiliation></authorAffiliationDetailsList></author><author><fullName>Welkhoff PA</fullName><firstName>Philip A</firstName><lastName>Welkhoff</lastName><initials>PA</initials><authorAffiliationDetailsList><authorAffiliation><affiliation>Institute for Disease Modeling, 3150 139th Ave SE, Bellevue, WA, 98005, USA.</affiliation></authorAffiliation></authorAffiliationDetailsList></author><author><fullName>Bershteyn A</fullName><firstName>Anna</firstName><lastName>Bershteyn</lastName><initials>A</initials><authorAffiliationDetailsList><authorAffiliation><affiliation>Institute for Disease Modeling, 3150 139th Ave SE, Bellevue, WA, 98005, USA. abershteyn@idmod.org.</affiliation></authorAffiliation></authorAffiliationDetailsList></author></authorList><authorIdList><authorId type="ORCID">0000-0002-4361-549X</authorId></authorIdList><dataLinksTagsList><dataLinkstag>supporting_data</dataLinkstag><dataLinkstag>altmetrics</dataLinkstag></dataLinksTagsList><journalInfo><issue>6</issue><volume>64</volume><journalIssueId>2836853</journalIssueId><dateOfPublication>2019 Jul</dateOfPublication><monthOfPublication>7</monthOfPublication><yearOfPublication>2019</yearOfPublication><printPublicationDate>2019-07-01</printPublicationDate><journal><title>International journal of public health</title><ISOAbbreviation>Int J Public Health</ISOAbbreviation><medlineAbbreviation>Int J Public Health</medlineAbbreviation><NLMid>101304551</NLMid><ISSN>1661-8556</ISSN><ESSN>1661-8564</ESSN></journal></journalInfo><pubYear>2019</pubYear><pageInfo>957-964</pageInfo><abstractText>&lt;h4&gt;Objectives&lt;/h4&gt;Mathematical models have unanimously predicted that a first-generation HIV vaccine would be useful and cost-effective to roll out, but that its overall impact would be insufficient to reverse the epidemic. Here, we explore what factors contribute most to limiting the impact of such a vaccine.&lt;h4&gt;Methods&lt;/h4&gt;Ranging from a theoretical ideal to a more realistic regimen, mirroring the one used in the currently ongoing trial in South Africa (HVTN 702), we model a nested hierarchy of vaccine attributes such as speed of scale-up, efficacy, durability, and return rates for booster doses.&lt;h4&gt;Results&lt;/h4&gt;The predominant reasons leading to a substantial loss of vaccine impact on the HIV epidemic are the time required to scale up mass vaccination, limited durability, and waning of efficacy.&lt;h4&gt;Conclusions&lt;/h4&gt;A first-generation partially effective vaccine would primarily serve as an intermediate milestone, furnishing correlates of immunity and platforms that could serve to accelerate future development of a highly effective, durable, and scalable next-generation vaccine capable of reversing the HIV epidemic.</abstractText><affiliation>Institute for Disease Modeling, 3150 139th Ave SE, Bellevue, WA, 98005, USA.</affiliation><publicationStatus>ppublish</publicationStatus><language>eng</language><pubModel>Print-Electronic</pubModel><pubTypeList><pubType>research-article</pubType><pubType>Journal Article</pubType></pubTypeList><grantsList><grant><grantId>OPP1110049</grantId><agency>Bill and Melinda Gates Foundation</agency><orderIn>0</orderIn></grant><grant><grantId>UM1 AI068614</grantId><agency>NIAID NIH HHS</agency><acronym>AI</acronym><orderIn>0</orderIn></grant></grantsList><meshHeadingList><meshHeading><majorTopic_YN>N</majorTopic_YN><descriptorName>Humans</descriptorName></meshHeading><meshHeading><majorTopic_YN>N</majorTopic_YN><descriptorName>HIV Infections</descriptorName><meshQualifierList><meshQualifier><abbreviation>PC</abbreviation><qualifierName>prevention &amp; control</qualifierName><majorTopic_YN>Y</majorTopic_YN></meshQualifier></meshQualifierList></meshHeading><meshHeading><majorTopic_YN>N</majorTopic_YN><descriptorName>AIDS Vaccines</descriptorName><meshQualifierList><meshQualifier><abbreviation>AD</abbreviation><qualifierName>administration &amp; dosage</qualifierName><majorTopic_YN>Y</majorTopic_YN></meshQualifier><meshQualifier><abbreviation>EC</abbreviation><qualifierName>economics</qualifierName><majorTopic_YN>Y</majorTopic_YN></meshQualifier></meshQualifierList></meshHeading><meshHeading><majorTopic_YN>N</majorTopic_YN><descriptorName>Models, Theoretical</descriptorName></meshHeading><meshHeading><majorTopic_YN>N</majorTopic_YN><descriptorName>Adolescent</descriptorName></meshHeading><meshHeading><majorTopic_YN>N</majorTopic_YN><descriptorName>Adult</descriptorName></meshHeading><meshHeading><majorTopic_YN>N</majorTopic_YN><descriptorName>Middle Aged</descriptorName></meshHeading><meshHeading><majorTopic_YN>N</majorTopic_YN><descriptorName>Cost-Benefit Analysis</descriptorName><meshQualifierList><meshQualifier><abbreviation>SN</abbreviation><qualifierName>statistics &amp; numerical data</qualifierName><majorTopic_YN>Y</majorTopic_YN></meshQualifier></meshQualifierList></meshHeading><meshHeading><majorTopic_YN>N</majorTopic_YN><descriptorName>South Africa</descriptorName></meshHeading><meshHeading><majorTopic_YN>N</majorTopic_YN><descriptorName>Female</descriptorName></meshHeading><meshHeading><majorTopic_YN>N</majorTopic_YN><descriptorName>Male</descriptorName></meshHeading><meshHeading><majorTopic_YN>N</majorTopic_YN><descriptorName>Young Adult</descriptorName></meshHeading></meshHeadingList><keywordList><keyword>Product development</keyword><keyword>South Africa</keyword><keyword>Hiv Vaccine</keyword><keyword>Epidemiological Modeling</keyword></keywordList><chemicalList><chemical><name>AIDS Vaccines</name><registryNumber>0</registryNumber></chemical></chemicalList><subsetList><subset><code>IM</code><name>Index Medicus</name></subset></subsetList><fullTextUrlList><fullTextUrl><availability>Subscription required</availability><availabilityCode>S</availabilityCode><documentStyle>doi</documentStyle><site>DOI</site><url>https://doi.org/10.1007/s00038-019-01234-z</url></fullTextUrl><fullTextUrl><availability>Open access</availability><availabilityCode>OA</availabilityCode><documentStyle>html</documentStyle><site>Europe_PMC</site><url>https://europepmc.org/articles/PMC6614161</url></fullTextUrl><fullTextUrl><availability>Open access</availability><availabilityCode>OA</availabilityCode><documentStyle>pdf</documentStyle><site>Europe_PMC</site><url>https://europepmc.org/articles/PMC6614161?pdf=render</url></fullTextUrl></fullTextUrlList><commentCorrectionList><commentCorrection><id>PPR66564</id><source>PPR</source><type>Preprint in</type><note>CrossRef Pre-print loader</note><orderIn>10002</orderIn></commentCorrection></commentCorrectionList><isOpenAccess>Y</isOpenAccess><inEPMC>Y</inEPMC><inPMC>N</inPMC><hasPDF>Y</hasPDF><hasBook>N</hasBook><hasSuppl>Y</hasSuppl><citedByCount>1</citedByCount><hasData>Y</hasData><hasReferences>Y</hasReferences><hasTextMinedTerms>Y</hasTextMinedTerms><hasDbCrossReferences>N</hasDbCrossReferences><hasLabsLinks>Y</hasLabsLinks><license>cc by</license><authMan>N</authMan><epmcAuthMan>N</epmcAuthMan><nihAuthMan>N</nihAuthMan><hasTMAccessionNumbers>N</hasTMAccessionNumbers><dateOfCompletion>2019-11-07</dateOfCompletion><dateOfCreation>2019-04-15</dateOfCreation><firstIndexDate>2019-04-15</firstIndexDate><fullTextReceivedDate>2020-07-09</fullTextReceivedDate><dateOfRevision>2019-11-07</dateOfRevision><electronicPublicationDate>2019-04-13</electronicPublicationDate><firstPublicationDate>2019-04-13</firstPublicationDate></result>
<result><id>30890385</id><source>MED</source><pmid>30890385</pmid><pmcid>PMC6684280</pmcid><fullTextIdList><fullTextId>PMC6684280</fullTextId></fullTextIdList><doi>10.1016/j.vaccine.2019.02.073</doi><title>Targeting and vaccine durability are key for population-level impact and cost-effectiveness of a pox-protein HIV vaccine regimen in South Africa.</title><authorString>Selinger C, Bershteyn A, Dimitrov DT, Adamson BJS, Revill P, Hallett TB, Phillips AN, Bekker LG, Rees H, Gray G.</authorString><authorList><author><fullName>Selinger C</fullName><firstName>Christian</firstName><lastName>Selinger</lastName><initials>C</initials><authorId type="ORCID">0000-0002-4361-549X</authorId><authorAffiliationDetailsList><authorAffiliation><affiliation>Institute for Disease Modeling, Bellevue, WA, United States. Electronic address: christian.selinger@gmail.com.</affiliation></authorAffiliation></authorAffiliationDetailsList></author><author><fullName>Bershteyn A</fullName><firstName>Anna</firstName><lastName>Bershteyn</lastName><initials>A</initials><authorAffiliationDetailsList><authorAffiliation><affiliation>Institute for Disease Modeling, Bellevue, WA, United States.</affiliation></authorAffiliation></authorAffiliationDetailsList></author><author><fullName>Dimitrov DT</fullName><firstName>Dobromir T</firstName><lastName>Dimitrov</lastName><initials>DT</initials><authorAffiliationDetailsList><authorAffiliation><affiliation>Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Research Center, Seattle, WA, United States.</affiliation></authorAffiliation></authorAffiliationDetailsList></author><author><fullName>Adamson BJS</fullName><firstName>Blythe J S</firstName><lastName>Adamson</lastName><initials>BJS</initials><authorAffiliationDetailsList><authorAffiliation><affiliation>Comparative Health Outcomes, Policy, and Economics (CHOICE) Institute, University of Washington, WA, United States; Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Research Center, Seattle, WA, United States.</affiliation></authorAffiliation></authorAffiliationDetailsList></author><author><fullName>Revill P</fullName><firstName>Paul</firstName><lastName>Revill</lastName><initials>P</initials><authorAffiliationDetailsList><authorAffiliation><affiliation>University of York, York, UK.</affiliation></authorAffiliation></authorAffiliationDetailsList></author><author><fullName>Hallett TB</fullName><firstName>Timothy B</firstName><lastName>Hallett</lastName><initials>TB</initials><authorId type="ORCID">0000-0002-9681-0424</authorId><authorAffiliationDetailsList><authorAffiliation><affiliation>Imperial College, London, UK.</affiliation></authorAffiliation></authorAffiliationDetailsList></author><author><fullName>Phillips AN</fullName><firstName>Andrew N</firstName><lastName>Phillips</lastName><initials>AN</initials><authorAffiliationDetailsList><authorAffiliation><affiliation>University College, London, UK.</affiliation></authorAffiliation></authorAffiliationDetailsList></author><author><fullName>Bekker LG</fullName><firstName>Linda-Gail</firstName><lastName>Bekker</lastName><initials>LG</initials><authorId type="ORCID">0000-0002-0755-4386</authorId><authorAffiliationDetailsList><authorAffiliation><affiliation>The Desmond Tutu HIV Centre, Cape Town, South Africa.</affiliation></authorAffiliation></authorAffiliationDetailsList></author><author><fullName>Rees H</fullName><firstName>Helen</firstName><lastName>Rees</lastName><initials>H</initials><authorAffiliationDetailsList><authorAffiliation><affiliation>Wits RHI, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.</affiliation></authorAffiliation></authorAffiliationDetailsList></author><author><fullName>Gray G</fullName><firstName>Glenda</firstName><lastName>Gray</lastName><initials>G</initials><authorAffiliationDetailsList><authorAffiliation><affiliation>Perinatal HIV Research Unit, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa; South African Medical Research Council, Cape Town, South Africa.</affiliation></authorAffiliation></authorAffiliationDetailsList></author></authorList><authorIdList><authorId type="ORCID">0000-0002-0755-4386</authorId><authorId type="ORCID">0000-0002-4361-549X</authorId><authorId type="ORCID">0000-0002-9681-0424</authorId></authorIdList><dataLinksTagsList><dataLinkstag>supporting_data</dataLinkstag><dataLinkstag>altmetrics</dataLinkstag></dataLinksTagsList><journalInfo><issue>16</issue><volume>37</volume><journalIssueId>2798516</journalIssueId><dateOfPublication>2019 Apr</dateOfPublication><monthOfPublication>4</monthOfPublication><yearOfPublication>2019</yearOfPublication><printPublicationDate>2019-04-01</printPublicationDate><journal><title>Vaccine</title><ISOAbbreviation>Vaccine</ISOAbbreviation><medlineAbbreviation>Vaccine</medlineAbbreviation><NLMid>8406899</NLMid><ISSN>0264-410X</ISSN><ESSN>1873-2518</ESSN></journal></journalInfo><pubYear>2019</pubYear><pageInfo>2258-2267</pageInfo><abstractText>&lt;h4&gt;Background&lt;/h4&gt;RV144 is to date the only HIV vaccine trial to demonstrate efficacy, albeit rapidly waning over time. The HVTN 702 trial is currently evaluating in South Africa a similar vaccine formulation to that of RV144 for subtype C HIV with additional boosters (pox-protein regimen). Using a detailed stochastic individual-based network model of disease transmission calibrated to the HIV epidemic, we investigate population-level impact and maximum cost of an HIV vaccine to remain cost-effective.&lt;h4&gt;Methods&lt;/h4&gt;Consistent with the original pox-protein regimen, we model a primary series of five vaccinations meeting the goal of 50% cumulative efficacy 24 months after the first dose and include two-yearly boosters that maintain durable efficacy over 10 years. We simulate vaccination programs in South Africa starting in 2027 under various vaccine targeting and HIV treatment and prevention assumptions.&lt;h4&gt;Results&lt;/h4&gt;Our analysis shows that this partially effective vaccine could prevent, at catch-up vaccination with 60% coverage, up to 941,000 (15.6%) new infections between 2027 and 2047 assuming current trends of antiretroviral treatment. An impact of up to 697,000 (11.5%) infections prevented could be achieved by targeting age cohorts of highest incidence. Economic evaluation indicates that, if treatment scale-up was achieved, vaccination could be cost-effective at a total cost of less than $385 and $62 per 10-year series (cost-effectiveness thresholds of $5,691 and $750).&lt;h4&gt;Conclusions&lt;/h4&gt;While a partially effective, rapidly waning vaccine could help to prevent HIV infections, it will not eliminate HIV as a public health priority in sub-Saharan Africa. Vaccination is expected to be most effective under targeted delivery to age groups of highest HIV incidence. Awaiting results of trial, the introduction of vaccination should go in parallel with continued innovation in HIV prevention, including studies to determine the costs of delivery and feasibility and further research into products with greater efficacy and durability.</abstractText><affiliation>Institute for Disease Modeling, Bellevue, WA, United States. Electronic address: christian.selinger@gmail.com.</affiliation><publicationStatus>ppublish</publicationStatus><language>eng</language><pubModel>Print-Electronic</pubModel><pubTypeList><pubType>Research Support, Non-U.S. Gov't</pubType><pubType>research-article</pubType><pubType>Journal Article</pubType></pubTypeList><grantsList><grant><grantId>MR/R015600/1</grantId><agency>Medical Research Council</agency><acronym>MRC_</acronym><orderIn>0</orderIn></grant><grant><grantId>UM1 AI068635</grantId><agency>NIAID NIH HHS</agency><acronym>AI</acronym><orderIn>0</orderIn></grant><grant><grantId>UM1 AI068614</grantId><agency>NIAID NIH HHS</agency><acronym>AI</acronym><orderIn>0</orderIn></grant></grantsList><meshHeadingList><meshHeading><majorTopic_YN>N</majorTopic_YN><descriptorName>Humans</descriptorName></meshHeading><meshHeading><majorTopic_YN>N</majorTopic_YN><descriptorName>HIV</descriptorName><meshQualifierList><meshQualifier><abbreviation>IM</abbreviation><qualifierName>immunology</qualifierName><majorTopic_YN>Y</majorTopic_YN></meshQualifier></meshQualifierList></meshHeading><meshHeading><majorTopic_YN>N</majorTopic_YN><descriptorName>HIV Infections</descriptorName><meshQualifierList><meshQualifier><abbreviation>IM</abbreviation><qualifierName>immunology</qualifierName><majorTopic_YN>Y</majorTopic_YN></meshQualifier><meshQualifier><abbreviation>EP</abbreviation><qualifierName>epidemiology</qualifierName><majorTopic_YN>N</majorTopic_YN></meshQualifier><meshQualifier><abbreviation>PC</abbreviation><qualifierName>prevention &amp; control</qualifierName><majorTopic_YN>Y</majorTopic_YN></meshQualifier></meshQualifierList></meshHeading><meshHeading><majorTopic_YN>N</majorTopic_YN><descriptorName>AIDS Vaccines</descriptorName><meshQualifierList><meshQualifier><abbreviation>EC</abbreviation><qualifierName>economics</qualifierName><majorTopic_YN>Y</majorTopic_YN></meshQualifier><meshQualifier><abbreviation>IM</abbreviation><qualifierName>immunology</qualifierName><majorTopic_YN>Y</majorTopic_YN></meshQualifier></meshQualifierList></meshHeading><meshHeading><majorTopic_YN>Y</majorTopic_YN><descriptorName>Vaccination</descriptorName><meshQualifierList><meshQualifier><abbreviation>EC</abbreviation><qualifierName>economics</qualifierName><majorTopic_YN>N</majorTopic_YN></meshQualifier><meshQualifier><abbreviation>MT</abbreviation><qualifierName>methods</qualifierName><majorTopic_YN>N</majorTopic_YN></meshQualifier></meshQualifierList></meshHeading><meshHeading><majorTopic_YN>N</majorTopic_YN><descriptorName>Population Surveillance</descriptorName></meshHeading><meshHeading><majorTopic_YN>N</majorTopic_YN><descriptorName>Incidence</descriptorName></meshHeading><meshHeading><majorTopic_YN>N</majorTopic_YN><descriptorName>Models, Theoretical</descriptorName></meshHeading><meshHeading><majorTopic_YN>N</majorTopic_YN><descriptorName>Time Factors</descriptorName></meshHeading><meshHeading><majorTopic_YN>N</majorTopic_YN><descriptorName>Immunization Programs</descriptorName></meshHeading><meshHeading><majorTopic_YN>Y</majorTopic_YN><descriptorName>Cost-Benefit Analysis</descriptorName></meshHeading><meshHeading><majorTopic_YN>N</majorTopic_YN><descriptorName>South Africa</descriptorName><meshQualifierList><meshQualifier><abbreviation>EP</abbreviation><qualifierName>epidemiology</qualifierName><majorTopic_YN>N</majorTopic_YN></meshQualifier></meshQualifierList></meshHeading><meshHeading><majorTopic_YN>N</majorTopic_YN><descriptorName>Immunogenicity, Vaccine</descriptorName></meshHeading><meshHeading><majorTopic_YN>N</majorTopic_YN><descriptorName>Outcome Assessment, Health Care</descriptorName></meshHeading></meshHeadingList><keywordList><keyword>South Africa</keyword><keyword>Cost-effectiveness</keyword><keyword>Hiv Vaccine</keyword><keyword>Agent-based Modeling</keyword></keywordList><chemicalList><chemical><name>AIDS Vaccines</name><registryNumber>0</registryNumber></chemical></chemicalList><subsetList><subset><code>IM</code><name>Index Medicus</name></subset></subsetList><fullTextUrlList><fullTextUrl><availability>Subscription required</availability><availabilityCode>S</availabilityCode><documentStyle>doi</documentStyle><site>DOI</site><url>https://doi.org/10.1016/j.vaccine.2019.02.073</url></fullTextUrl><fullTextUrl><availability>Open access</availability><availabilityCode>OA</availabilityCode><documentStyle>html</documentStyle><site>Europe_PMC</site><url>https://europepmc.org/articles/PMC6684280</url></fullTextUrl><fullTextUrl><availability>Open access</availability><availabilityCode>OA</availabilityCode><documentStyle>pdf</documentStyle><site>Europe_PMC</site><url>https://europepmc.org/articles/PMC6684280?pdf=render</url></fullTextUrl></fullTextUrlList><commentCorrectionList><commentCorrection><id>PPR60795</id><source>PPR</source><type>Preprint in</type><note>CrossRef Pre-print loader</note><orderIn>10002</orderIn></commentCorrection></commentCorrectionList><isOpenAccess>Y</isOpenAccess><inEPMC>Y</inEPMC><inPMC>N</inPMC><hasPDF>Y</hasPDF><hasBook>N</hasBook><hasSuppl>Y</hasSuppl><citedByCount>5</citedByCount><hasData>Y</hasData><hasReferences>Y</hasReferences><hasTextMinedTerms>Y</hasTextMinedTerms><hasDbCrossReferences>N</hasDbCrossReferences><hasLabsLinks>Y</hasLabsLinks><license>cc by</license><authMan>Y</authMan><epmcAuthMan>N</epmcAuthMan><nihAuthMan>Y</nihAuthMan><manuscriptId>NIHMS1043540</manuscriptId><hasTMAccessionNumbers>N</hasTMAccessionNumbers><dateOfCompletion>2020-08-14</dateOfCompletion><dateOfCreation>2019-03-21</dateOfCreation><firstIndexDate>2019-03-21</firstIndexDate><fullTextReceivedDate>2020-10-26</fullTextReceivedDate><dateOfRevision>2021-01-09</dateOfRevision><electronicPublicationDate>2019-03-16</electronicPublicationDate><firstPublicationDate>2019-03-16</firstPublicationDate><embargoDate>2020-04-10</embargoDate></result>
<result><id>29702638</id><source>MED</source><pmid>29702638</pmid><pmcid>PMC5942853</pmcid><fullTextIdList><fullTextId>PMC5942853</fullTextId></fullTextIdList><doi>10.1371/journal.pbio.2002468</doi><title>Assessing the stability of polio eradication after the withdrawal of oral polio vaccine.</title><authorString>Famulare M, Selinger C, McCarthy KA, Eckhoff PA, Chabot-Couture G.</authorString><authorList><author><fullName>Famulare M</fullName><firstName>Michael</firstName><lastName>Famulare</lastName><initials>M</initials><authorId type="ORCID">0000-0001-9275-7454</authorId><authorAffiliationDetailsList><authorAffiliation><affiliation>Institute for Disease Modeling, Bellevue, Washington, United States of America.</affiliation></authorAffiliation></authorAffiliationDetailsList></author><author><fullName>Selinger C</fullName><firstName>Christian</firstName><lastName>Selinger</lastName><initials>C</initials><authorId type="ORCID">0000-0002-4361-549X</authorId><authorAffiliationDetailsList><authorAffiliation><affiliation>Institute for Disease Modeling, Bellevue, Washington, United States of America.</affiliation></authorAffiliation></authorAffiliationDetailsList></author><author><fullName>McCarthy KA</fullName><firstName>Kevin A</firstName><lastName>McCarthy</lastName><initials>KA</initials><authorAffiliationDetailsList><authorAffiliation><affiliation>Institute for Disease Modeling, Bellevue, Washington, United States of America.</affiliation></authorAffiliation></authorAffiliationDetailsList></author><author><fullName>Eckhoff PA</fullName><firstName>Philip A</firstName><lastName>Eckhoff</lastName><initials>PA</initials><authorAffiliationDetailsList><authorAffiliation><affiliation>Institute for Disease Modeling, Bellevue, Washington, United States of America.</affiliation></authorAffiliation></authorAffiliationDetailsList></author><author><fullName>Chabot-Couture G</fullName><firstName>Guillaume</firstName><lastName>Chabot-Couture</lastName><initials>G</initials><authorAffiliationDetailsList><authorAffiliation><affiliation>Institute for Disease Modeling, Bellevue, Washington, United States of America.</affiliation></authorAffiliation></authorAffiliationDetailsList></author></authorList><authorIdList><authorId type="ORCID">0000-0001-9275-7454</authorId><authorId type="ORCID">0000-0002-4361-549X</authorId></authorIdList><dataLinksTagsList><dataLinkstag>supporting_data</dataLinkstag><dataLinkstag>altmetrics</dataLinkstag></dataLinksTagsList><journalInfo><issue>4</issue><volume>16</volume><journalIssueId>2667069</journalIssueId><dateOfPublication>2018 Apr</dateOfPublication><monthOfPublication>4</monthOfPublication><yearOfPublication>2018</yearOfPublication><printPublicationDate>2018-04-01</printPublicationDate><journal><title>PLoS biology</title><ISOAbbreviation>PLoS Biol</ISOAbbreviation><medlineAbbreviation>PLoS Biol</medlineAbbreviation><NLMid>101183755</NLMid><ISSN>1544-9173</ISSN><ESSN>1545-7885</ESSN></journal></journalInfo><pubYear>2018</pubYear><pageInfo>e2002468</pageInfo><abstractText>The oral polio vaccine (OPV) contains live-attenuated polioviruses that induce immunity by causing low virulence infections in vaccine recipients and their close contacts. Widespread immunization with OPV has reduced the annual global burden of paralytic poliomyelitis by a factor of 10,000 or more and has driven wild poliovirus (WPV) to the brink of eradication. However, in instances that have so far been rare, OPV can paralyze vaccine recipients and generate vaccine-derived polio outbreaks. To complete polio eradication, OPV use should eventually cease, but doing so will leave a growing population fully susceptible to infection. If poliovirus is reintroduced after OPV cessation, under what conditions will OPV vaccination be required to interrupt transmission? Can conditions exist in which OPV and WPV reintroduction present similar risks of transmission? To answer these questions, we built a multi-scale mathematical model of infection and transmission calibrated to data from clinical trials and field epidemiology studies. At the within-host level, the model describes the effects of vaccination and waning immunity on shedding and oral susceptibility to infection. At the between-host level, the model emulates the interaction of shedding and oral susceptibility with sanitation and person-to-person contact patterns to determine the transmission rate in communities. Our results show that inactivated polio vaccine (IPV) is sufficient to prevent outbreaks in low transmission rate settings and that OPV can be reintroduced and withdrawn as needed in moderate transmission rate settings. However, in high transmission rate settings, the conditions that support vaccine-derived outbreaks have only been rare because population immunity has been high. Absent population immunity, the Sabin strains from OPV will be nearly as capable of causing outbreaks as WPV. If post-cessation outbreak responses are followed by new vaccine-derived outbreaks, strategies to restore population immunity will be required to ensure the stability of polio eradication.</abstractText><affiliation>Institute for Disease Modeling, Bellevue, Washington, United States of America.</affiliation><publicationStatus>epublish</publicationStatus><language>eng</language><pubModel>Electronic-eCollection</pubModel><pubTypeList><pubType>Research Support, Non-U.S. Gov't</pubType><pubType>research-article</pubType><pubType>Journal Article</pubType></pubTypeList><meshHeadingList><meshHeading><majorTopic_YN>N</majorTopic_YN><descriptorName>Humans</descriptorName></meshHeading><meshHeading><majorTopic_YN>N</majorTopic_YN><descriptorName>Poliovirus</descriptorName><meshQualifierList><meshQualifier><abbreviation>IM</abbreviation><qualifierName>immunology</qualifierName><majorTopic_YN>Y</majorTopic_YN></meshQualifier></meshQualifierList></meshHeading><meshHeading><majorTopic_YN>N</majorTopic_YN><descriptorName>Poliomyelitis</descriptorName><meshQualifierList><meshQualifier><abbreviation>IM</abbreviation><qualifierName>immunology</qualifierName><majorTopic_YN>N</majorTopic_YN></meshQualifier><meshQualifier><abbreviation>EP</abbreviation><qualifierName>epidemiology</qualifierName><majorTopic_YN>N</majorTopic_YN></meshQualifier><meshQualifier><abbreviation>PC</abbreviation><qualifierName>prevention &amp; control</qualifierName><majorTopic_YN>Y</majorTopic_YN></meshQualifier><meshQualifier><abbreviation>TM</abbreviation><qualifierName>transmission</qualifierName><majorTopic_YN>N</majorTopic_YN></meshQualifier></meshQualifierList></meshHeading><meshHeading><majorTopic_YN>N</majorTopic_YN><descriptorName>Poliovirus Vaccine, Inactivated</descriptorName><meshQualifierList><meshQualifier><abbreviation>AD</abbreviation><qualifierName>administration &amp; dosage</qualifierName><majorTopic_YN>Y</majorTopic_YN></meshQualifier></meshQualifierList></meshHeading><meshHeading><majorTopic_YN>N</majorTopic_YN><descriptorName>Poliovirus Vaccine, Oral</descriptorName><meshQualifierList><meshQualifier><abbreviation>AD</abbreviation><qualifierName>administration &amp; dosage</qualifierName><majorTopic_YN>Y</majorTopic_YN></meshQualifier></meshQualifierList></meshHeading><meshHeading><majorTopic_YN>N</majorTopic_YN><descriptorName>Immunization Schedule</descriptorName></meshHeading><meshHeading><majorTopic_YN>N</majorTopic_YN><descriptorName>Models, Statistical</descriptorName></meshHeading><meshHeading><majorTopic_YN>N</majorTopic_YN><descriptorName>Disease Outbreaks</descriptorName><meshQualifierList><meshQualifier><abbreviation>PC</abbreviation><qualifierName>prevention &amp; control</qualifierName><majorTopic_YN>Y</majorTopic_YN></meshQualifier></meshQualifierList></meshHeading><meshHeading><majorTopic_YN>N</majorTopic_YN><descriptorName>Immunity, Active</descriptorName></meshHeading><meshHeading><majorTopic_YN>Y</majorTopic_YN><descriptorName>Immunity, Herd</descriptorName></meshHeading><meshHeading><majorTopic_YN>N</majorTopic_YN><descriptorName>Mass Vaccination</descriptorName><meshQualifierList><meshQualifier><abbreviation>SN</abbreviation><qualifierName>statistics &amp; numerical data</qualifierName><majorTopic_YN>N</majorTopic_YN></meshQualifier></meshQualifierList></meshHeading><meshHeading><majorTopic_YN>N</majorTopic_YN><descriptorName>Global Health</descriptorName></meshHeading></meshHeadingList><chemicalList><chemical><name>Poliovirus Vaccine, Oral</name><registryNumber>0</registryNumber></chemical><chemical><name>Poliovirus Vaccine, Inactivated</name><registryNumber>0</registryNumber></chemical></chemicalList><subsetList><subset><code>IM</code><name>Index Medicus</name></subset></subsetList><fullTextUrlList><fullTextUrl><availability>Subscription required</availability><availabilityCode>S</availabilityCode><documentStyle>doi</documentStyle><site>DOI</site><url>https://doi.org/10.1371/journal.pbio.2002468</url></fullTextUrl><fullTextUrl><availability>Open access</availability><availabilityCode>OA</availabilityCode><documentStyle>html</documentStyle><site>Europe_PMC</site><url>https://europepmc.org/articles/PMC5942853</url></fullTextUrl><fullTextUrl><availability>Open access</availability><availabilityCode>OA</availabilityCode><documentStyle>pdf</documentStyle><site>Europe_PMC</site><url>https://europepmc.org/articles/PMC5942853?pdf=render</url></fullTextUrl></fullTextUrlList><commentCorrectionList><commentCorrection><id>PPR18018</id><source>PPR</source><type>Preprint in</type><note>CrossRef Pre-print loader</note><orderIn>10002</orderIn></commentCorrection></commentCorrectionList><isOpenAccess>Y</isOpenAccess><inEPMC>Y</inEPMC><inPMC>N</inPMC><hasPDF>Y</hasPDF><hasBook>N</hasBook><hasSuppl>Y</hasSuppl><citedByCount>3</citedByCount><hasData>Y</hasData><hasReferences>Y</hasReferences><hasTextMinedTerms>Y</hasTextMinedTerms><hasDbCrossReferences>N</hasDbCrossReferences><hasLabsLinks>Y</hasLabsLinks><license>cc by</license><authMan>N</authMan><epmcAuthMan>N</epmcAuthMan><nihAuthMan>N</nihAuthMan><hasTMAccessionNumbers>N</hasTMAccessionNumbers><dateOfCompletion>2019-03-27</dateOfCompletion><dateOfCreation>2018-04-28</dateOfCreation><firstIndexDate>2018-04-28</firstIndexDate><fullTextReceivedDate>2020-07-12</fullTextReceivedDate><dateOfRevision>2019-03-27</dateOfRevision><electronicPublicationDate>2018-04-27</electronicPublicationDate><firstPublicationDate>2018-04-27</firstPublicationDate></result>
<result><id>29317618</id><source>MED</source><pmid>29317618</pmid><pmcid>PMC5760734</pmcid><fullTextIdList><fullTextId>PMC5760734</fullTextId></fullTextIdList><doi>10.1038/s41467-017-02294-6</doi><title>Development of an oral once-weekly drug delivery system for HIV antiretroviral therapy.</title><authorString>Kirtane AR, Abouzid O, Minahan D, Bensel T, Hill AL, Selinger C, Bershteyn A, Craig M, Mo SS, Mazdiyasni H, Cleveland C, Rogner J, Lee YL, Booth L, Javid F, Wu SJ, Grant T, Bellinger AM, Nikolic B, Hayward A, Wood L, Eckhoff PA, Nowak MA, Langer R, Traverso G.</authorString><authorList><author><fullName>Kirtane AR</fullName><firstName>Ameya R</firstName><lastName>Kirtane</lastName><initials>AR</initials><authorId type="ORCID">0000-0002-3779-0363</authorId><authorAffiliationDetailsList><authorAffiliation><affiliation>Department of Chemical Engineering and David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA.</affiliation></authorAffiliation></authorAffiliationDetailsList></author><author><fullName>Abouzid O</fullName><firstName>Omar</firstName><lastName>Abouzid</lastName><initials>O</initials><authorAffiliationDetailsList><authorAffiliation><affiliation>Department of Chemical Engineering and David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA.</affiliation></authorAffiliation><authorAffiliation><affiliation>Département Biosciences, Institut National des Sciences Appliquées de Lyon, 20 Avenue Albert Einstein, Villeurbanne, France, 69100.</affiliation></authorAffiliation></authorAffiliationDetailsList></author><author><fullName>Minahan D</fullName><firstName>Daniel</firstName><lastName>Minahan</lastName><initials>D</initials><authorId type="ORCID">0000-0003-3065-055X</authorId><authorAffiliationDetailsList><authorAffiliation><affiliation>Department of Chemical Engineering and David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA.</affiliation></authorAffiliation></authorAffiliationDetailsList></author><author><fullName>Bensel T</fullName><firstName>Taylor</firstName><lastName>Bensel</lastName><initials>T</initials><authorAffiliationDetailsList><authorAffiliation><affiliation>Department of Chemical Engineering and David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA.</affiliation></authorAffiliation></authorAffiliationDetailsList></author><author><fullName>Hill AL</fullName><firstName>Alison L</firstName><lastName>Hill</lastName><initials>AL</initials><authorId type="ORCID">0000-0002-6583-3623</authorId><authorAffiliationDetailsList><authorAffiliation><affiliation>Program for Evolutionary Dynamics, Harvard University, Cambridge, Massachusetts, 02138, USA.</affiliation></authorAffiliation></authorAffiliationDetailsList></author><author><fullName>Selinger C</fullName><firstName>Christian</firstName><lastName>Selinger</lastName><initials>C</initials><authorId type="ORCID">0000-0002-4361-549X</authorId><authorAffiliationDetailsList><authorAffiliation><affiliation>Institute for Disease Modeling, Bellevue, WA, 98005, USA.</affiliation></authorAffiliation></authorAffiliationDetailsList></author><author><fullName>Bershteyn A</fullName><firstName>Anna</firstName><lastName>Bershteyn</lastName><initials>A</initials><authorAffiliationDetailsList><authorAffiliation><affiliation>Institute for Disease Modeling, Bellevue, WA, 98005, USA.</affiliation></authorAffiliation></authorAffiliationDetailsList></author><author><fullName>Craig M</fullName><firstName>Morgan</firstName><lastName>Craig</lastName><initials>M</initials><authorId type="ORCID">0000-0003-4852-4770</authorId><authorAffiliationDetailsList><authorAffiliation><affiliation>Program for Evolutionary Dynamics, Harvard University, Cambridge, Massachusetts, 02138, USA.</affiliation></authorAffiliation></authorAffiliationDetailsList></author><author><fullName>Mo SS</fullName><firstName>Shirley S</firstName><lastName>Mo</lastName><initials>SS</initials><authorAffiliationDetailsList><authorAffiliation><affiliation>Program for Evolutionary Dynamics, Harvard University, Cambridge, Massachusetts, 02138, USA.</affiliation></authorAffiliation></authorAffiliationDetailsList></author><author><fullName>Mazdiyasni H</fullName><firstName>Hormoz</firstName><lastName>Mazdiyasni</lastName><initials>H</initials><authorAffiliationDetailsList><authorAffiliation><affiliation>Department of Chemical Engineering and David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA.</affiliation></authorAffiliation></authorAffiliationDetailsList></author><author><fullName>Cleveland C</fullName><firstName>Cody</firstName><lastName>Cleveland</lastName><initials>C</initials><authorId type="ORCID">0000-0002-2973-8530</authorId><authorAffiliationDetailsList><authorAffiliation><affiliation>Department of Chemical Engineering and David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA.</affiliation></authorAffiliation><authorAffiliation><affiliation>Division of Gastroenterology Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 02115, USA.</affiliation></authorAffiliation></authorAffiliationDetailsList></author><author><fullName>Rogner J</fullName><firstName>Jaimie</firstName><lastName>Rogner</lastName><initials>J</initials><authorAffiliationDetailsList><authorAffiliation><affiliation>Department of Chemical Engineering and David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA.</affiliation></authorAffiliation></authorAffiliationDetailsList></author><author><fullName>Lee YL</fullName><firstName>Young-Ah Lucy</firstName><lastName>Lee</lastName><initials>YL</initials><authorId type="ORCID">0000-0002-2167-3939</authorId><authorAffiliationDetailsList><authorAffiliation><affiliation>Department of Chemical Engineering and David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA.</affiliation></authorAffiliation></authorAffiliationDetailsList></author><author><fullName>Booth L</fullName><firstName>Lucas</firstName><lastName>Booth</lastName><initials>L</initials><authorAffiliationDetailsList><authorAffiliation><affiliation>Department of Chemical Engineering and David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA.</affiliation></authorAffiliation></authorAffiliationDetailsList></author><author><fullName>Javid F</fullName><firstName>Farhad</firstName><lastName>Javid</lastName><initials>F</initials></author><author><fullName>Wu SJ</fullName><firstName>Sarah J</firstName><lastName>Wu</lastName><initials>SJ</initials><authorAffiliationDetailsList><authorAffiliation><affiliation>Department of Mechanical Engineering, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA.</affiliation></authorAffiliation></authorAffiliationDetailsList></author><author><fullName>Grant T</fullName><firstName>Tyler</firstName><lastName>Grant</lastName><initials>T</initials><authorAffiliationDetailsList><authorAffiliation><affiliation>Lyndra Inc, Watertown, MA, 02472, USA.</affiliation></authorAffiliation></authorAffiliationDetailsList></author><author><fullName>Bellinger AM</fullName><firstName>Andrew M</firstName><lastName>Bellinger</lastName><initials>AM</initials><authorAffiliationDetailsList><authorAffiliation><affiliation>Lyndra Inc, Watertown, MA, 02472, USA.</affiliation></authorAffiliation></authorAffiliationDetailsList></author><author><fullName>Nikolic B</fullName><firstName>Boris</firstName><lastName>Nikolic</lastName><initials>B</initials><authorAffiliationDetailsList><authorAffiliation><affiliation>Biomatics Capital, 1107 1st Avenue, Apartment 1305, Seattle, WA, 98101, USA.</affiliation></authorAffiliation></authorAffiliationDetailsList></author><author><fullName>Hayward A</fullName><firstName>Alison</firstName><lastName>Hayward</lastName><initials>A</initials><authorAffiliationDetailsList><authorAffiliation><affiliation>Department of Chemical Engineering and David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA.</affiliation></authorAffiliation></authorAffiliationDetailsList></author><author><fullName>Wood L</fullName><firstName>Lowell</firstName><lastName>Wood</lastName><initials>L</initials><authorAffiliationDetailsList><authorAffiliation><affiliation>Institute for Disease Modeling, Bellevue, WA, 98005, USA.</affiliation></authorAffiliation></authorAffiliationDetailsList></author><author><fullName>Eckhoff PA</fullName><firstName>Philip A</firstName><lastName>Eckhoff</lastName><initials>PA</initials><authorId type="ORCID">0000-0002-1278-3765</authorId><authorAffiliationDetailsList><authorAffiliation><affiliation>Institute for Disease Modeling, Bellevue, WA, 98005, USA.</affiliation></authorAffiliation></authorAffiliationDetailsList></author><author><fullName>Nowak MA</fullName><firstName>Martin A</firstName><lastName>Nowak</lastName><initials>MA</initials><authorId type="ORCID">0000-0001-5489-0908</authorId><authorAffiliationDetailsList><authorAffiliation><affiliation>Program for Evolutionary Dynamics, Harvard University, Cambridge, Massachusetts, 02138, USA.</affiliation></authorAffiliation></authorAffiliationDetailsList></author><author><fullName>Langer R</fullName><firstName>Robert</firstName><lastName>Langer</lastName><initials>R</initials><authorAffiliationDetailsList><authorAffiliation><affiliation>Department of Chemical Engineering and David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA. rlanger@mit.edu.</affiliation></authorAffiliation><authorAffiliation><affiliation>Media Lab, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA. rlanger@mit.edu.</affiliation></authorAffiliation><authorAffiliation><affiliation>Institute for Medical Engineering and Science, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA. rlanger@mit.edu.</affiliation></authorAffiliation></authorAffiliationDetailsList></author><author><fullName>Traverso G</fullName><firstName>Giovanni</firstName><lastName>Traverso</lastName><initials>G</initials><authorId type="ORCID">0000-0001-7851-4077</authorId><authorAffiliationDetailsList><authorAffiliation><affiliation>Department of Chemical Engineering and David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA. ctraverso@bwh.harvard.edu.</affiliation></authorAffiliation><authorAffiliation><affiliation>Division of Gastroenterology Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 02115, USA. ctraverso@bwh.harvard.edu.</affiliation></authorAffiliation></authorAffiliationDetailsList></author></authorList><authorIdList><authorId type="ORCID">0000-0001-5489-0908</authorId><authorId type="ORCID">0000-0001-7851-4077</authorId><authorId type="ORCID">0000-0002-1278-3765</authorId><authorId type="ORCID">0000-0002-2167-3939</authorId><authorId type="ORCID">0000-0002-2973-8530</authorId><authorId type="ORCID">0000-0002-3779-0363</authorId><authorId type="ORCID">0000-0002-4361-549X</authorId><authorId type="ORCID">0000-0002-6583-3623</authorId><authorId type="ORCID">0000-0003-3065-055X</authorId><authorId type="ORCID">0000-0003-4852-4770</authorId></authorIdList><dataLinksTagsList><dataLinkstag>supporting_data</dataLinkstag><dataLinkstag>altmetrics</dataLinkstag></dataLinksTagsList><journalInfo><issue>1</issue><volume>9</volume><journalIssueId>2634211</journalIssueId><dateOfPublication>2018 Jan</dateOfPublication><monthOfPublication>1</monthOfPublication><yearOfPublication>2018</yearOfPublication><printPublicationDate>2018-01-01</printPublicationDate><journal><title>Nature communications</title><ISOAbbreviation>Nat Commun</ISOAbbreviation><medlineAbbreviation>Nat Commun</medlineAbbreviation><NLMid>101528555</NLMid><ISSN>2041-1723</ISSN><ESSN>2041-1723</ESSN></journal></journalInfo><pubYear>2018</pubYear><pageInfo>2</pageInfo><abstractText>The efficacy of antiretroviral therapy is significantly compromised by medication non-adherence. Long-acting enteral systems that can ease the burden of daily adherence have not yet been developed. Here we describe an oral dosage form composed of distinct drug-polymer matrices which achieved week-long systemic drug levels of the antiretrovirals dolutegravir, rilpivirine and cabotegravir in a pig. Simulations of viral dynamics and patient adherence patterns indicate that such systems would significantly reduce therapeutic failures and epidemiological modelling suggests that using such an intervention prophylactically could avert hundreds of thousands of new HIV cases. In sum, weekly administration of long-acting antiretrovirals via a novel oral dosage form is a promising intervention to help control the HIV epidemic worldwide.</abstractText><affiliation>Department of Chemical Engineering and David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA.</affiliation><publicationStatus>epublish</publicationStatus><language>eng</language><pubModel>Electronic</pubModel><pubTypeList><pubType>Research Support, Non-U.S. Gov't</pubType><pubType>research-article</pubType><pubType>Journal Article</pubType><pubType>Research Support, N.I.H., Extramural</pubType></pubTypeList><grantsList><grant><grantId>R01 AI131416</grantId><agency>NIAID NIH HHS</agency><acronym>AI</acronym><orderIn>0</orderIn></grant><grant><grantId>R37 EB000244</grantId><agency>NIBIB NIH HHS</agency><acronym>EB</acronym><orderIn>0</orderIn></grant><grant><grantId>P30 AI060354</grantId><agency>NIAID NIH HHS</agency><acronym>AI</acronym><orderIn>0</orderIn></grant><grant><grantId>R01 EB000244</grantId><agency>NIBIB NIH HHS</agency><acronym>EB</acronym><orderIn>0</orderIn></grant><grant><grantId>DP5 OD019851</grantId><agency>NIH HHS</agency><acronym>OD</acronym><orderIn>0</orderIn></grant></grantsList><meshHeadingList><meshHeading><majorTopic_YN>N</majorTopic_YN><descriptorName>Animals</descriptorName></meshHeading><meshHeading><majorTopic_YN>N</majorTopic_YN><descriptorName>Swine</descriptorName></meshHeading><meshHeading><majorTopic_YN>N</majorTopic_YN><descriptorName>Humans</descriptorName></meshHeading><meshHeading><majorTopic_YN>N</majorTopic_YN><descriptorName>Pyridones</descriptorName><meshQualifierList><meshQualifier><abbreviation>AD</abbreviation><qualifierName>administration &amp; dosage</qualifierName><majorTopic_YN>Y</majorTopic_YN></meshQualifier><meshQualifier><abbreviation>PK</abbreviation><qualifierName>pharmacokinetics</qualifierName><majorTopic_YN>N</majorTopic_YN></meshQualifier><meshQualifier><abbreviation>TU</abbreviation><qualifierName>therapeutic use</qualifierName><majorTopic_YN>N</majorTopic_YN></meshQualifier></meshQualifierList></meshHeading><meshHeading><majorTopic_YN>N</majorTopic_YN><descriptorName>Heterocyclic Compounds, 3-Ring</descriptorName><meshQualifierList><meshQualifier><abbreviation>AD</abbreviation><qualifierName>administration &amp; dosage</qualifierName><majorTopic_YN>Y</majorTopic_YN></meshQualifier><meshQualifier><abbreviation>PK</abbreviation><qualifierName>pharmacokinetics</qualifierName><majorTopic_YN>N</majorTopic_YN></meshQualifier><meshQualifier><abbreviation>TU</abbreviation><qualifierName>therapeutic use</qualifierName><majorTopic_YN>N</majorTopic_YN></meshQualifier></meshQualifierList></meshHeading><meshHeading><majorTopic_YN>N</majorTopic_YN><descriptorName>Anti-HIV Agents</descriptorName><meshQualifierList><meshQualifier><abbreviation>AD</abbreviation><qualifierName>administration &amp; dosage</qualifierName><majorTopic_YN>Y</majorTopic_YN></meshQualifier><meshQualifier><abbreviation>PK</abbreviation><qualifierName>pharmacokinetics</qualifierName><majorTopic_YN>N</majorTopic_YN></meshQualifier><meshQualifier><abbreviation>TU</abbreviation><qualifierName>therapeutic use</qualifierName><majorTopic_YN>N</majorTopic_YN></meshQualifier></meshQualifierList></meshHeading><meshHeading><majorTopic_YN>N</majorTopic_YN><descriptorName>Drug Delivery Systems</descriptorName><meshQualifierList><meshQualifier><abbreviation>MT</abbreviation><qualifierName>methods</qualifierName><majorTopic_YN>Y</majorTopic_YN></meshQualifier></meshQualifierList></meshHeading><meshHeading><majorTopic_YN>N</majorTopic_YN><descriptorName>Administration, Oral</descriptorName></meshHeading><meshHeading><majorTopic_YN>N</majorTopic_YN><descriptorName>Drug Evaluation, Preclinical</descriptorName></meshHeading><meshHeading><majorTopic_YN>N</majorTopic_YN><descriptorName>Patient Compliance</descriptorName></meshHeading><meshHeading><majorTopic_YN>N</majorTopic_YN><descriptorName>Models, Theoretical</descriptorName></meshHeading><meshHeading><majorTopic_YN>N</majorTopic_YN><descriptorName>Rilpivirine</descriptorName><meshQualifierList><meshQualifier><abbreviation>AD</abbreviation><qualifierName>administration &amp; dosage</qualifierName><majorTopic_YN>Y</majorTopic_YN></meshQualifier><meshQualifier><abbreviation>PK</abbreviation><qualifierName>pharmacokinetics</qualifierName><majorTopic_YN>N</majorTopic_YN></meshQualifier><meshQualifier><abbreviation>TU</abbreviation><qualifierName>therapeutic use</qualifierName><majorTopic_YN>N</majorTopic_YN></meshQualifier></meshQualifierList></meshHeading><meshHeading><majorTopic_YN>N</majorTopic_YN><descriptorName>Proof of Concept Study</descriptorName></meshHeading></meshHeadingList><chemicalList><chemical><name>Pyridones</name><registryNumber>0</registryNumber></chemical><chemical><name>Heterocyclic Compounds, 3-Ring</name><registryNumber>0</registryNumber></chemical><chemical><name>Anti-HIV Agents</name><registryNumber>0</registryNumber></chemical><chemical><name>dolutegravir</name><registryNumber>DKO1W9H7M1</registryNumber></chemical><chemical><name>Rilpivirine</name><registryNumber>FI96A8X663</registryNumber></chemical><chemical><name>cabotegravir</name><registryNumber>HMH0132Z1Q</registryNumber></chemical></chemicalList><subsetList><subset><code>IM</code><name>Index Medicus</name></subset></subsetList><fullTextUrlList><fullTextUrl><availability>Subscription required</availability><availabilityCode>S</availabilityCode><documentStyle>doi</documentStyle><site>DOI</site><url>https://doi.org/10.1038/s41467-017-02294-6</url></fullTextUrl><fullTextUrl><availability>Open access</availability><availabilityCode>OA</availabilityCode><documentStyle>html</documentStyle><site>Europe_PMC</site><url>https://europepmc.org/articles/PMC5760734</url></fullTextUrl><fullTextUrl><availability>Open access</availability><availabilityCode>OA</availabilityCode><documentStyle>pdf</documentStyle><site>Europe_PMC</site><url>https://europepmc.org/articles/PMC5760734?pdf=render</url></fullTextUrl></fullTextUrlList><isOpenAccess>Y</isOpenAccess><inEPMC>Y</inEPMC><inPMC>N</inPMC><hasPDF>Y</hasPDF><hasBook>N</hasBook><hasSuppl>Y</hasSuppl><citedByCount>31</citedByCount><hasData>Y</hasData><hasReferences>Y</hasReferences><hasTextMinedTerms>Y</hasTextMinedTerms><hasDbCrossReferences>N</hasDbCrossReferences><hasLabsLinks>Y</hasLabsLinks><license>cc by</license><authMan>N</authMan><epmcAuthMan>N</epmcAuthMan><nihAuthMan>N</nihAuthMan><hasTMAccessionNumbers>Y</hasTMAccessionNumbers><tmAccessionTypeList><accessionType>nct</accessionType></tmAccessionTypeList><dateOfCompletion>2018-03-05</dateOfCompletion><dateOfCreation>2018-01-11</dateOfCreation><firstIndexDate>2018-01-11</firstIndexDate><fullTextReceivedDate>2020-07-11</fullTextReceivedDate><dateOfRevision>2020-11-25</dateOfRevision><electronicPublicationDate>2018-01-09</electronicPublicationDate><firstPublicationDate>2018-01-09</firstPublicationDate></result>
<result><id>26867183</id><source>MED</source><pmid>26867183</pmid><pmcid>PMC5271177</pmcid><fullTextIdList><fullTextId>PMC5271177</fullTextId></fullTextIdList><doi>10.1016/j.chom.2016.01.002</doi><title>Integrated Omics Analysis of Pathogenic Host Responses during Pandemic H1N1 Influenza Virus Infection: The Crucial Role of Lipid Metabolism.</title><authorString>Tisoncik-Go J, Gasper DJ, Kyle JE, Eisfeld AJ, Selinger C, Hatta M, Morrison J, Korth MJ, Zink EM, Kim YM, Schepmoes AA, Nicora CD, Purvine SO, Weitz KK, Peng X, Green RR, Tilton SC, Webb-Robertson BJ, Waters KM, Metz TO, Smith RD, Kawaoka Y, Suresh M, Josset L, Katze MG.</authorString><authorList><author><fullName>Tisoncik-Go J</fullName><firstName>Jennifer</firstName><lastName>Tisoncik-Go</lastName><initials>J</initials><authorAffiliationDetailsList><authorAffiliation><affiliation>Department of Microbiology, University of Washington, Seattle, WA 98195, USA.</affiliation></authorAffiliation></authorAffiliationDetailsList></author><author><fullName>Gasper DJ</fullName><firstName>David J</firstName><lastName>Gasper</lastName><initials>DJ</initials><authorAffiliationDetailsList><authorAffiliation><affiliation>Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin, Madison, WI 53706, USA.</affiliation></authorAffiliation></authorAffiliationDetailsList></author><author><fullName>Kyle JE</fullName><firstName>Jennifer E</firstName><lastName>Kyle</lastName><initials>JE</initials><authorAffiliationDetailsList><authorAffiliation><affiliation>Biological Sciences Division, Pacific Northwest National Laboratory, Richland, WA 99354, USA.</affiliation></authorAffiliation></authorAffiliationDetailsList></author><author><fullName>Eisfeld AJ</fullName><firstName>Amie J</firstName><lastName>Eisfeld</lastName><initials>AJ</initials><authorAffiliationDetailsList><authorAffiliation><affiliation>Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin, Madison, WI 53706, USA.</affiliation></authorAffiliation></authorAffiliationDetailsList></author><author><fullName>Selinger C</fullName><firstName>Christian</firstName><lastName>Selinger</lastName><initials>C</initials><authorId type="ORCID">0000-0002-4361-549X</authorId><authorAffiliationDetailsList><authorAffiliation><affiliation>Department of Microbiology, University of Washington, Seattle, WA 98195, USA.</affiliation></authorAffiliation></authorAffiliationDetailsList></author><author><fullName>Hatta M</fullName><firstName>Masato</firstName><lastName>Hatta</lastName><initials>M</initials><authorAffiliationDetailsList><authorAffiliation><affiliation>Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin, Madison, WI 53706, USA.</affiliation></authorAffiliation></authorAffiliationDetailsList></author><author><fullName>Morrison J</fullName><firstName>Juliet</firstName><lastName>Morrison</lastName><initials>J</initials><authorId type="ORCID">0000-0001-7387-6351</authorId><authorAffiliationDetailsList><authorAffiliation><affiliation>Department of Microbiology, University of Washington, Seattle, WA 98195, USA.</affiliation></authorAffiliation></authorAffiliationDetailsList></author><author><fullName>Korth MJ</fullName><firstName>Marcus J</firstName><lastName>Korth</lastName><initials>MJ</initials><authorAffiliationDetailsList><authorAffiliation><affiliation>Department of Microbiology, University of Washington, Seattle, WA 98195, USA.</affiliation></authorAffiliation></authorAffiliationDetailsList></author><author><fullName>Zink EM</fullName><firstName>Erika M</firstName><lastName>Zink</lastName><initials>EM</initials><authorAffiliationDetailsList><authorAffiliation><affiliation>Biological Sciences Division, Pacific Northwest National Laboratory, Richland, WA 99354, USA.</affiliation></authorAffiliation></authorAffiliationDetailsList></author><author><fullName>Kim YM</fullName><firstName>Young-Mo</firstName><lastName>Kim</lastName><initials>YM</initials><authorId type="ORCID">0000-0002-8972-7593</authorId><authorAffiliationDetailsList><authorAffiliation><affiliation>Biological Sciences Division, Pacific Northwest National Laboratory, Richland, WA 99354, USA.</affiliation></authorAffiliation></authorAffiliationDetailsList></author><author><fullName>Schepmoes AA</fullName><firstName>Athena A</firstName><lastName>Schepmoes</lastName><initials>AA</initials><authorAffiliationDetailsList><authorAffiliation><affiliation>Biological Sciences Division, Pacific Northwest National Laboratory, Richland, WA 99354, USA.</affiliation></authorAffiliation></authorAffiliationDetailsList></author><author><fullName>Nicora CD</fullName><firstName>Carrie D</firstName><lastName>Nicora</lastName><initials>CD</initials><authorAffiliationDetailsList><authorAffiliation><affiliation>Biological Sciences Division, Pacific Northwest National Laboratory, Richland, WA 99354, USA.</affiliation></authorAffiliation></authorAffiliationDetailsList></author><author><fullName>Purvine SO</fullName><firstName>Samuel O</firstName><lastName>Purvine</lastName><initials>SO</initials><authorId type="ORCID">0000-0002-2257-2400</authorId><authorAffiliationDetailsList><authorAffiliation><affiliation>Environmental Molecular Sciences Laboratory, Pacific Northwest National Laboratory, Richland, WA 99354, USA.</affiliation></authorAffiliation></authorAffiliationDetailsList></author><author><fullName>Weitz KK</fullName><firstName>Karl K</firstName><lastName>Weitz</lastName><initials>KK</initials><authorAffiliationDetailsList><authorAffiliation><affiliation>Biological Sciences Division, Pacific Northwest National Laboratory, Richland, WA 99354, USA.</affiliation></authorAffiliation></authorAffiliationDetailsList></author><author><fullName>Peng X</fullName><firstName>Xinxia</firstName><lastName>Peng</lastName><initials>X</initials><authorAffiliationDetailsList><authorAffiliation><affiliation>Department of Microbiology, University of Washington, Seattle, WA 98195, USA.</affiliation></authorAffiliation></authorAffiliationDetailsList></author><author><fullName>Green RR</fullName><firstName>Richard R</firstName><lastName>Green</lastName><initials>RR</initials><authorAffiliationDetailsList><authorAffiliation><affiliation>Department of Microbiology, University of Washington, Seattle, WA 98195, USA.</affiliation></authorAffiliation></authorAffiliationDetailsList></author><author><fullName>Tilton SC</fullName><firstName>Susan C</firstName><lastName>Tilton</lastName><initials>SC</initials><authorAffiliationDetailsList><authorAffiliation><affiliation>Biological Sciences Division, Pacific Northwest National Laboratory, Richland, WA 99354, USA.</affiliation></authorAffiliation></authorAffiliationDetailsList></author><author><fullName>Webb-Robertson BJ</fullName><firstName>Bobbie-Jo</firstName><lastName>Webb-Robertson</lastName><initials>BJ</initials><authorId type="ORCID">0000-0002-4744-2397</authorId><authorAffiliationDetailsList><authorAffiliation><affiliation>Computational and Statistical Analytics Division, Pacific Northwest National Laboratory, Richland, WA 99354, USA.</affiliation></authorAffiliation></authorAffiliationDetailsList></author><author><fullName>Waters KM</fullName><firstName>Katrina M</firstName><lastName>Waters</lastName><initials>KM</initials><authorId type="ORCID">0000-0003-4696-5396</authorId><authorAffiliationDetailsList><authorAffiliation><affiliation>Biological Sciences Division, Pacific Northwest National Laboratory, Richland, WA 99354, USA.</affiliation></authorAffiliation></authorAffiliationDetailsList></author><author><fullName>Metz TO</fullName><firstName>Thomas O</firstName><lastName>Metz</lastName><initials>TO</initials><authorAffiliationDetailsList><authorAffiliation><affiliation>Biological Sciences Division, Pacific Northwest National Laboratory, Richland, WA 99354, USA.</affiliation></authorAffiliation></authorAffiliationDetailsList></author><author><fullName>Smith RD</fullName><firstName>Richard D</firstName><lastName>Smith</lastName><initials>RD</initials><authorAffiliationDetailsList><authorAffiliation><affiliation>Biological Sciences Division, Pacific Northwest National Laboratory, Richland, WA 99354, USA.</affiliation></authorAffiliation></authorAffiliationDetailsList></author><author><fullName>Kawaoka Y</fullName><firstName>Yoshihiro</firstName><lastName>Kawaoka</lastName><initials>Y</initials><authorAffiliationDetailsList><authorAffiliation><affiliation>Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin, Madison, WI 53706, USA; Division of Virology, Department of Microbiology and Immunology, Institute of Medical Science, University of Tokyo, Minato-ku, Tokyo 108-8639, Japan; Japan Department of Special Pathogens, International Research Center for Infectious Diseases, Institute of Medical Science, University of Tokyo, Minato-ku, Tokyo 108-8639, Japan; Laboratory of Bioresponses Regulation, Department of Biological Responses, Institute for Virus Research, Kyoto University, Kyoto 606-8507, Japan.</affiliation></authorAffiliation></authorAffiliationDetailsList></author><author><fullName>Suresh M</fullName><firstName>M</firstName><lastName>Suresh</lastName><initials>M</initials><authorId type="ORCID">0000-0003-1794-3358</authorId><authorAffiliationDetailsList><authorAffiliation><affiliation>Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin, Madison, WI 53706, USA.</affiliation></authorAffiliation></authorAffiliationDetailsList></author><author><fullName>Josset L</fullName><firstName>Laurence</firstName><lastName>Josset</lastName><initials>L</initials><authorId type="ORCID">0000-0002-7158-1186</authorId><authorAffiliationDetailsList><authorAffiliation><affiliation>Laboratoire de Virologie, Centre de Biologie Est des Hospices Civils de Lyon, Université Claude Bernard Lyon 1, 69495 Lyon, France.</affiliation></authorAffiliation></authorAffiliationDetailsList></author><author><fullName>Katze MG</fullName><firstName>Michael G</firstName><lastName>Katze</lastName><initials>MG</initials><authorAffiliationDetailsList><authorAffiliation><affiliation>Department of Microbiology, University of Washington, Seattle, WA 98195, USA; Washington National Primate Research Center, Seattle, WA 98195, USA. Electronic address: honey@uw.edu.</affiliation></authorAffiliation></authorAffiliationDetailsList></author></authorList><authorIdList><authorId type="ORCID">0000-0001-7387-6351</authorId><authorId type="ORCID">0000-0002-2257-2400</authorId><authorId type="ORCID">0000-0002-4361-549X</authorId><authorId type="ORCID">0000-0002-4744-2397</authorId><authorId type="ORCID">0000-0002-7158-1186</authorId><authorId type="ORCID">0000-0002-8972-7593</authorId><authorId type="ORCID">0000-0003-1794-3358</authorId><authorId type="ORCID">0000-0003-4696-5396</authorId></authorIdList><dataLinksTagsList><dataLinkstag>supporting_data</dataLinkstag><dataLinkstag>altmetrics</dataLinkstag></dataLinksTagsList><journalInfo><issue>2</issue><volume>19</volume><journalIssueId>2374478</journalIssueId><dateOfPublication>2016 Feb</dateOfPublication><monthOfPublication>2</monthOfPublication><yearOfPublication>2016</yearOfPublication><printPublicationDate>2016-02-01</printPublicationDate><journal><title>Cell host &amp; microbe</title><ISOAbbreviation>Cell Host Microbe</ISOAbbreviation><medlineAbbreviation>Cell Host Microbe</medlineAbbreviation><NLMid>101302316</NLMid><ISSN>1931-3128</ISSN><ESSN>1934-6069</ESSN></journal></journalInfo><pubYear>2016</pubYear><pageInfo>254-266</pageInfo><abstractText>Pandemic influenza viruses modulate proinflammatory responses that can lead to immunopathogenesis. We present an extensive and systematic profiling of lipids, metabolites, and proteins in respiratory compartments of ferrets infected with either 1918 or 2009 human pandemic H1N1 influenza viruses. Integrative analysis of high-throughput omics data with virologic and histopathologic data uncovered relationships between host responses and phenotypic outcomes of viral infection. Proinflammatory lipid precursors in the trachea following 1918 infection correlated with severe tracheal lesions. Using an algorithm to infer cell quantity changes from gene expression data, we found enrichment of distinct T cell subpopulations in the trachea. There was also a predicted increase in inflammatory monocytes in the lung of 1918 virus-infected animals that was sustained throughout infection. This study presents a unique resource to the influenza research community and demonstrates the utility of an integrative systems approach for characterization of lipid metabolism alterations underlying respiratory responses to viruses.</abstractText><affiliation>Department of Microbiology, University of Washington, Seattle, WA 98195, USA.</affiliation><publicationStatus>ppublish</publicationStatus><language>eng</language><pubModel>Print</pubModel><pubTypeList><pubType>Research Support, Non-U.S. Gov't</pubType><pubType>research-article</pubType><pubType>Research Support, U.S. Gov't, Non-P.H.S.</pubType><pubType>Journal Article</pubType><pubType>Research Support, N.I.H., Extramural</pubType></pubTypeList><grantsList><grant><grantId>HHSN272200800060C</grantId><agency>NIAID NIH HHS</agency><acronym>AI</acronym><orderIn>0</orderIn></grant><grant><grantId>HHSN272201400005C</grantId><agency>NIAID NIH HHS</agency><acronym>AI</acronym><orderIn>0</orderIn></grant><grant><grantId>HHSN272201400005C</grantId><agency>PHS HHS</agency><orderIn>0</orderIn></grant><grant><grantId>HHSN272201400006C</grantId><agency>NIAID NIH HHS</agency><acronym>AI</acronym><orderIn>0</orderIn></grant><grant><grantId>HHSN272201400006C</grantId><agency>PHS HHS</agency><orderIn>0</orderIn></grant><grant><grantId>P41 GM103493</grantId><agency>NIGMS NIH HHS</agency><acronym>GM</acronym><orderIn>0</orderIn></grant><grant><grantId>P51OD010425</grantId><agency>NIH HHS</agency><acronym>OD</acronym><orderIn>0</orderIn></grant><grant><grantId>5T32OD010423-07</grantId><agency>NIH HHS</agency><acronym>OD</acronym><orderIn>0</orderIn></grant><grant><grantId>T32 OD010423</grantId><agency>NIH HHS</agency><acronym>OD</acronym><orderIn>0</orderIn></grant><grant><grantId>U19 AI109761</grantId><agency>NIAID NIH HHS</agency><acronym>AI</acronym><orderIn>0</orderIn></grant><grant><grantId>U19AI109761</grantId><agency>NIAID NIH HHS</agency><acronym>AI</acronym><orderIn>0</orderIn></grant><grant><grantId>P51 OD010425</grantId><agency>NIH HHS</agency><acronym>OD</acronym><orderIn>0</orderIn></grant></grantsList><meshHeadingList><meshHeading><majorTopic_YN>N</majorTopic_YN><descriptorName>Lung</descriptorName><meshQualifierList><meshQualifier><abbreviation>ME</abbreviation><qualifierName>metabolism</qualifierName><majorTopic_YN>N</majorTopic_YN></meshQualifier><meshQualifier><abbreviation>PA</abbreviation><qualifierName>pathology</qualifierName><majorTopic_YN>N</majorTopic_YN></meshQualifier><meshQualifier><abbreviation>VI</abbreviation><qualifierName>virology</qualifierName><majorTopic_YN>N</majorTopic_YN></meshQualifier></meshQualifierList></meshHeading><meshHeading><majorTopic_YN>N</majorTopic_YN><descriptorName>Animals</descriptorName></meshHeading><meshHeading><majorTopic_YN>N</majorTopic_YN><descriptorName>Ferrets</descriptorName></meshHeading><meshHeading><majorTopic_YN>N</majorTopic_YN><descriptorName>Humans</descriptorName></meshHeading><meshHeading><majorTopic_YN>N</majorTopic_YN><descriptorName>Disease Models, Animal</descriptorName></meshHeading><meshHeading><majorTopic_YN>N</majorTopic_YN><descriptorName>Lipids</descriptorName><meshQualifierList><meshQualifier><abbreviation>CH</abbreviation><qualifierName>chemistry</qualifierName><majorTopic_YN>N</majorTopic_YN></meshQualifier></meshQualifierList></meshHeading><meshHeading><majorTopic_YN>N</majorTopic_YN><descriptorName>Gene Expression</descriptorName></meshHeading><meshHeading><majorTopic_YN>Y</majorTopic_YN><descriptorName>Lipid Metabolism</descriptorName></meshHeading><meshHeading><majorTopic_YN>N</majorTopic_YN><descriptorName>Influenza, Human</descriptorName><meshQualifierList><meshQualifier><abbreviation>GE</abbreviation><qualifierName>genetics</qualifierName><majorTopic_YN>N</majorTopic_YN></meshQualifier><meshQualifier><abbreviation>ME</abbreviation><qualifierName>metabolism</qualifierName><majorTopic_YN>Y</majorTopic_YN></meshQualifier><meshQualifier><abbreviation>EP</abbreviation><qualifierName>epidemiology</qualifierName><majorTopic_YN>N</majorTopic_YN></meshQualifier><meshQualifier><abbreviation>PA</abbreviation><qualifierName>pathology</qualifierName><majorTopic_YN>N</majorTopic_YN></meshQualifier></meshQualifierList></meshHeading><meshHeading><majorTopic_YN>N</majorTopic_YN><descriptorName>Influenza A Virus, H1N1 Subtype</descriptorName><meshQualifierList><meshQualifier><abbreviation>PH</abbreviation><qualifierName>physiology</qualifierName><majorTopic_YN>Y</majorTopic_YN></meshQualifier></meshQualifierList></meshHeading><meshHeading><majorTopic_YN>N</majorTopic_YN><descriptorName>Host-Pathogen Interactions</descriptorName></meshHeading><meshHeading><majorTopic_YN>N</majorTopic_YN><descriptorName>Metabolomics</descriptorName></meshHeading></meshHeadingList><chemicalList><chemical><name>Lipids</name><registryNumber>0</registryNumber></chemical></chemicalList><subsetList><subset><code>IM</code><name>Index Medicus</name></subset></subsetList><fullTextUrlList><fullTextUrl><availability>Subscription required</availability><availabilityCode>S</availabilityCode><documentStyle>doi</documentStyle><site>DOI</site><url>https://doi.org/10.1016/j.chom.2016.01.002</url></fullTextUrl><fullTextUrl><availability>Free</availability><availabilityCode>F</availabilityCode><documentStyle>html</documentStyle><site>Europe_PMC</site><url>https://europepmc.org/articles/PMC5271177</url></fullTextUrl><fullTextUrl><availability>Free</availability><availabilityCode>F</availabilityCode><documentStyle>pdf</documentStyle><site>Europe_PMC</site><url>https://europepmc.org/articles/PMC5271177?pdf=render</url></fullTextUrl><fullTextUrl><availability>Free</availability><availabilityCode>F</availabilityCode><documentStyle>doi</documentStyle><site>DOI</site><url>https://doi.org/10.1016/j.chom.2016.01.002</url></fullTextUrl></fullTextUrlList><isOpenAccess>N</isOpenAccess><inEPMC>Y</inEPMC><inPMC>N</inPMC><hasPDF>Y</hasPDF><hasBook>N</hasBook><hasSuppl>Y</hasSuppl><citedByCount>30</citedByCount><hasData>Y</hasData><hasReferences>Y</hasReferences><hasTextMinedTerms>Y</hasTextMinedTerms><hasDbCrossReferences>N</hasDbCrossReferences><hasLabsLinks>Y</hasLabsLinks><authMan>Y</authMan><epmcAuthMan>N</epmcAuthMan><nihAuthMan>Y</nihAuthMan><manuscriptId>NIHMS754407</manuscriptId><hasTMAccessionNumbers>Y</hasTMAccessionNumbers><tmAccessionTypeList><accessionType>bioproject</accessionType><accessionType>metabolights</accessionType></tmAccessionTypeList><dateOfCompletion>2016-10-31</dateOfCompletion><dateOfCreation>2016-02-12</dateOfCreation><firstIndexDate>2016-02-12</firstIndexDate><fullTextReceivedDate>2020-09-30</fullTextReceivedDate><dateOfRevision>2020-09-28</dateOfRevision><firstPublicationDate>2016-02-01</firstPublicationDate></result>
<result><id>26656717</id><source>MED</source><pmid>26656717</pmid><pmcid>PMC4810726</pmcid><fullTextIdList><fullTextId>PMC4810726</fullTextId></fullTextIdList><doi>10.1128/jvi.02974-15</doi><title>The 1918 Influenza Virus PB2 Protein Enhances Virulence through the Disruption of Inflammatory and Wnt-Mediated Signaling in Mice.</title><authorString>Forero A, Tisoncik-Go J, Watanabe T, Zhong G, Hatta M, Tchitchek N, Selinger C, Chang J, Barker K, Morrison J, Berndt JD, Moon RT, Josset L, Kawaoka Y, Katze MG.</authorString><authorList><author><fullName>Forero A</fullName><firstName>Adriana</firstName><lastName>Forero</lastName><initials>A</initials><authorAffiliationDetailsList><authorAffiliation><affiliation>Department of Microbiology, University of Washington, Seattle, Washington, USA.</affiliation></authorAffiliation></authorAffiliationDetailsList></author><author><fullName>Tisoncik-Go J</fullName><firstName>Jennifer</firstName><lastName>Tisoncik-Go</lastName><initials>J</initials><authorAffiliationDetailsList><authorAffiliation><affiliation>Department of Microbiology, University of Washington, Seattle, Washington, USA.</affiliation></authorAffiliation></authorAffiliationDetailsList></author><author><fullName>Watanabe T</fullName><firstName>Tokiko</firstName><lastName>Watanabe</lastName><initials>T</initials><authorAffiliationDetailsList><authorAffiliation><affiliation>Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin-Madison, Madison, Wisconsin, USA.</affiliation></authorAffiliation></authorAffiliationDetailsList></author><author><fullName>Zhong G</fullName><firstName>Gongxun</firstName><lastName>Zhong</lastName><initials>G</initials><authorAffiliationDetailsList><authorAffiliation><affiliation>Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin-Madison, Madison, Wisconsin, USA.</affiliation></authorAffiliation></authorAffiliationDetailsList></author><author><fullName>Hatta M</fullName><firstName>Masato</firstName><lastName>Hatta</lastName><initials>M</initials><authorAffiliationDetailsList><authorAffiliation><affiliation>Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin-Madison, Madison, Wisconsin, USA.</affiliation></authorAffiliation></authorAffiliationDetailsList></author><author><fullName>Tchitchek N</fullName><firstName>Nicolas</firstName><lastName>Tchitchek</lastName><initials>N</initials><authorAffiliationDetailsList><authorAffiliation><affiliation>Department of Microbiology, University of Washington, Seattle, Washington, USA.</affiliation></authorAffiliation></authorAffiliationDetailsList></author><author><fullName>Selinger C</fullName><firstName>Christian</firstName><lastName>Selinger</lastName><initials>C</initials><authorId type="ORCID">0000-0002-4361-549X</authorId><authorAffiliationDetailsList><authorAffiliation><affiliation>Department of Microbiology, University of Washington, Seattle, Washington, USA.</affiliation></authorAffiliation></authorAffiliationDetailsList></author><author><fullName>Chang J</fullName><firstName>Jean</firstName><lastName>Chang</lastName><initials>J</initials><authorAffiliationDetailsList><authorAffiliation><affiliation>Department of Microbiology, University of Washington, Seattle, Washington, USA.</affiliation></authorAffiliation></authorAffiliationDetailsList></author><author><fullName>Barker K</fullName><firstName>Kristi</firstName><lastName>Barker</lastName><initials>K</initials><authorAffiliationDetailsList><authorAffiliation><affiliation>Department of Microbiology, University of Washington, Seattle, Washington, USA.</affiliation></authorAffiliation></authorAffiliationDetailsList></author><author><fullName>Morrison J</fullName><firstName>Juliet</firstName><lastName>Morrison</lastName><initials>J</initials><authorId type="ORCID">0000-0001-7387-6351</authorId><authorAffiliationDetailsList><authorAffiliation><affiliation>Department of Microbiology, University of Washington, Seattle, Washington, USA.</affiliation></authorAffiliation></authorAffiliationDetailsList></author><author><fullName>Berndt JD</fullName><firstName>Jason D</firstName><lastName>Berndt</lastName><initials>JD</initials><authorAffiliationDetailsList><authorAffiliation><affiliation>Howard Hughes Medical Institute, Institute for Stem Cell and Regenerative Medicine, and Department of Pharmacology, University of Washington School of Medicine, Seattle, Washington, USA.</affiliation></authorAffiliation></authorAffiliationDetailsList></author><author><fullName>Moon RT</fullName><firstName>Randall T</firstName><lastName>Moon</lastName><initials>RT</initials><authorAffiliationDetailsList><authorAffiliation><affiliation>Howard Hughes Medical Institute, Institute for Stem Cell and Regenerative Medicine, and Department of Pharmacology, University of Washington School of Medicine, Seattle, Washington, USA.</affiliation></authorAffiliation></authorAffiliationDetailsList></author><author><fullName>Josset L</fullName><firstName>Laurence</firstName><lastName>Josset</lastName><initials>L</initials><authorId type="ORCID">0000-0002-7158-1186</authorId><authorAffiliationDetailsList><authorAffiliation><affiliation>Laboratory of Virology, National Influenza Centre (South of France), Hospices Civils de Lyon, Bron, France, and Laboratorie Virpath EA4610, Université Claude Bernard Lyon 1, Lyon, France.</affiliation></authorAffiliation></authorAffiliationDetailsList></author><author><fullName>Kawaoka Y</fullName><firstName>Yoshihiro</firstName><lastName>Kawaoka</lastName><initials>Y</initials><authorAffiliationDetailsList><authorAffiliation><affiliation>Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin-Madison, Madison, Wisconsin, USA.</affiliation></authorAffiliation></authorAffiliationDetailsList></author><author><fullName>Katze MG</fullName><firstName>Michael G</firstName><lastName>Katze</lastName><initials>MG</initials><authorAffiliationDetailsList><authorAffiliation><affiliation>Department of Microbiology, University of Washington, Seattle, Washington, USA Washington National Primate Research Center, University of Washington, Seattle, Washington, USA honey@uw.edu.</affiliation></authorAffiliation></authorAffiliationDetailsList></author></authorList><authorIdList><authorId type="ORCID">0000-0001-7387-6351</authorId><authorId type="ORCID">0000-0002-4361-549X</authorId><authorId type="ORCID">0000-0002-7158-1186</authorId></authorIdList><dataLinksTagsList><dataLinkstag>supporting_data</dataLinkstag><dataLinkstag>altmetrics</dataLinkstag></dataLinksTagsList><journalInfo><issue>5</issue><volume>90</volume><journalIssueId>2477015</journalIssueId><dateOfPublication>2015 Dec</dateOfPublication><monthOfPublication>12</monthOfPublication><yearOfPublication>2015</yearOfPublication><printPublicationDate>2015-12-01</printPublicationDate><journal><title>Journal of virology</title><ISOAbbreviation>J Virol</ISOAbbreviation><medlineAbbreviation>J Virol</medlineAbbreviation><NLMid>0113724</NLMid><ISSN>0022-538X</ISSN><ESSN>1098-5514</ESSN></journal></journalInfo><pubYear>2015</pubYear><pageInfo>2240-2253</pageInfo><abstractText>&lt;h4&gt;Unlabelled&lt;/h4&gt;The 1918-1919 influenza pandemic remains the single greatest infectious disease outbreak in the past century. Mouse and nonhuman primate infection models have shown that the 1918 virus induces overly aggressive innate and proinflammatory responses. To understand the response to viral infection and the role of individual 1918 genes on the host response to the 1918 virus, we examined reassortant avian viruses nearly identical to the pandemic 1918 virus (1918-like avian virus) carrying either the 1918 hemagglutinin (HA) or PB2 gene. In mice, both genes enhanced 1918-like avian virus replication, but only the mammalian host adaptation of the 1918-like avian virus through reassortment of the 1918 PB2 led to increased lethality. Through the combination of viral genetics and host transcriptional profiling, we provide a multidimensional view of the molecular mechanisms by which the 1918 PB2 gene drives viral pathogenicity. We demonstrate that 1918 PB2 enhances immune and inflammatory responses concomitant with increased cellular infiltration in the lung. We also show for the first time, that 1918 PB2 expression results in the repression of both canonical and noncanonical Wnt signaling pathways, which are crucial for inflammation-mediated lung regeneration and repair. Finally, we utilize regulatory enrichment and network analysis to define the molecular regulators of inflammation, epithelial regeneration, and lung immunopathology that are dysregulated during influenza virus infection. Taken together, our data suggest that while both HA and PB2 are important for viral replication, only 1918 PB2 exacerbates lung damage in mice infected with a reassortant 1918-like avian virus.&lt;h4&gt;Importance&lt;/h4&gt;As viral pathogenesis is determined in part by the host response, understanding the key host molecular driver(s) of virus-mediated disease, in relation to individual viral genes, is a promising approach to host-oriented drug efforts in preventing disease. Previous studies have demonstrated the importance of host adaptive genes, HA and PB2, in mediating disease although the mechanisms by which they do so are still poorly understood. Here, we combine viral genetics and host transcriptional profiling to show that although both 1918 HA and 1918 PB2 are important mediators of efficient viral replication, only 1918 PB2 impacts the pathogenicity of an avian influenza virus sharing high homology to the 1918 pandemic influenza virus. We demonstrate that 1918 PB2 enhances deleterious inflammatory responses and the inhibition of regeneration and repair functions coordinated by Wnt signaling in the lungs of infected mice, thereby promoting virus-associated disease.</abstractText><affiliation>Department of Microbiology, University of Washington, Seattle, Washington, USA.</affiliation><publicationStatus>epublish</publicationStatus><language>eng</language><pubModel>Electronic</pubModel><pubTypeList><pubType>Research Support, N.I.H., Intramural</pubType><pubType>Research Support, Non-U.S. Gov't</pubType><pubType>research-article</pubType><pubType>Journal Article</pubType><pubType>Research Support, N.I.H., Extramural</pubType></pubTypeList><grantsList><grant><grantId>P51OD010425</grantId><agency>NIH HHS</agency><acronym>OD</acronym><orderIn>0</orderIn></grant><grant><agency>Intramural NIH HHS</agency><orderIn>0</orderIn></grant><grant><grantId>P51 OD010425</grantId><agency>NIH HHS</agency><acronym>OD</acronym><orderIn>0</orderIn></grant><grant><grantId>R01AI080598</grantId><agency>NIAID NIH HHS</agency><acronym>AI</acronym><orderIn>0</orderIn></grant><grant><grantId>U19 AI109761</grantId><agency>NIAID NIH HHS</agency><acronym>AI</acronym><orderIn>0</orderIn></grant><grant><grantId>R01 AI080598</grantId><agency>NIAID NIH HHS</agency><acronym>AI</acronym><orderIn>0</orderIn></grant><grant><grantId>U19AI109761</grantId><agency>NIAID NIH HHS</agency><acronym>AI</acronym><orderIn>0</orderIn></grant></grantsList><meshHeadingList><meshHeading><majorTopic_YN>N</majorTopic_YN><descriptorName>Lung</descriptorName><meshQualifierList><meshQualifier><abbreviation>PA</abbreviation><qualifierName>pathology</qualifierName><majorTopic_YN>N</majorTopic_YN></meshQualifier><meshQualifier><abbreviation>VI</abbreviation><qualifierName>virology</qualifierName><majorTopic_YN>N</majorTopic_YN></meshQualifier></meshQualifierList></meshHeading><meshHeading><majorTopic_YN>N</majorTopic_YN><descriptorName>Cell Line</descriptorName></meshHeading><meshHeading><majorTopic_YN>N</majorTopic_YN><descriptorName>Animals</descriptorName></meshHeading><meshHeading><majorTopic_YN>N</majorTopic_YN><descriptorName>Mice, Inbred BALB C</descriptorName></meshHeading><meshHeading><majorTopic_YN>N</majorTopic_YN><descriptorName>Humans</descriptorName></meshHeading><meshHeading><majorTopic_YN>N</majorTopic_YN><descriptorName>Reassortant Viruses</descriptorName><meshQualifierList><meshQualifier><abbreviation>EN</abbreviation><qualifierName>enzymology</qualifierName><majorTopic_YN>N</majorTopic_YN></meshQualifier><meshQualifier><abbreviation>PY</abbreviation><qualifierName>pathogenicity</qualifierName><majorTopic_YN>N</majorTopic_YN></meshQualifier></meshQualifierList></meshHeading><meshHeading><majorTopic_YN>N</majorTopic_YN><descriptorName>Orthomyxoviridae Infections</descriptorName><meshQualifierList><meshQualifier><abbreviation>PA</abbreviation><qualifierName>pathology</qualifierName><majorTopic_YN>Y</majorTopic_YN></meshQualifier><meshQualifier><abbreviation>VI</abbreviation><qualifierName>virology</qualifierName><majorTopic_YN>Y</majorTopic_YN></meshQualifier></meshQualifierList></meshHeading><meshHeading><majorTopic_YN>N</majorTopic_YN><descriptorName>Disease Models, Animal</descriptorName></meshHeading><meshHeading><majorTopic_YN>N</majorTopic_YN><descriptorName>Inflammation</descriptorName><meshQualifierList><meshQualifier><abbreviation>PA</abbreviation><qualifierName>pathology</qualifierName><majorTopic_YN>N</majorTopic_YN></meshQualifier></meshQualifierList></meshHeading><meshHeading><majorTopic_YN>N</majorTopic_YN><descriptorName>RNA Replicase</descriptorName><meshQualifierList><meshQualifier><abbreviation>GE</abbreviation><qualifierName>genetics</qualifierName><majorTopic_YN>N</majorTopic_YN></meshQualifier><meshQualifier><abbreviation>ME</abbreviation><qualifierName>metabolism</qualifierName><majorTopic_YN>Y</majorTopic_YN></meshQualifier></meshQualifierList></meshHeading><meshHeading><majorTopic_YN>N</majorTopic_YN><descriptorName>Viral Proteins</descriptorName><meshQualifierList><meshQualifier><abbreviation>GE</abbreviation><qualifierName>genetics</qualifierName><majorTopic_YN>N</majorTopic_YN></meshQualifier><meshQualifier><abbreviation>ME</abbreviation><qualifierName>metabolism</qualifierName><majorTopic_YN>Y</majorTopic_YN></meshQualifier></meshQualifierList></meshHeading><meshHeading><majorTopic_YN>N</majorTopic_YN><descriptorName>Hemagglutinin Glycoproteins, Influenza Virus</descriptorName><meshQualifierList><meshQualifier><abbreviation>GE</abbreviation><qualifierName>genetics</qualifierName><majorTopic_YN>N</majorTopic_YN></meshQualifier><meshQualifier><abbreviation>ME</abbreviation><qualifierName>metabolism</qualifierName><majorTopic_YN>N</majorTopic_YN></meshQualifier></meshQualifierList></meshHeading><meshHeading><majorTopic_YN>N</majorTopic_YN><descriptorName>Virulence Factors</descriptorName><meshQualifierList><meshQualifier><abbreviation>GE</abbreviation><qualifierName>genetics</qualifierName><majorTopic_YN>N</majorTopic_YN></meshQualifier><meshQualifier><abbreviation>ME</abbreviation><qualifierName>metabolism</qualifierName><majorTopic_YN>Y</majorTopic_YN></meshQualifier></meshQualifierList></meshHeading><meshHeading><majorTopic_YN>N</majorTopic_YN><descriptorName>Gene Expression Profiling</descriptorName></meshHeading><meshHeading><majorTopic_YN>N</majorTopic_YN><descriptorName>Virulence</descriptorName></meshHeading><meshHeading><majorTopic_YN>N</majorTopic_YN><descriptorName>Female</descriptorName></meshHeading><meshHeading><majorTopic_YN>N</majorTopic_YN><descriptorName>Influenza A Virus, H1N1 Subtype</descriptorName><meshQualifierList><meshQualifier><abbreviation>EN</abbreviation><qualifierName>enzymology</qualifierName><majorTopic_YN>Y</majorTopic_YN></meshQualifier><meshQualifier><abbreviation>GE</abbreviation><qualifierName>genetics</qualifierName><majorTopic_YN>N</majorTopic_YN></meshQualifier><meshQualifier><abbreviation>IM</abbreviation><qualifierName>immunology</qualifierName><majorTopic_YN>N</majorTopic_YN></meshQualifier><meshQualifier><abbreviation>PY</abbreviation><qualifierName>pathogenicity</qualifierName><majorTopic_YN>Y</majorTopic_YN></meshQualifier></meshQualifierList></meshHeading><meshHeading><majorTopic_YN>N</majorTopic_YN><descriptorName>Wnt Signaling Pathway</descriptorName><meshQualifierList><meshQualifier><abbreviation>IM</abbreviation><qualifierName>immunology</qualifierName><majorTopic_YN>Y</majorTopic_YN></meshQualifier></meshQualifierList></meshHeading></meshHeadingList><chemicalList><chemical><name>hemagglutinin, human influenza A virus</name><registryNumber>0</registryNumber></chemical><chemical><name>Viral Proteins</name><registryNumber>0</registryNumber></chemical><chemical><name>RNA Replicase</name><registryNumber>EC 2.7.7.48</registryNumber></chemical><chemical><name>Hemagglutinin Glycoproteins, Influenza Virus</name><registryNumber>0</registryNumber></chemical><chemical><name>Virulence Factors</name><registryNumber>0</registryNumber></chemical><chemical><name>PB2 protein, Influenzavirus A</name><registryNumber>0</registryNumber></chemical></chemicalList><subsetList><subset><code>IM</code><name>Index Medicus</name></subset></subsetList><fullTextUrlList><fullTextUrl><availability>Subscription required</availability><availabilityCode>S</availabilityCode><documentStyle>doi</documentStyle><site>DOI</site><url>https://doi.org/10.1128/JVI.02974-15</url></fullTextUrl><fullTextUrl><availability>Free</availability><availabilityCode>F</availabilityCode><documentStyle>html</documentStyle><site>Europe_PMC</site><url>https://europepmc.org/articles/PMC4810726</url></fullTextUrl><fullTextUrl><availability>Free</availability><availabilityCode>F</availabilityCode><documentStyle>pdf</documentStyle><site>Europe_PMC</site><url>https://europepmc.org/articles/PMC4810726?pdf=render</url></fullTextUrl><fullTextUrl><availability>Free</availability><availabilityCode>F</availabilityCode><documentStyle>doi</documentStyle><site>DOI</site><url>https://doi.org/10.1128/jvi.02974-15</url></fullTextUrl></fullTextUrlList><isOpenAccess>N</isOpenAccess><inEPMC>Y</inEPMC><inPMC>N</inPMC><hasPDF>Y</hasPDF><hasBook>N</hasBook><hasSuppl>N</hasSuppl><citedByCount>14</citedByCount><hasData>Y</hasData><hasReferences>Y</hasReferences><hasTextMinedTerms>Y</hasTextMinedTerms><hasDbCrossReferences>N</hasDbCrossReferences><hasLabsLinks>Y</hasLabsLinks><authMan>N</authMan><epmcAuthMan>N</epmcAuthMan><nihAuthMan>N</nihAuthMan><hasTMAccessionNumbers>Y</hasTMAccessionNumbers><tmAccessionTypeList><accessionType>geo</accessionType></tmAccessionTypeList><dateOfCompletion>2016-06-21</dateOfCompletion><dateOfCreation>2015-12-15</dateOfCreation><firstIndexDate>2015-12-22</firstIndexDate><fullTextReceivedDate>2020-07-11</fullTextReceivedDate><dateOfRevision>2018-11-13</dateOfRevision><electronicPublicationDate>2015-12-09</electronicPublicationDate><firstPublicationDate>2015-12-09</firstPublicationDate></result>
<result><id>25534508</id><source>MED</source><pmid>25534508</pmid><pmcid>PMC4522970</pmcid><fullTextIdList><fullTextId>PMC4522970</fullTextId></fullTextIdList><doi>10.1186/1471-2164-15-1161</doi><title>Cytokine systems approach demonstrates differences in innate and pro-inflammatory host responses between genetically distinct MERS-CoV isolates.</title><authorString>Selinger C, Tisoncik-Go J, Menachery VD, Agnihothram S, Law GL, Chang J, Kelly SM, Sova P, Baric RS, Katze MG.</authorString><authorList><author><fullName>Selinger C</fullName><firstName>Christian</firstName><lastName>Selinger</lastName><initials>C</initials><authorId type="ORCID">0000-0002-4361-549X</authorId><authorAffiliationDetailsList><authorAffiliation><affiliation>Department of Microbiology, School of Medicine, University of Washington, Seattle, Washington, USA. csel@uw.edu.</affiliation></authorAffiliation></authorAffiliationDetailsList></author><author><fullName>Tisoncik-Go J</fullName><firstName>Jennifer</firstName><lastName>Tisoncik-Go</lastName><initials>J</initials><authorAffiliationDetailsList><authorAffiliation><affiliation>Department of Microbiology, School of Medicine, University of Washington, Seattle, Washington, USA. tisoncik@uw.edu.</affiliation></authorAffiliation></authorAffiliationDetailsList></author><author><fullName>Menachery VD</fullName><firstName>Vineet D</firstName><lastName>Menachery</lastName><initials>VD</initials><authorId type="ORCID">0000-0001-8803-7606</authorId><authorAffiliationDetailsList><authorAffiliation><affiliation>Department of Epidemiology, University of North Carolina-Chapel Hill, Chapel Hill, North Carolina, USA. vineet@email.unc.edu.</affiliation></authorAffiliation></authorAffiliationDetailsList></author><author><fullName>Agnihothram S</fullName><firstName>Sudhakar</firstName><lastName>Agnihothram</lastName><initials>S</initials><authorAffiliationDetailsList><authorAffiliation><affiliation>Department of Epidemiology, University of North Carolina-Chapel Hill, Chapel Hill, North Carolina, USA. agniss@email.unc.edu.</affiliation></authorAffiliation></authorAffiliationDetailsList></author><author><fullName>Law GL</fullName><firstName>G Lynn</firstName><lastName>Law</lastName><initials>GL</initials><authorAffiliationDetailsList><authorAffiliation><affiliation>Department of Microbiology, School of Medicine, University of Washington, Seattle, Washington, USA. gllaw@uw.edu.</affiliation></authorAffiliation></authorAffiliationDetailsList></author><author><fullName>Chang J</fullName><firstName>Jean</firstName><lastName>Chang</lastName><initials>J</initials><authorAffiliationDetailsList><authorAffiliation><affiliation>Department of Microbiology, School of Medicine, University of Washington, Seattle, Washington, USA. mspiggy1@uw.edu.</affiliation></authorAffiliation></authorAffiliationDetailsList></author><author><fullName>Kelly SM</fullName><firstName>Sara M</firstName><lastName>Kelly</lastName><initials>SM</initials><authorAffiliationDetailsList><authorAffiliation><affiliation>Department of Microbiology, School of Medicine, University of Washington, Seattle, Washington, USA. smkelly@uw.edu.</affiliation></authorAffiliation></authorAffiliationDetailsList></author><author><fullName>Sova P</fullName><firstName>Pavel</firstName><lastName>Sova</lastName><initials>P</initials><authorAffiliationDetailsList><authorAffiliation><affiliation>Department of Microbiology, School of Medicine, University of Washington, Seattle, Washington, USA. ps44@uw.edu.</affiliation></authorAffiliation></authorAffiliationDetailsList></author><author><fullName>Baric RS</fullName><firstName>Ralph S</firstName><lastName>Baric</lastName><initials>RS</initials><authorAffiliationDetailsList><authorAffiliation><affiliation>Department of Epidemiology, University of North Carolina-Chapel Hill, Chapel Hill, North Carolina, USA. rbaric@email.unc.edu.</affiliation></authorAffiliation></authorAffiliationDetailsList></author><author><fullName>Katze MG</fullName><firstName>Michael G</firstName><lastName>Katze</lastName><initials>MG</initials><authorAffiliationDetailsList><authorAffiliation><affiliation>Department of Microbiology, School of Medicine, University of Washington, Seattle, Washington, USA. honey@uw.edu.</affiliation></authorAffiliation></authorAffiliationDetailsList></author></authorList><authorIdList><authorId type="ORCID">0000-0001-8803-7606</authorId><authorId type="ORCID">0000-0002-4361-549X</authorId></authorIdList><dataLinksTagsList><dataLinkstag>related_data</dataLinkstag><dataLinkstag>supporting_data</dataLinkstag><dataLinkstag>altmetrics</dataLinkstag></dataLinksTagsList><journalInfo><volume>15</volume><journalIssueId>2474675</journalIssueId><dateOfPublication>2014 Dec</dateOfPublication><monthOfPublication>12</monthOfPublication><yearOfPublication>2014</yearOfPublication><printPublicationDate>2014-12-01</printPublicationDate><journal><title>BMC genomics</title><ISOAbbreviation>BMC Genomics</ISOAbbreviation><medlineAbbreviation>BMC Genomics</medlineAbbreviation><NLMid>100965258</NLMid><ISSN>1471-2164</ISSN><ESSN>1471-2164</ESSN></journal></journalInfo><pubYear>2014</pubYear><pageInfo>1161</pageInfo><abstractText>&lt;h4&gt;Background&lt;/h4&gt;The recent emergence of a novel coronavirus in the Middle East (designated MERS-CoV) is a reminder of the zoonotic and pathogenic potential of emerging coronaviruses in humans. Clinical features of Middle East respiratory syndrome (MERS) include atypical pneumonia and progressive respiratory failure that is highly reminiscent of severe acute respiratory syndrome (SARS) caused by SARS-CoV. The host response is a key component of highly pathogenic respiratory virus infection. Here, we computationally analyzed gene expression changes in a human airway epithelial cell line infected with two genetically distinct MERS-CoV strains obtained from human patients, MERS-CoV SA 1 and MERS-CoV Eng 1.&lt;h4&gt;Results&lt;/h4&gt;Using topological techniques, including persistence homology and filtered clustering, we performed a comparative transcriptional analysis of human Calu-3 cell host responses to the different MERS-CoV strains, with MERS-CoV Eng 1 inducing early kinetic changes, between 3 and 12 hours post infection, compared to MERS-CoV SA 1. Robust transcriptional changes distinguished the two MERS-CoV strains predominantly at the late time points. Combining statistical analysis of infection and cytokine-stimulated Calu-3 transcriptomics, we identified differential innate responses, including up-regulation of extracellular remodeling genes following MERS-CoV Eng 1 infection and differential pro-inflammatory responses.&lt;h4&gt;Conclusions&lt;/h4&gt;Through our genomics-based approach, we found topological differences in the kinetics and magnitude of the host response to MERS-CoV SA 1 and MERS-CoV Eng 1, with differential expression of innate immune and pro-inflammatory responsive genes as a result of IFN, TNF and IL-1α signaling. Predicted activation for STAT3 mediating gene expression relevant for epithelial cell-to-cell adherens and junction signaling in MERS-CoV Eng 1 infection suggest that these transcriptional differences may be the result of amino acid differences in viral proteins known to modulate innate immunity during MERS-CoV infection.</abstractText><affiliation>Department of Microbiology, School of Medicine, University of Washington, Seattle, Washington, USA. csel@uw.edu.</affiliation><publicationStatus>epublish</publicationStatus><language>eng</language><pubModel>Electronic</pubModel><pubTypeList><pubType>research-article</pubType><pubType>Journal Article</pubType><pubType>Research Support, N.I.H., Extramural</pubType></pubTypeList><grantsList><grant><grantId>P51 OD010425</grantId><agency>NIH HHS</agency><acronym>OD</acronym><orderIn>0</orderIn></grant><grant><grantId>U54AI081680</grantId><agency>NIAID NIH HHS</agency><acronym>AI</acronym><orderIn>0</orderIn></grant><grant><grantId>HHSN272200800060C</grantId><agency>NIAID NIH HHS</agency><acronym>AI</acronym><orderIn>0</orderIn></grant><grant><grantId>U19 AI100625</grantId><agency>NIAID NIH HHS</agency><acronym>AI</acronym><orderIn>0</orderIn></grant><grant><grantId>U54 AI081680</grantId><agency>NIAID NIH HHS</agency><acronym>AI</acronym><orderIn>0</orderIn></grant></grantsList><meshHeadingList><meshHeading><majorTopic_YN>N</majorTopic_YN><descriptorName>Cell Line</descriptorName></meshHeading><meshHeading><majorTopic_YN>N</majorTopic_YN><descriptorName>Humans</descriptorName></meshHeading><meshHeading><majorTopic_YN>N</majorTopic_YN><descriptorName>Inflammation</descriptorName><meshQualifierList><meshQualifier><abbreviation>VI</abbreviation><qualifierName>virology</qualifierName><majorTopic_YN>N</majorTopic_YN></meshQualifier></meshQualifierList></meshHeading><meshHeading><majorTopic_YN>N</majorTopic_YN><descriptorName>Cytokines</descriptorName><meshQualifierList><meshQualifier><abbreviation>PD</abbreviation><qualifierName>pharmacology</qualifierName><majorTopic_YN>Y</majorTopic_YN></meshQualifier></meshQualifierList></meshHeading><meshHeading><majorTopic_YN>Y</majorTopic_YN><descriptorName>Gene Expression Profiling</descriptorName></meshHeading><meshHeading><majorTopic_YN>Y</majorTopic_YN><descriptorName>Genomics</descriptorName></meshHeading><meshHeading><majorTopic_YN>N</majorTopic_YN><descriptorName>Time Factors</descriptorName></meshHeading><meshHeading><majorTopic_YN>N</majorTopic_YN><descriptorName>STAT3 Transcription Factor</descriptorName><meshQualifierList><meshQualifier><abbreviation>ME</abbreviation><qualifierName>metabolism</qualifierName><majorTopic_YN>N</majorTopic_YN></meshQualifier></meshQualifierList></meshHeading><meshHeading><majorTopic_YN>N</majorTopic_YN><descriptorName>Host-Pathogen Interactions</descriptorName><meshQualifierList><meshQualifier><abbreviation>IM</abbreviation><qualifierName>immunology</qualifierName><majorTopic_YN>Y</majorTopic_YN></meshQualifier></meshQualifierList></meshHeading><meshHeading><majorTopic_YN>Y</majorTopic_YN><descriptorName>Immunity, Innate</descriptorName><meshQualifierList><meshQualifier><abbreviation>DE</abbreviation><qualifierName>drug effects</qualifierName><majorTopic_YN>N</majorTopic_YN></meshQualifier></meshQualifierList></meshHeading><meshHeading><majorTopic_YN>N</majorTopic_YN><descriptorName>Middle East Respiratory Syndrome Coronavirus</descriptorName><meshQualifierList><meshQualifier><abbreviation>GE</abbreviation><qualifierName>genetics</qualifierName><majorTopic_YN>Y</majorTopic_YN></meshQualifier><meshQualifier><abbreviation>IP</abbreviation><qualifierName>isolation &amp; purification</qualifierName><majorTopic_YN>N</majorTopic_YN></meshQualifier><meshQualifier><abbreviation>PH</abbreviation><qualifierName>physiology</qualifierName><majorTopic_YN>Y</majorTopic_YN></meshQualifier></meshQualifierList></meshHeading></meshHeadingList><chemicalList><chemical><name>Cytokines</name><registryNumber>0</registryNumber></chemical><chemical><name>STAT3 Transcription Factor</name><registryNumber>0</registryNumber></chemical></chemicalList><subsetList><subset><code>IM</code><name>Index Medicus</name></subset></subsetList><fullTextUrlList><fullTextUrl><availability>Subscription required</availability><availabilityCode>S</availabilityCode><documentStyle>doi</documentStyle><site>DOI</site><url>https://doi.org/10.1186/1471-2164-15-1161</url></fullTextUrl><fullTextUrl><availability>Open access</availability><availabilityCode>OA</availabilityCode><documentStyle>html</documentStyle><site>Europe_PMC</site><url>https://europepmc.org/articles/PMC4522970</url></fullTextUrl><fullTextUrl><availability>Open access</availability><availabilityCode>OA</availabilityCode><documentStyle>pdf</documentStyle><site>Europe_PMC</site><url>https://europepmc.org/articles/PMC4522970?pdf=render</url></fullTextUrl></fullTextUrlList><isOpenAccess>Y</isOpenAccess><inEPMC>Y</inEPMC><inPMC>N</inPMC><hasPDF>Y</hasPDF><hasBook>N</hasBook><hasSuppl>Y</hasSuppl><citedByCount>13</citedByCount><hasData>Y</hasData><hasReferences>Y</hasReferences><hasTextMinedTerms>Y</hasTextMinedTerms><hasDbCrossReferences>Y</hasDbCrossReferences><dbCrossReferenceList><dbName>ARXPR</dbName><dbName>EMBL</dbName></dbCrossReferenceList><hasLabsLinks>Y</hasLabsLinks><authMan>N</authMan><epmcAuthMan>N</epmcAuthMan><nihAuthMan>N</nihAuthMan><hasTMAccessionNumbers>Y</hasTMAccessionNumbers><tmAccessionTypeList><accessionType>geo</accessionType><accessionType>gen</accessionType></tmAccessionTypeList><dateOfCompletion>2016-01-04</dateOfCompletion><dateOfCreation>2014-12-24</dateOfCreation><firstIndexDate>2014-12-28</firstIndexDate><fullTextReceivedDate>2020-07-14</fullTextReceivedDate><dateOfRevision>2020-12-18</dateOfRevision><electronicPublicationDate>2014-12-22</electronicPublicationDate><firstPublicationDate>2014-12-22</firstPublicationDate></result>
<result><id>25274805</id><source>MED</source><pmid>25274805</pmid><pmcid>PMC4248781</pmcid><fullTextIdList><fullTextId>PMC4248781</fullTextId></fullTextIdList><doi>10.1128/cvi.00455-14</doi><title>Multiple low-dose challenges in a rhesus macaque AIDS vaccine trial result in an evolving host response that affects protective outcome.</title><authorString>Selinger C, Strbo N, Gonzalez L, Aicher L, Weiss JM, Law GL, Palermo RE, Vaccari M, Franchini G, Podack ER, Katze MG.</authorString><authorList><author><fullName>Selinger C</fullName><firstName>Christian</firstName><lastName>Selinger</lastName><initials>C</initials><authorId type="ORCID">0000-0002-4361-549X</authorId><authorAffiliationDetailsList><authorAffiliation><affiliation>Department of Microbiology, University of Washington, Seattle, Washington, USA.</affiliation></authorAffiliation></authorAffiliationDetailsList></author><author><fullName>Strbo N</fullName><firstName>Natasa</firstName><lastName>Strbo</lastName><initials>N</initials><authorAffiliationDetailsList><authorAffiliation><affiliation>Department of Microbiology and Immunology, Miller School of Medicine, University of Miami, Miami, Florida, USA.</affiliation></authorAffiliation></authorAffiliationDetailsList></author><author><fullName>Gonzalez L</fullName><firstName>Louis</firstName><lastName>Gonzalez</lastName><initials>L</initials><authorAffiliationDetailsList><authorAffiliation><affiliation>Department of Microbiology and Immunology, Miller School of Medicine, University of Miami, Miami, Florida, USA.</affiliation></authorAffiliation></authorAffiliationDetailsList></author><author><fullName>Aicher L</fullName><firstName>Lauri</firstName><lastName>Aicher</lastName><initials>L</initials><authorAffiliationDetailsList><authorAffiliation><affiliation>Department of Microbiology, University of Washington, Seattle, Washington, USA.</affiliation></authorAffiliation></authorAffiliationDetailsList></author><author><fullName>Weiss JM</fullName><firstName>Jeffrey M</firstName><lastName>Weiss</lastName><initials>JM</initials><authorAffiliationDetailsList><authorAffiliation><affiliation>Department of Microbiology, University of Washington, Seattle, Washington, USA.</affiliation></authorAffiliation></authorAffiliationDetailsList></author><author><fullName>Law GL</fullName><firstName>G Lynn</firstName><lastName>Law</lastName><initials>GL</initials><authorAffiliationDetailsList><authorAffiliation><affiliation>Department of Microbiology, University of Washington, Seattle, Washington, USA.</affiliation></authorAffiliation></authorAffiliationDetailsList></author><author><fullName>Palermo RE</fullName><firstName>Robert E</firstName><lastName>Palermo</lastName><initials>RE</initials><authorAffiliationDetailsList><authorAffiliation><affiliation>Department of Microbiology, University of Washington, Seattle, Washington, USA Washington National Primate Research Center, University of Washington, Seattle, Washington, USA.</affiliation></authorAffiliation></authorAffiliationDetailsList></author><author><fullName>Vaccari M</fullName><firstName>Monica</firstName><lastName>Vaccari</lastName><initials>M</initials><authorAffiliationDetailsList><authorAffiliation><affiliation>Animal Models and Retroviral Vaccines, National Cancer Institute, Bethesda, Maryland, USA.</affiliation></authorAffiliation></authorAffiliationDetailsList></author><author><fullName>Franchini G</fullName><firstName>Genoveffa</firstName><lastName>Franchini</lastName><initials>G</initials><authorAffiliationDetailsList><authorAffiliation><affiliation>Animal Models and Retroviral Vaccines, National Cancer Institute, Bethesda, Maryland, USA.</affiliation></authorAffiliation></authorAffiliationDetailsList></author><author><fullName>Podack ER</fullName><firstName>Eckhard R</firstName><lastName>Podack</lastName><initials>ER</initials><authorAffiliationDetailsList><authorAffiliation><affiliation>Department of Microbiology and Immunology, Miller School of Medicine, University of Miami, Miami, Florida, USA.</affiliation></authorAffiliation></authorAffiliationDetailsList></author><author><fullName>Katze MG</fullName><firstName>Michael G</firstName><lastName>Katze</lastName><initials>MG</initials><authorAffiliationDetailsList><authorAffiliation><affiliation>Department of Microbiology, University of Washington, Seattle, Washington, USA Washington National Primate Research Center, University of Washington, Seattle, Washington, USA honey@uw.edu.</affiliation></authorAffiliation></authorAffiliationDetailsList></author></authorList><authorIdList><authorId type="ORCID">0000-0002-4361-549X</authorId></authorIdList><dataLinksTagsList><dataLinkstag>related_data</dataLinkstag><dataLinkstag>supporting_data</dataLinkstag><dataLinkstag>altmetrics</dataLinkstag></dataLinksTagsList><journalInfo><issue>12</issue><volume>21</volume><journalIssueId>2222767</journalIssueId><dateOfPublication>2014 Dec</dateOfPublication><monthOfPublication>12</monthOfPublication><yearOfPublication>2014</yearOfPublication><printPublicationDate>2014-12-01</printPublicationDate><journal><title>Clinical and vaccine immunology : CVI</title><ISOAbbreviation>Clin Vaccine Immunol</ISOAbbreviation><medlineAbbreviation>Clin Vaccine Immunol</medlineAbbreviation><NLMid>101252125</NLMid><ISSN>1556-6811</ISSN><ESSN>1556-679X</ESSN></journal></journalInfo><pubYear>2014</pubYear><pageInfo>1650-1660</pageInfo><abstractText>Using whole-blood transcriptional profiling, we investigated differences in the host response to vaccination and challenge in a rhesus macaque AIDS vaccine trial. Samples were collected from animals prior to and after vaccination with live, irradiated vaccine cells secreting the modified endoplasmic reticulum chaperone gp96-Ig loaded with simian immunodeficiency virus (SIV) peptides, either alone or in combination with a SIV-gp120 protein boost. Additional samples were collected following multiple low-dose rectal challenges with SIVmac251. Animals in the boosted group had a 73% reduced risk of infection. Surprisingly, few changes in gene expression were observed during the vaccination phase. Focusing on postchallenge comparisons, in particular for protected animals, we identified a host response signature of protection comprised of strong interferon signaling after the first challenge, which then largely abated after further challenges. We also identified a host response signature, comprised of early macrophage-mediated inflammatory responses, in animals with undetectable viral loads 5 days after the first challenge but with unusually high viral titers after subsequent challenges. Statistical analysis showed that prime-boost vaccination significantly lowered the probability of infection in a time-consistent manner throughout several challenges. Given that humoral responses in the prime-boost group were highly significant prechallenge correlates of protection, the strong innate signaling after the first challenge suggests that interferon signaling may enhance vaccine-induced antibody responses and is an important contributor to protection from infection during repeated low-dose exposure to SIV.</abstractText><affiliation>Department of Microbiology, University of Washington, Seattle, Washington, USA.</affiliation><publicationStatus>ppublish</publicationStatus><language>eng</language><pubModel>Print-Electronic</pubModel><pubTypeList><pubType>research-article</pubType><pubType>Journal Article</pubType><pubType>Research Support, N.I.H., Extramural</pubType></pubTypeList><grantsList><grant><grantId>KL2 TR000461</grantId><agency>NCATS NIH HHS</agency><acronym>TR</acronym><orderIn>0</orderIn></grant><grant><grantId>P01AI096396</grantId><agency>NIAID NIH HHS</agency><acronym>AI</acronym><orderIn>0</orderIn></grant><grant><grantId>P510D010425</grantId><agency>PHS HHS</agency><orderIn>0</orderIn></grant><grant><grantId>HHSN272201300010C</grantId><agency>NIAID NIH HHS</agency><acronym>AO</acronym><orderIn>0</orderIn></grant><grant><grantId>HHSN272201300010I</grantId><agency>NIAID NIH HHS</agency><acronym>AI</acronym><orderIn>0</orderIn></grant><grant><grantId>N01-A30018</grantId><agency>PHS HHS</agency><orderIn>0</orderIn></grant><grant><grantId>P01 AI096396</grantId><agency>NIAID NIH HHS</agency><acronym>AI</acronym><orderIn>0</orderIn></grant><grant><grantId>P51 OD010425</grantId><agency>NIH HHS</agency><acronym>OD</acronym><orderIn>0</orderIn></grant></grantsList><meshHeadingList><meshHeading><majorTopic_YN>N</majorTopic_YN><descriptorName>Animals</descriptorName></meshHeading><meshHeading><majorTopic_YN>N</majorTopic_YN><descriptorName>Macaca mulatta</descriptorName></meshHeading><meshHeading><majorTopic_YN>N</majorTopic_YN><descriptorName>Simian Acquired Immunodeficiency Syndrome</descriptorName><meshQualifierList><meshQualifier><abbreviation>IM</abbreviation><qualifierName>immunology</qualifierName><majorTopic_YN>Y</majorTopic_YN></meshQualifier><meshQualifier><abbreviation>PC</abbreviation><qualifierName>prevention &amp; control</qualifierName><majorTopic_YN>N</majorTopic_YN></meshQualifier></meshQualifierList></meshHeading><meshHeading><majorTopic_YN>N</majorTopic_YN><descriptorName>AIDS Vaccines</descriptorName><meshQualifierList><meshQualifier><abbreviation>IM</abbreviation><qualifierName>immunology</qualifierName><majorTopic_YN>Y</majorTopic_YN></meshQualifier></meshQualifierList></meshHeading><meshHeading><majorTopic_YN>N</majorTopic_YN><descriptorName>SAIDS Vaccines</descriptorName><meshQualifierList><meshQualifier><abbreviation>AD</abbreviation><qualifierName>administration &amp; dosage</qualifierName><majorTopic_YN>N</majorTopic_YN></meshQualifier><meshQualifier><abbreviation>IM</abbreviation><qualifierName>immunology</qualifierName><majorTopic_YN>Y</majorTopic_YN></meshQualifier></meshQualifierList></meshHeading><meshHeading><majorTopic_YN>N</majorTopic_YN><descriptorName>Antibodies, Viral</descriptorName><meshQualifierList><meshQualifier><abbreviation>BL</abbreviation><qualifierName>blood</qualifierName><majorTopic_YN>Y</majorTopic_YN></meshQualifier></meshQualifierList></meshHeading><meshHeading><majorTopic_YN>N</majorTopic_YN><descriptorName>Vaccination</descriptorName></meshHeading><meshHeading><majorTopic_YN>N</majorTopic_YN><descriptorName>Female</descriptorName></meshHeading><meshHeading><majorTopic_YN>N</majorTopic_YN><descriptorName>Male</descriptorName></meshHeading><meshHeading><majorTopic_YN>N</majorTopic_YN><descriptorName>Simian immunodeficiency virus</descriptorName><meshQualifierList><meshQualifier><abbreviation>GE</abbreviation><qualifierName>genetics</qualifierName><majorTopic_YN>N</majorTopic_YN></meshQualifier></meshQualifierList></meshHeading><meshHeading><majorTopic_YN>N</majorTopic_YN><descriptorName>Host-Pathogen Interactions</descriptorName></meshHeading></meshHeadingList><chemicalList><chemical><name>Antibodies, Viral</name><registryNumber>0</registryNumber></chemical><chemical><name>AIDS Vaccines</name><registryNumber>0</registryNumber></chemical><chemical><name>SAIDS Vaccines</name><registryNumber>0</registryNumber></chemical></chemicalList><subsetList><subset><code>IM</code><name>Index Medicus</name></subset></subsetList><fullTextUrlList><fullTextUrl><availability>Subscription required</availability><availabilityCode>S</availabilityCode><documentStyle>doi</documentStyle><site>DOI</site><url>https://doi.org/10.1128/CVI.00455-14</url></fullTextUrl><fullTextUrl><availability>Free</availability><availabilityCode>F</availabilityCode><documentStyle>html</documentStyle><site>Europe_PMC</site><url>https://europepmc.org/articles/PMC4248781</url></fullTextUrl><fullTextUrl><availability>Free</availability><availabilityCode>F</availabilityCode><documentStyle>pdf</documentStyle><site>Europe_PMC</site><url>https://europepmc.org/articles/PMC4248781?pdf=render</url></fullTextUrl><fullTextUrl><availability>Free</availability><availabilityCode>F</availabilityCode><documentStyle>doi</documentStyle><site>DOI</site><url>https://doi.org/10.1128/cvi.00455-14</url></fullTextUrl></fullTextUrlList><isOpenAccess>N</isOpenAccess><inEPMC>Y</inEPMC><inPMC>N</inPMC><hasPDF>Y</hasPDF><hasBook>N</hasBook><hasSuppl>Y</hasSuppl><citedByCount>7</citedByCount><hasData>Y</hasData><hasReferences>Y</hasReferences><hasTextMinedTerms>Y</hasTextMinedTerms><hasDbCrossReferences>Y</hasDbCrossReferences><dbCrossReferenceList><dbName>EMBL</dbName></dbCrossReferenceList><hasLabsLinks>Y</hasLabsLinks><authMan>N</authMan><epmcAuthMan>N</epmcAuthMan><nihAuthMan>N</nihAuthMan><hasTMAccessionNumbers>Y</hasTMAccessionNumbers><tmAccessionTypeList><accessionType>geo</accessionType></tmAccessionTypeList><dateOfCompletion>2016-03-21</dateOfCompletion><dateOfCreation>2014-10-03</dateOfCreation><firstIndexDate>2014-10-03</firstIndexDate><fullTextReceivedDate>2020-07-12</fullTextReceivedDate><dateOfRevision>2020-12-15</dateOfRevision><electronicPublicationDate>2014-10-01</electronicPublicationDate><firstPublicationDate>2014-10-01</firstPublicationDate></result>
<result><id>24931612</id><source>MED</source><pmid>24931612</pmid><doi>10.1016/j.celrep.2014.05.029</doi><title>MicroRNAs establish robustness and adaptability of a critical gene network to regulate progenitor fate decisions during cortical neurogenesis.</title><authorString>Ghosh T, Aprea J, Nardelli J, Engel H, Selinger C, Mombereau C, Lemonnier T, Moutkine I, Schwendimann L, Dori M, Irinopoulou T, Henrion-Caude A, Benecke AG, Arnold SJ, Gressens P, Calegari F, Groszer M.</authorString><authorList><author><fullName>Ghosh T</fullName><firstName>Tanay</firstName><lastName>Ghosh</lastName><initials>T</initials><authorAffiliationDetailsList><authorAffiliation><affiliation>Inserm, UMR-S839, Paris 75005, France; Sorbonne Universités, UPMC Université Paris 06, Paris 75005, France; Institut du Fer à Moulin, Paris 75005, France.</affiliation></authorAffiliation></authorAffiliationDetailsList></author><author><fullName>Aprea J</fullName><firstName>Julieta</firstName><lastName>Aprea</lastName><initials>J</initials><authorId type="ORCID">0000-0002-8749-7878</authorId><authorAffiliationDetailsList><authorAffiliation><affiliation>Center for Regenerative Therapies, TU-Dresden, Fetscherstraße 105, 01307 Dresden, Germany.</affiliation></authorAffiliation></authorAffiliationDetailsList></author><author><fullName>Nardelli J</fullName><firstName>Jeannette</firstName><lastName>Nardelli</lastName><initials>J</initials><authorAffiliationDetailsList><authorAffiliation><affiliation>Inserm, U1141, Paris, 75019, France; Université Paris Diderot, Sorbonne Paris Cité, UMRS 1141, Paris 75019, France.</affiliation></authorAffiliation></authorAffiliationDetailsList></author><author><fullName>Engel H</fullName><firstName>Hannes</firstName><lastName>Engel</lastName><initials>H</initials><authorAffiliationDetailsList><authorAffiliation><affiliation>Renal Department, University Medical Center, Breisacher Strasse 66, Freiburg 79106, Germany.</affiliation></authorAffiliation></authorAffiliationDetailsList></author><author><fullName>Selinger C</fullName><firstName>Christian</firstName><lastName>Selinger</lastName><initials>C</initials><authorId type="ORCID">0000-0002-4361-549X</authorId><authorAffiliationDetailsList><authorAffiliation><affiliation>Department of Microbiology, School of Medicine, University of Washington, Seattle, WA 98195-8070, USA.</affiliation></authorAffiliation></authorAffiliationDetailsList></author><author><fullName>Mombereau C</fullName><firstName>Cedric</firstName><lastName>Mombereau</lastName><initials>C</initials><authorAffiliationDetailsList><authorAffiliation><affiliation>Inserm, UMR-S839, Paris 75005, France; Sorbonne Universités, UPMC Université Paris 06, Paris 75005, France; Institut du Fer à Moulin, Paris 75005, France.</affiliation></authorAffiliation></authorAffiliationDetailsList></author><author><fullName>Lemonnier T</fullName><firstName>Thomas</firstName><lastName>Lemonnier</lastName><initials>T</initials><authorAffiliationDetailsList><authorAffiliation><affiliation>Inserm, UMR-S839, Paris 75005, France; Sorbonne Universités, UPMC Université Paris 06, Paris 75005, France; Institut du Fer à Moulin, Paris 75005, France.</affiliation></authorAffiliation></authorAffiliationDetailsList></author><author><fullName>Moutkine I</fullName><firstName>Imane</firstName><lastName>Moutkine</lastName><initials>I</initials><authorAffiliationDetailsList><authorAffiliation><affiliation>Inserm, UMR-S839, Paris 75005, France; Sorbonne Universités, UPMC Université Paris 06, Paris 75005, France; Institut du Fer à Moulin, Paris 75005, France.</affiliation></authorAffiliation></authorAffiliationDetailsList></author><author><fullName>Schwendimann L</fullName><firstName>Leslie</firstName><lastName>Schwendimann</lastName><initials>L</initials><authorAffiliationDetailsList><authorAffiliation><affiliation>Inserm, U1141, Paris, 75019, France; Université Paris Diderot, Sorbonne Paris Cité, UMRS 1141, Paris 75019, France.</affiliation></authorAffiliation></authorAffiliationDetailsList></author><author><fullName>Dori M</fullName><firstName>Martina</firstName><lastName>Dori</lastName><initials>M</initials><authorId type="ORCID">0000-0002-1053-2006</authorId><authorAffiliationDetailsList><authorAffiliation><affiliation>Center for Regenerative Therapies, TU-Dresden, Fetscherstraße 105, 01307 Dresden, Germany.</affiliation></authorAffiliation></authorAffiliationDetailsList></author><author><fullName>Irinopoulou T</fullName><firstName>Theano</firstName><lastName>Irinopoulou</lastName><initials>T</initials><authorAffiliationDetailsList><authorAffiliation><affiliation>Inserm, UMR-S839, Paris 75005, France; Sorbonne Universités, UPMC Université Paris 06, Paris 75005, France; Institut du Fer à Moulin, Paris 75005, France.</affiliation></authorAffiliation></authorAffiliationDetailsList></author><author><fullName>Henrion-Caude A</fullName><firstName>Alexandra</firstName><lastName>Henrion-Caude</lastName><initials>A</initials><authorAffiliationDetailsList><authorAffiliation><affiliation>Inserm, UMR1163, GenAtlas, Institute Imagine, Université Paris Descartes, Paris 75015, France.</affiliation></authorAffiliation></authorAffiliationDetailsList></author><author><fullName>Benecke AG</fullName><firstName>Arndt G</firstName><lastName>Benecke</lastName><initials>AG</initials><authorAffiliationDetailsList><authorAffiliation><affiliation>Institut des Hautes Etudes Scientifiques, Bures sur Yvette 91440, France; CNRS UMR 7224, Université Pierre and Marie Curie, Paris 75005, France.</affiliation></authorAffiliation></authorAffiliationDetailsList></author><author><fullName>Arnold SJ</fullName><firstName>Sebastian J</firstName><lastName>Arnold</lastName><initials>SJ</initials><authorId type="ORCID">0000-0002-2688-9210</authorId><authorAffiliationDetailsList><authorAffiliation><affiliation>Renal Department, University Medical Center, Breisacher Strasse 66, Freiburg 79106, Germany; BIOSS Centre of Biological Signalling Studies, Albert-Ludwigs-University, Freiburg 79085, Germany.</affiliation></authorAffiliation></authorAffiliationDetailsList></author><author><fullName>Gressens P</fullName><firstName>Pierre</firstName><lastName>Gressens</lastName><initials>P</initials><authorAffiliationDetailsList><authorAffiliation><affiliation>Inserm, U1141, Paris, 75019, France; Université Paris Diderot, Sorbonne Paris Cité, UMRS 1141, Paris 75019, France; Centre for the Developing Brain, King's College, St Thomas' Campus, WC2R2LS London, UK.</affiliation></authorAffiliation></authorAffiliationDetailsList></author><author><fullName>Calegari F</fullName><firstName>Federico</firstName><lastName>Calegari</lastName><initials>F</initials><authorId type="ORCID">0000-0002-3703-2802</authorId><authorAffiliationDetailsList><authorAffiliation><affiliation>Center for Regenerative Therapies, TU-Dresden, Fetscherstraße 105, 01307 Dresden, Germany.</affiliation></authorAffiliation></authorAffiliationDetailsList></author><author><fullName>Groszer M</fullName><firstName>Matthias</firstName><lastName>Groszer</lastName><initials>M</initials><authorId type="ORCID">0000-0002-6209-305X</authorId><authorAffiliationDetailsList><authorAffiliation><affiliation>Inserm, UMR-S839, Paris 75005, France; Sorbonne Universités, UPMC Université Paris 06, Paris 75005, France; Institut du Fer à Moulin, Paris 75005, France. Electronic address: matthias.groszer@inserm.fr.</affiliation></authorAffiliation></authorAffiliationDetailsList></author></authorList><authorIdList><authorId type="ORCID">0000-0002-1053-2006</authorId><authorId type="ORCID">0000-0002-2688-9210</authorId><authorId type="ORCID">0000-0002-3703-2802</authorId><authorId type="ORCID">0000-0002-4361-549X</authorId><authorId type="ORCID">0000-0002-6209-305X</authorId><authorId type="ORCID">0000-0002-8749-7878</authorId></authorIdList><dataLinksTagsList><dataLinkstag>related_data</dataLinkstag><dataLinkstag>altmetrics</dataLinkstag></dataLinksTagsList><journalInfo><issue>6</issue><volume>7</volume><journalIssueId>2174741</journalIssueId><dateOfPublication>2014 Jun</dateOfPublication><monthOfPublication>6</monthOfPublication><yearOfPublication>2014</yearOfPublication><printPublicationDate>2014-06-01</printPublicationDate><journal><title>Cell reports</title><ISOAbbreviation>Cell Rep</ISOAbbreviation><medlineAbbreviation>Cell Rep</medlineAbbreviation><NLMid>101573691</NLMid><ISSN>2211-1247</ISSN><ESSN>2211-1247</ESSN></journal></journalInfo><pubYear>2014</pubYear><pageInfo>1779-1788</pageInfo><abstractText>Over the course of cortical neurogenesis, the transition of progenitors from proliferation to differentiation requires a precise regulation of involved gene networks under varying environmental conditions. In order to identify such regulatory mechanisms, we analyzed microRNA (miRNA) target networks in progenitors during early and late stages of neurogenesis. We found that cyclin D1 is a network hub whose expression is miRNA-dosage sensitive. Experimental validation revealed a feedback regulation between cyclin D1 and its regulating miRNAs miR-20a, miR-20b, and miR-23a. Cyclin D1 induces expression of miR-20a and miR-20b, whereas it represses miR-23a. Inhibition of any of these miRNAs increases the developmental stage-specific mean and dynamic expression range (variance) of cyclin D1 protein in progenitors, leading to reduced neuronal differentiation. Thus, miRNAs establish robustness and stage-specific adaptability to a critical dosage-sensitive gene network during cortical neurogenesis. Understanding such network regulatory mechanisms for key developmental events can provide insights into individual susceptibilities for genetically complex neuropsychiatric disorders.</abstractText><affiliation>Inserm, UMR-S839, Paris 75005, France; Sorbonne Universités, UPMC Université Paris 06, Paris 75005, France; Institut du Fer à Moulin, Paris 75005, France.</affiliation><publicationStatus>ppublish</publicationStatus><language>eng</language><pubModel>Print-Electronic</pubModel><pubTypeList><pubType>Research Support, Non-U.S. Gov't</pubType><pubType>Journal Article</pubType></pubTypeList><meshHeadingList><meshHeading><majorTopic_YN>N</majorTopic_YN><descriptorName>Stem Cells</descriptorName><meshQualifierList><meshQualifier><abbreviation>CY</abbreviation><qualifierName>cytology</qualifierName><majorTopic_YN>Y</majorTopic_YN></meshQualifier></meshQualifierList></meshHeading><meshHeading><majorTopic_YN>N</majorTopic_YN><descriptorName>Animals</descriptorName></meshHeading><meshHeading><majorTopic_YN>N</majorTopic_YN><descriptorName>Mice, Transgenic</descriptorName></meshHeading><meshHeading><majorTopic_YN>N</majorTopic_YN><descriptorName>Humans</descriptorName></meshHeading><meshHeading><majorTopic_YN>N</majorTopic_YN><descriptorName>Mice</descriptorName></meshHeading><meshHeading><majorTopic_YN>N</majorTopic_YN><descriptorName>MicroRNAs</descriptorName><meshQualifierList><meshQualifier><abbreviation>GE</abbreviation><qualifierName>genetics</qualifierName><majorTopic_YN>Y</majorTopic_YN></meshQualifier></meshQualifierList></meshHeading><meshHeading><majorTopic_YN>N</majorTopic_YN><descriptorName>Cell Differentiation</descriptorName><meshQualifierList><meshQualifier><abbreviation>GE</abbreviation><qualifierName>genetics</qualifierName><majorTopic_YN>N</majorTopic_YN></meshQualifier></meshQualifierList></meshHeading><meshHeading><majorTopic_YN>Y</majorTopic_YN><descriptorName>Gene Regulatory Networks</descriptorName></meshHeading><meshHeading><majorTopic_YN>N</majorTopic_YN><descriptorName>Neurogenesis</descriptorName><meshQualifierList><meshQualifier><abbreviation>GE</abbreviation><qualifierName>genetics</qualifierName><majorTopic_YN>Y</majorTopic_YN></meshQualifier></meshQualifierList></meshHeading></meshHeadingList><chemicalList><chemical><name>MicroRNAs</name><registryNumber>0</registryNumber></chemical></chemicalList><subsetList><subset><code>IM</code><name>Index Medicus</name></subset></subsetList><fullTextUrlList><fullTextUrl><availability>Subscription required</availability><availabilityCode>S</availabilityCode><documentStyle>doi</documentStyle><site>DOI</site><url>https://doi.org/10.1016/j.celrep.2014.05.029</url></fullTextUrl></fullTextUrlList><isOpenAccess>N</isOpenAccess><inEPMC>N</inEPMC><inPMC>N</inPMC><hasPDF>N</hasPDF><hasBook>N</hasBook><hasSuppl>N</hasSuppl><citedByCount>20</citedByCount><hasData>Y</hasData><hasReferences>Y</hasReferences><hasTextMinedTerms>Y</hasTextMinedTerms><hasDbCrossReferences>Y</hasDbCrossReferences><dbCrossReferenceList><dbName>EMBL</dbName><dbName>UNIPROT</dbName></dbCrossReferenceList><hasLabsLinks>Y</hasLabsLinks><authMan>N</authMan><epmcAuthMan>N</epmcAuthMan><nihAuthMan>N</nihAuthMan><hasTMAccessionNumbers>N</hasTMAccessionNumbers><dateOfCompletion>2015-04-16</dateOfCompletion><dateOfCreation>2014-06-28</dateOfCreation><firstIndexDate>2014-06-17</firstIndexDate><electronicPublicationDate>2014-06-12</electronicPublicationDate><firstPublicationDate>2014-06-12</firstPublicationDate></result>
<result><id>23896280</id><source>MED</source><pmid>23896280</pmid><doi>10.1016/j.coviro.2013.06.015</doi><title>Mathematical models of viral latency.</title><authorString>Selinger C, Katze MG.</authorString><authorList><author><fullName>Selinger C</fullName><firstName>Christian</firstName><lastName>Selinger</lastName><initials>C</initials><authorId type="ORCID">0000-0002-4361-549X</authorId><authorAffiliationDetailsList><authorAffiliation><affiliation>Department of Microbiology, University of Washington, Box 358070, Seattle, WA 98195-8070, USA. Electronic address: csel@uw.edu.</affiliation></authorAffiliation></authorAffiliationDetailsList></author><author><fullName>Katze MG</fullName><firstName>Michael G</firstName><lastName>Katze</lastName><initials>MG</initials></author></authorList><authorIdList><authorId type="ORCID">0000-0002-4361-549X</authorId></authorIdList><dataLinksTagsList><dataLinkstag>altmetrics</dataLinkstag></dataLinksTagsList><journalInfo><issue>4</issue><volume>3</volume><journalIssueId>2067140</journalIssueId><dateOfPublication>2013 Aug</dateOfPublication><monthOfPublication>8</monthOfPublication><yearOfPublication>2013</yearOfPublication><printPublicationDate>2013-08-01</printPublicationDate><journal><title>Current opinion in virology</title><ISOAbbreviation>Curr Opin Virol</ISOAbbreviation><medlineAbbreviation>Curr Opin Virol</medlineAbbreviation><NLMid>101560941</NLMid><ISSN>1879-6257</ISSN><ESSN>1879-6265</ESSN></journal></journalInfo><pubYear>2013</pubYear><pageInfo>402-407</pageInfo><abstractText>While viral latency remains one of the biggest challenges for successful antiviral therapy, it has also inspired mathematical modelers to develop dynamical system approaches with the aim of predicting the impact of drug efficacy on disease progression and the persistence of latent viral reservoirs. In this review we present several differential equation models and assess their relative success in giving advice to the working clinician and their predictive power for inferring long term viral eradication from short term abatement. Many models predict that there is a considerable likelihood of viral rebound due to continuous reseeding of latent reservoirs. Most mathematical models of HIV latency suffer from being reductionist by ignoring the growing variety of different cell types harboring latent virus, the considerable intercellular delay involved in reactivation, and host-related epigenetic modifications which may alter considerably the dynamical system of immune cell populations.</abstractText><affiliation>Department of Microbiology, University of Washington, Box 358070, Seattle, WA 98195-8070, USA. Electronic address: csel@uw.edu.</affiliation><publicationStatus>ppublish</publicationStatus><language>eng</language><pubModel>Print-Electronic</pubModel><pubTypeList><pubType>Review</pubType><pubType>Research Support, U.S. Gov't, Non-P.H.S.</pubType><pubType>Journal Article</pubType><pubType>Research Support, N.I.H., Extramural</pubType></pubTypeList><grantsList><grant><grantId>P30 DA015625</grantId><agency>NIDA NIH HHS</agency><acronym>DA</acronym><orderIn>0</orderIn></grant><grant><grantId>U54AI081680</grantId><agency>NIAID NIH HHS</agency><acronym>AI</acronym><orderIn>0</orderIn></grant><grant><grantId>P30DA015625</grantId><agency>NIDA NIH HHS</agency><acronym>DA</acronym><orderIn>0</orderIn></grant><grant><grantId>P51 RR000166</grantId><agency>NCRR NIH HHS</agency><acronym>RR</acronym><orderIn>0</orderIn></grant><grant><grantId>P51RR00166</grantId><agency>NCRR NIH HHS</agency><acronym>RR</acronym><orderIn>0</orderIn></grant><grant><grantId>U54 AI081680</grantId><agency>NIAID NIH HHS</agency><acronym>AI</acronym><orderIn>0</orderIn></grant><grant><grantId>HHSN272200800060C</grantId><agency>PHS HHS</agency><orderIn>0</orderIn></grant><grant><grantId>R24 OD011157</grantId><agency>NIH HHS</agency><acronym>OD</acronym><orderIn>0</orderIn></grant><grant><grantId>R24 OD011172</grantId><agency>NIH HHS</agency><acronym>OD</acronym><orderIn>0</orderIn></grant></grantsList><meshHeadingList><meshHeading><majorTopic_YN>N</majorTopic_YN><descriptorName>Animals</descriptorName></meshHeading><meshHeading><majorTopic_YN>N</majorTopic_YN><descriptorName>Humans</descriptorName></meshHeading><meshHeading><majorTopic_YN>N</majorTopic_YN><descriptorName>Simplexvirus</descriptorName><meshQualifierList><meshQualifier><abbreviation>GE</abbreviation><qualifierName>genetics</qualifierName><majorTopic_YN>N</majorTopic_YN></meshQualifier><meshQualifier><abbreviation>PH</abbreviation><qualifierName>physiology</qualifierName><majorTopic_YN>Y</majorTopic_YN></meshQualifier><meshQualifier><abbreviation>CH</abbreviation><qualifierName>chemistry</qualifierName><majorTopic_YN>N</majorTopic_YN></meshQualifier></meshQualifierList></meshHeading><meshHeading><majorTopic_YN>N</majorTopic_YN><descriptorName>HIV-1</descriptorName><meshQualifierList><meshQualifier><abbreviation>GE</abbreviation><qualifierName>genetics</qualifierName><majorTopic_YN>N</majorTopic_YN></meshQualifier><meshQualifier><abbreviation>PH</abbreviation><qualifierName>physiology</qualifierName><majorTopic_YN>Y</majorTopic_YN></meshQualifier><meshQualifier><abbreviation>CH</abbreviation><qualifierName>chemistry</qualifierName><majorTopic_YN>N</majorTopic_YN></meshQualifier></meshQualifierList></meshHeading><meshHeading><majorTopic_YN>N</majorTopic_YN><descriptorName>Herpes Simplex</descriptorName><meshQualifierList><meshQualifier><abbreviation>VI</abbreviation><qualifierName>virology</qualifierName><majorTopic_YN>N</majorTopic_YN></meshQualifier></meshQualifierList></meshHeading><meshHeading><majorTopic_YN>N</majorTopic_YN><descriptorName>HIV Infections</descriptorName><meshQualifierList><meshQualifier><abbreviation>VI</abbreviation><qualifierName>virology</qualifierName><majorTopic_YN>N</majorTopic_YN></meshQualifier></meshQualifierList></meshHeading><meshHeading><majorTopic_YN>Y</majorTopic_YN><descriptorName>Virus Latency</descriptorName></meshHeading><meshHeading><majorTopic_YN>Y</majorTopic_YN><descriptorName>Models, Theoretical</descriptorName></meshHeading></meshHeadingList><subsetList><subset><code>IM</code><name>Index Medicus</name></subset></subsetList><fullTextUrlList><fullTextUrl><availability>Subscription required</availability><availabilityCode>S</availabilityCode><documentStyle>doi</documentStyle><site>DOI</site><url>https://doi.org/10.1016/j.coviro.2013.06.015</url></fullTextUrl></fullTextUrlList><isOpenAccess>N</isOpenAccess><inEPMC>N</inEPMC><inPMC>N</inPMC><hasPDF>N</hasPDF><hasBook>N</hasBook><hasSuppl>N</hasSuppl><citedByCount>2</citedByCount><hasData>N</hasData><hasReferences>Y</hasReferences><hasTextMinedTerms>Y</hasTextMinedTerms><hasDbCrossReferences>N</hasDbCrossReferences><hasLabsLinks>Y</hasLabsLinks><authMan>N</authMan><epmcAuthMan>N</epmcAuthMan><nihAuthMan>N</nihAuthMan><hasTMAccessionNumbers>N</hasTMAccessionNumbers><dateOfCompletion>2014-02-27</dateOfCompletion><dateOfCreation>2013-07-31</dateOfCreation><firstIndexDate>2013-07-31</firstIndexDate><dateOfRevision>2019-05-08</dateOfRevision><electronicPublicationDate>2013-07-26</electronicPublicationDate><firstPublicationDate>2013-07-26</firstPublicationDate></result></response>